Payload Information

General Information of This Payload
Payload ID
PAY0WUZLC
Name
Camptothecin
Synonyms
Camptothecin; 7689-03-4; Camptothecine; (S)-(+)-Camptothecin; Campathecin; (+)-Camptothecine; d-Camptothecin; (+)-Camptothecin; 20(S)-Camptothecine; 21,22-Secocamptothecin-21-oic acid lactone; NSC94600; Camptothecine (S,+); CHEMBL65; (S)-4-ethyl-4-hydroxy-1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; NSC-94600; MLS000766223; XT3Z54Z28A; CHEBI:27656; MFCD00081076; (4S)-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione; (S)-Camptothecin; (19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione; 1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-, (4S)-; 1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-, (S)-; 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-, (4S)-; 20(S)-Camptothecin; 4-ETHYL-4-HYDROXY-1,12-DIHYDRO-4H-2-OXA-6,12A-DIAZA-DIBENZO[B,H]FLUORENE-3,13-DIONE; SR-01000075798; SR-01000597379; d-camptothecine; (s)-camptothecine; Camptothecin,(S); (4S)-4-ETHYL-4-HYDROXY-1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-3,14(4H,12H)-DIONE; (S)-4-ethyl-4-hydroxy-1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-4-Ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-(4H,12H)-dione; 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-, (S)-; Prestwick_102; (+)-Camptothecin;; Camptothecine (8CI); Spectrum_000299; Tocris-1100; SpecPlus_000712; Prestwick0_000200; Prestwick1_000200; Prestwick2_000200; Prestwick3_000200; Spectrum2_000903; Spectrum3_001203; Spectrum4_000738; Spectrum5_001126; CAMPTOTHECIN [MI]; Lopac-C-9911; D09YDM; SCHEMBL6038; UNII-XT3Z54Z28A; Lopac0_000341; BSPBio_000159; BSPBio_002586; KBioGR_001036; KBioSS_000779; KBioSS_002283; cid_24360; CAMPTOTHECIN [WHO-DD]; DivK1c_000826; DivK1c_006808; SPECTRUM1502232; SPBio_000746; SPBio_002080; BPBio1_000175; DTXSID0030956; HMS502J08; KBio1_000826; KBio1_001752; KBio2_000779; KBio2_003347; KBio2_005915; KBio3_002086; 4-Ethyl-4-hydroxy-1H-pyrano-[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; NINDS_000826; Bio1_000400; Bio1_000889; Bio1_001378; HMS1568H21; HMS1921N08; HMS2089F08; HMS2095H21; HMS3261E03; HMS3414J17; HMS3654D13; HMS3678J15; HMS3712H21; BCP02857; Tox21_500341; AC-202; BBL033963; BDBM50008923; CCG-40255; GR-301; s1288; STK801886; AKOS004119861; CS-1049; DB04690; KS-5235; LP00341; SDCCGMLS-0066688.P001; SDCCGSBI-0050329.P003; CAS-2114454; IDI1_000826; NCGC00015290-01; NCGC00016994-01; NCGC00016994-02; NCGC00016994-03; NCGC00016994-04; NCGC00016994-05; NCGC00016994-06; NCGC00016994-07; NCGC00016994-08; NCGC00016994-09; NCGC00016994-10; NCGC00016994-11; NCGC00016994-12; NCGC00016994-16; NCGC00016994-29; NCGC00024997-01; NCGC00024997-02; NCGC00024997-03; NCGC00024997-04; NCGC00024997-05; NCGC00024997-06; NCGC00178592-01; NCGC00178592-02; NCGC00261026-01; HY-16560; NCI60_042105; SMR000445686; SY010324; EU-0100341; SW196414-3; C 9911; C01897; M01564; AB00052452-08; AB00052452-09; AB00052452_10; EN300-1725804; (S)-(+)-Camptothecin, >=90% (HPLC), powder; A838882; Q419964; Q-200785; SR-01000075798-1; SR-01000075798-4; SR-01000597379-1; SR-01000597379-3; BRD-K37890730-001-09-4; BRD-K37890730-001-10-2; Z1741982070; (S)-4-ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]florene-3,13-dione; (S)-4-ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione; 4-Ethyl-4-hydroxy-1H-pyrano-[3[,4[:6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione; (S)-4-Ethyl-4-hydroxy-1H-pyrano-[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-4-Ethyl-4-hydroxy-1H-pyrano-[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione;(S)-(+)-Camptothecin; (S)-4-Ethyl-4-hydroxy-1H-pyrano[3 inverted exclamation mark ,4 inverted exclamation mark :6,7]indolizino[1,2-b]quinoline-3,14-(4H,12H)-dione; 1H-Pyrano[3',7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-, (S)-; 4(S)-Ethyl-4-hydroxy-1H-pyrano-[3',4':6,7]indolizino[1,2-b]quinoline-3,14 (4H,12H)-dione; 4-ethyl-4-hydroxy-(4S)-3,4,12,14-tetrahydro-1H-pyrano[3'',4'':6,7]indolizino[1,2-b]quinoline-3,14-dione; 4-Ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione (camptothecin or CPT); 4-Ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione (Camptothecin); 4-Ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione (CPT, Camptothecin)
   Click to Show/Hide
Target(s) DNA topoisomerase 1 (TOP1)
 Target Info 
Structure
Formula
C20H16N2O4
Isosmiles
CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O
PubChem CID
24360
InChI
InChI=1S/C20H16N2O4/c1-2-20(25)14-8-16-17-12(7-11-5-3-4-6-15(11)21-17)9-22(16)18(23)13(14)10-26-19(20)24/h3-8,25H,2,9-10H2,1H3/t20-/m0/s1
InChIKey
VSJKWCGYPAHWDS-FQEVSTJZSA-N
IUPAC Name
(19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
Pharmaceutical Properties
Molecule Weight
348.4
Polar area
79.7
Complexity
742
xlogp Value
1
Heavy Count
26
Rot Bonds
1
Hbond acc
5
Hbond Donor
1
The activity data of This Payload
Standard Type Value Units Cell line Disease Model Cell line ID Reference
Half Maximal Inhibitory Concentration (IC50) 0.001 ug/mL
Lu-99 cells
Lung giant cell carcinoma
CVCL_3015 
Half Maximal Inhibitory Concentration (IC50) 0.00463 ug/mL
QG-56 cells
Lung squamous cell carcinoma
CVCL_6943 
[1]
Half Maximal Inhibitory Concentration (IC50) 0.00463 ug/mL
QG-56 cells
Lung squamous cell carcinoma
CVCL_6943 
[2]
Half Maximal Inhibitory Concentration (IC50) 0.00474 ug/mL
P388 cells
Lymphoma
CVCL_7222 
[1]
Half Maximal Inhibitory Concentration (IC50) 0.00474 ug/mL
P388 cells
Lymphoma
CVCL_7222 
[2]
Half Maximal Inhibitory Concentration (IC50) 0.005 ug/mL
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
Half Maximal Inhibitory Concentration (IC50) <0.005 ug/mL
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[3]
Half Maximal Inhibitory Concentration (IC50) <0.005 ug/mL
HCT-8 cells
Ileocecal adenocarcinoma
CVCL_2478 
[3]
Half Maximal Inhibitory Concentration (IC50) 0.005 ug/mL
P388 cells
Lymphoma
CVCL_7222 
Half Maximal Inhibitory Concentration (IC50) 0.01 ug/mL
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
Half Maximal Inhibitory Concentration (IC50) 0.01 ug/mL
SW480 cells
Colon adenocarcinoma
CVCL_0546 
Half Maximal Inhibitory Concentration (IC50) 0.01 ug/mL
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[4]
Half Maximal Inhibitory Concentration (IC50) 0.0147 ug/mL
HOC-21 cells
Ovarian adenocarcinoma
CVCL_8692 
[1]
Half Maximal Inhibitory Concentration (IC50) 0.0147 ug/mL
HOC-21 cells
Ovarian adenocarcinoma
CVCL_8692 
[2]
Half Maximal Inhibitory Concentration (IC50) 0.02 ug/mL
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
Half Maximal Inhibitory Concentration (IC50) 0.02 ug/mL
Vero cells
Normal
CVCL_0059 
[5]
Half Maximal Inhibitory Concentration (IC50) 0.02 ug/mL
HEp-2 cells
Laryngeal carcinoma
CVCL_1906 
[6]
Half Maximal Inhibitory Concentration (IC50) <0.024 ug/mL
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[7]
Half Maximal Inhibitory Concentration (IC50) 0.03 ug/mL
KB VCR R cells
Normal
Undisclosed
Half Maximal Inhibitory Concentration (IC50) 0.03 ug/mL
WI-38 cells
Normal
CVCL_0579 
[8]
Half Maximal Inhibitory Concentration (IC50) 0.04 ug/mL
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
Half Maximal Inhibitory Concentration (IC50) 0.054 ug/mL
Vero cells
Normal
CVCL_0059 
[9]
Half Maximal Inhibitory Concentration (IC50) 0.054 ug/mL
Vero cells
Normal
CVCL_0059 
[10]
Half Maximal Inhibitory Concentration (IC50) 0.07 ug/mL
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
[11]
Half Maximal Inhibitory Concentration (IC50) 0.07 ug/mL
WiDr cells
Colon adenocarcinoma
CVCL_2760 
[6]
Half Maximal Inhibitory Concentration (IC50) 0.072 ug/mL
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[12]
Half Maximal Inhibitory Concentration (IC50) 0.09 ug/mL
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
Half Maximal Inhibitory Concentration (IC50) 0.096 ug/mL
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[12]
Half Maximal Inhibitory Concentration (IC50) 0.19 ug/mL
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[6]
Half Maximal Inhibitory Concentration (IC50) 0.28 ug/mL
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[13]
Half Maximal Inhibitory Concentration (IC50) 0.4 ug/mL
WI-38 cells
Normal
CVCL_0579 
[14]
Half Maximal Inhibitory Concentration (IC50) 0.6 ug/mL
Vero cells
Normal
CVCL_0059 
[15]
Half Maximal Inhibitory Concentration (IC50) 1.54 ug/mL
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[12]
Half Maximal Inhibitory Concentration (IC50) 11.71 ug/mL
L-M(TK-) cells
Normal
CVCL_4536 
[16]
Half Maximal Inhibitory Concentration (IC50) <2 ug/mL
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[17]
Half Maximal Inhibitory Concentration (IC50) 2 ug/mL
CCD 19Lu cells
Normal
CVCL_2382 
Half Maximal Inhibitory Concentration (IC50) 2.05 ug/mL
RPMI-8226 cells
Plasma cell myeloma
CVCL_0014 
[16]
Half Maximal Inhibitory Concentration (IC50) 2.72 ug/mL
Bel-7402 cells
Hepatoma
CVCL_5492 
[3]
Half Maximal Inhibitory Concentration (IC50) 5.87 ug/mL
Embryonic fibroblast MEF cells
Normal
Undisclosed [16]
Half Maximal Inhibitory Concentration (IC50) 58 ug/mL
Vero cells
Normal
CVCL_0059 
[13]
Half Maximal Inhibitory Concentration (IC50) 6.88 ug/mL
SK-MEL-2 cells (MEK inhibitor-resistant)
Melanoma
CVCL_0069 
[12]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 0.023 nM
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
[18]
Half Maximal Inhibitory Concentration (IC50) 0.02543 nM
ES7 cells
Ewing sarcoma
CVCL_1203 
Half Maximal Inhibitory Concentration (IC50) 0.04 nM
MOLT-4 cells
Adult T acute lymphoblastic leukemia
CVCL_0013 
[19]
Half Maximal Inhibitory Concentration (IC50) 0.04843 nM
NCI-H209 cells
Lung small cell carcinoma
CVCL_1525 
Half Maximal Inhibitory Concentration (IC50) 0.09574 nM
ES1 cells
Ewing sarcoma
CVCL_1198 
Half Maximal Inhibitory Concentration (IC50) 0.1016 nM
P12-Ichikawa cells
T-cell leukemia
CVCL_1630 
Half Maximal Inhibitory Concentration (IC50) 0.1214 nM
EW-16 cells
Ewing sarcoma
CVCL_1212 
Half Maximal Inhibitory Concentration (IC50) 0.1293 nM
MHH-ES-1 cells
Ewing sarcoma
CVCL_1411 
Half Maximal Inhibitory Concentration (IC50) 0.1315 nM
D-566MG cells
Glioblastoma
CVCL_1166 
Half Maximal Inhibitory Concentration (IC50) 0.1398 nM
BFTC-905 cells
Bladder carcinoma
CVCL_1083 
Half Maximal Inhibitory Concentration (IC50) 0.15 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[20]
Half Maximal Inhibitory Concentration (IC50) 0.1714 nM
639-V cells
Ureter urothelial carcinoma
CVCL_1048 
Half Maximal Inhibitory Concentration (IC50) 0.1816 nM
HSC-4 cells
Cervical lymph node
CVCL_1289 
Half Maximal Inhibitory Concentration (IC50) 0.1936 nM
NBsusSR cells
Neuroblastoma
CVCL_1450 
Half Maximal Inhibitory Concentration (IC50) 0.2119 nM
HT-3 cells
Cervical carcinoma
CVCL_1293 
Half Maximal Inhibitory Concentration (IC50) 0.2738 nM
NTERA-2-cl-D1 cells
Teratocarcinoma
CVCL_3407 
Half Maximal Inhibitory Concentration (IC50) 0.3192 nM
EW-3 cells
Ewing sarcoma
CVCL_1216 
Half Maximal Inhibitory Concentration (IC50) 0.32 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[21]
Half Maximal Inhibitory Concentration (IC50) 0.32 nM
Huh-7 cells
Adult hepatocellular carcinoma
CVCL_0336 
[21]
Half Maximal Inhibitory Concentration (IC50) 0.32 nM
LN-229 cells
Glioblastoma
CVCL_0393 
[21]
Half Maximal Inhibitory Concentration (IC50) 0.32 nM
LoVo cells
Colon adenocarcinoma
CVCL_0399 
[21]
Half Maximal Inhibitory Concentration (IC50) 0.32 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[21]
Half Maximal Inhibitory Concentration (IC50) 0.32 nM
MHCC97H cells
Hepatocellular carcinoma
CVCL_4972 
[21]
Half Maximal Inhibitory Concentration (IC50) 0.3582 nM
H9 cells
Sezary syndrome
CVCL_1240 
Half Maximal Inhibitory Concentration (IC50) 0.4281 nM
COLO-800 cells
Cutaneous melanoma
CVCL_1135 
Half Maximal Inhibitory Concentration (IC50) 0.4292 nM
CTB-1 cells
Diffuse large B-cell lymphoma
CVCL_1149 
Half Maximal Inhibitory Concentration (IC50) 0.441 nM
NKM-1 cells
Acute myeloid leukemia
CVCL_1607 
Half Maximal Inhibitory Concentration (IC50) 0.4809 nM
Daoy cells
Medulloblastoma
CVCL_1167 
Half Maximal Inhibitory Concentration (IC50) 0.5 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[22]
Half Maximal Inhibitory Concentration (IC50) 0.513 nM
MC-IXC cells
Askin tumor
CVCL_1398 
Half Maximal Inhibitory Concentration (IC50) 0.5292 nM
NCI-H1048 cells
Lung small cell carcinoma
CVCL_1453 
Half Maximal Inhibitory Concentration (IC50) 0.5392 nM
FaDu cells
Hypopharyngeal squamous cell carcinoma
CVCL_1218 
Half Maximal Inhibitory Concentration (IC50) 0.5566 nM
EW-22 cells
Ewing sarcoma
CVCL_1214 
Half Maximal Inhibitory Concentration (IC50) 0.56 nM
HEK293 cells
Normal
CVCL_0045 
[23]
Half Maximal Inhibitory Concentration (IC50) 0.5694 nM
NB69 cells
Neuroblastoma
CVCL_1448 
Half Maximal Inhibitory Concentration (IC50) 0.5865 nM
LU-134-A cells
Lung small cell carcinoma
CVCL_1387 
Half Maximal Inhibitory Concentration (IC50) 0.6 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[20]
Half Maximal Inhibitory Concentration (IC50) 0.6022 nM
DoHH2 CDX model cells
Diffuse large B-cell lymphoma germinal center B-cell type
CVCL_1179 
Half Maximal Inhibitory Concentration (IC50) 0.6143 nM
NB10 cells
Neuroblastoma
CVCL_1441 
Half Maximal Inhibitory Concentration (IC50) 0.6154 nM
H4 cells
Neuroglioma
CVCL_1239 
Half Maximal Inhibitory Concentration (IC50) 0.7 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[24]
Half Maximal Inhibitory Concentration (IC50) 0.701 nM
GR-ST cells
B acute lymphoblastic leukemia
CVCL_1236 
Half Maximal Inhibitory Concentration (IC50) 0.7058 nM
MV4-11 cells
Childhood acute monocytic leukemia
CVCL_0064 
Half Maximal Inhibitory Concentration (IC50) 0.7058 nM
GOTO cells
Adrenal gland neuroblastoma
CVCL_1234 
Half Maximal Inhibitory Concentration (IC50) 0.7318 nM
MOLT-16 cells
T acute lymphoblastic leukemia
CVCL_1424 
Half Maximal Inhibitory Concentration (IC50) 0.7479 nM
NCI-H1623 cells
Lung adenocarcinoma
CVCL_1481 
Half Maximal Inhibitory Concentration (IC50) 0.7735 nM
ES5 cells
Ewing sarcoma
CVCL_1201 
Half Maximal Inhibitory Concentration (IC50) 0.7753 nM
QIMR-WIL cells
Acute myeloid leukemia
CVCL_1645 
Half Maximal Inhibitory Concentration (IC50) 0.7956 nM
ES8 cells
Ewing sarcoma
CVCL_1204 
Half Maximal Inhibitory Concentration (IC50) 0.8149 nM
A673 cells
Rhabdomyosarcoma
CVCL_0080 
Half Maximal Inhibitory Concentration (IC50) 0.8157 nM
DEL/BVR cells
Anaplastic large cell lymphoma
CVCL_1170 
Half Maximal Inhibitory Concentration (IC50) 0.8385 nM
HO-1-N-1 cells
Buccal mucosa squamous cell carcinoma
CVCL_1284 
Half Maximal Inhibitory Concentration (IC50) 0.84 nM
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
[25]
Half Maximal Inhibitory Concentration (IC50) 0.8418 nM
MHH-NB-11 cells
Neuroblastoma
CVCL_1412 
Half Maximal Inhibitory Concentration (IC50) 0.8814 nM
HuP-T4 cells
Pancreatic adenocarcinoma
CVCL_1300 
Half Maximal Inhibitory Concentration (IC50) 0.8868 nM
OCI-AML-2 cells
Adult acute myeloid leukemia
CVCL_1619 
Half Maximal Inhibitory Concentration (IC50) 0.8964 nM
647-V cells
Bladder carcinoma
CVCL_1049 
Half Maximal Inhibitory Concentration (IC50) 0.9022 nM
RS4
11 cells
Adult B acute lymphoblastic leukemia
CVCL_0093 
Half Maximal Inhibitory Concentration (IC50) 0.9054 nM
CTV-1 cells
T acute lymphoblastic leukemia
CVCL_1150 
Half Maximal Inhibitory Concentration (IC50) 0.9071 nM
NB14 cells
Neuroblastoma
CVCL_1444 
Half Maximal Inhibitory Concentration (IC50) 0.9311 nM
ES3 cells
Ewing sarcoma
CVCL_1199 
Half Maximal Inhibitory Concentration (IC50) 0.981 nM
PA-1 cells
Ovarian mixed germ cell tumor
CVCL_0479 
Half Maximal Inhibitory Concentration (IC50) 0.9836 nM
CAL-62 cells
Thyroid gland anaplastic carcinoma
CVCL_1112 
Half Maximal Inhibitory Concentration (IC50) 1 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[26]
Half Maximal Inhibitory Concentration (IC50) 1 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[27]
Half Maximal Inhibitory Concentration (IC50) 1 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[23]
Half Maximal Inhibitory Concentration (IC50) 1 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[28]
Half Maximal Inhibitory Concentration (IC50) 1 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[29]
Half Maximal Inhibitory Concentration (IC50) 1 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[30]
Half Maximal Inhibitory Concentration (IC50) 1 nM
NCI-H69 cells
Small cell lung carcinoma
CVCL_1579 
[31]
Half Maximal Inhibitory Concentration (IC50) 1.026 nM
CHP-212 cells
Neuroblastoma
CVCL_1125 
Half Maximal Inhibitory Concentration (IC50) 1.028 nM
NCI-H526 cells
Lung small cell carcinoma
CVCL_1569 
Half Maximal Inhibitory Concentration (IC50) 1.11 nM
KG-1 cells
Adult acute myeloid leukemia
CVCL_0374 
Half Maximal Inhibitory Concentration (IC50) 1.16 nM
SK-PN-DW cells
Primitive neuroectodermal tumor
CVCL_1703 
Half Maximal Inhibitory Concentration (IC50) 1.161 nM
DB cells
Diffuse large B-cell lymphoma
CVCL_1168 
Half Maximal Inhibitory Concentration (IC50) 1.188 nM
NCI-H1155 cells
Lung large cell carcinoma
CVCL_1456 
Half Maximal Inhibitory Concentration (IC50) 1.227 nM
SK-NEP-1 cells
Ewing sarcoma
CVCL_0631 
Half Maximal Inhibitory Concentration (IC50) 1.241 nM
SAS cells
Tongue squamous cell carcinoma
CVCL_1675 
Half Maximal Inhibitory Concentration (IC50) 1.398 nM
HOS cells
Osteosarcoma
CVCL_0312 
Half Maximal Inhibitory Concentration (IC50) 1.399 nM
HN cells
Cervical lymph node
CVCL_1283 
Half Maximal Inhibitory Concentration (IC50) 1.4 nM
Jurkat cells
T acute lymphoblastic leukemia
CVCL_0065 
[32]
Half Maximal Inhibitory Concentration (IC50) 1.4 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[33]
Half Maximal Inhibitory Concentration (IC50) 1.474 nM
ES4 cells
Ewing sarcoma
CVCL_1200 
Half Maximal Inhibitory Concentration (IC50) 1.502 nM
8-MG-BA cells
Glioblastoma
CVCL_1052 
Half Maximal Inhibitory Concentration (IC50) 1.527 nM
GAMG cells
Glioblastoma
CVCL_1226 
Half Maximal Inhibitory Concentration (IC50) 1.534 nM
ALL-PO cells
B acute lymphoblastic leukemia
CVCL_1069 
Half Maximal Inhibitory Concentration (IC50) 1.535 nM
KE-37 cells
T acute lymphoblastic leukemia
CVCL_1327 
Half Maximal Inhibitory Concentration (IC50) 1.557 nM
NOMO-1 cells
Acute monocytic leukemia
CVCL_1609 
Half Maximal Inhibitory Concentration (IC50) 1.6 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[34]
Half Maximal Inhibitory Concentration (IC50) 1.6 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[35]
Half Maximal Inhibitory Concentration (IC50) 1.614 nM
T24 cells
Bladder carcinoma
CVCL_0554 
Half Maximal Inhibitory Concentration (IC50) 1.616 nM
MOLT-4 cells
Adult T acute lymphoblastic leukemia
CVCL_0013 
Half Maximal Inhibitory Concentration (IC50) 1.634 nM
HD-MY-Z cells
Acute myeloid leukemia
CVCL_1273 
Half Maximal Inhibitory Concentration (IC50) 1.669 nM
A3-KAW cells
Diffuse large B-cell lymphoma
CVCL_1062 
Half Maximal Inhibitory Concentration (IC50) 1.699 nM
NCI-H510A cells
Lung small cell carcinoma
CVCL_1565 
Half Maximal Inhibitory Concentration (IC50) 1.725 nM
RPMI-8866 cells
Chronic myelogenous leukemia
CVCL_1668 
Half Maximal Inhibitory Concentration (IC50) 1.749 nM
A4-Fuk cells
B acute lymphoblastic leukemia
CVCL_1064 
Half Maximal Inhibitory Concentration (IC50) 1.759 nM
GT3TKB cells
Lung squamous cell carcinoma
CVCL_1237 
Half Maximal Inhibitory Concentration (IC50) 1.777 nM
EW-1 cells
Ewing sarcoma
CVCL_1208 
Half Maximal Inhibitory Concentration (IC50) 1.787 nM
MOLT-13 cells
T acute lymphoblastic leukemia
CVCL_1422 
Half Maximal Inhibitory Concentration (IC50) <1.8 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[36]
Half Maximal Inhibitory Concentration (IC50) <1.8 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[36]
Half Maximal Inhibitory Concentration (IC50) <1.8 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[36]
Half Maximal Inhibitory Concentration (IC50) 1.814 nM
HCE-4 cells
Esophageal squamous cell carcinoma
CVCL_1271 
Half Maximal Inhibitory Concentration (IC50) 1.822 nM
BHT-101 cells
Anaplastic thyroid carcinoma
CVCL_1085 
Half Maximal Inhibitory Concentration (IC50) 1.853 nM
BB65-RCC cells
Renal cell carcinoma
CVCL_1078 
Half Maximal Inhibitory Concentration (IC50) 1.869 nM
U-251MG cells
Astrocytoma
CVCL_0021 
Half Maximal Inhibitory Concentration (IC50) 1.869 nM
L-363 cells
Plasma cell myeloma
CVCL_1357 
Half Maximal Inhibitory Concentration (IC50) 1.925 nM
NB5 cells
Neuroblastoma
CVCL_8822 
Half Maximal Inhibitory Concentration (IC50) <10 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[37]
Half Maximal Inhibitory Concentration (IC50) <10 nM
SK-BR-3 cells
Breast adenocarcinoma
CVCL_0033 
[38]
Half Maximal Inhibitory Concentration (IC50) <10 nM
ZR-75-1 cells
Invasive breast carcinoma
CVCL_0588 
[38]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
MOLT-4 cells
Adult T acute lymphoblastic leukemia
CVCL_0013 
[39]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
U-251MG cells
Astrocytoma
CVCL_0021 
[40]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[41]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[39]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[42]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[43]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[44]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[45]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[46]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[47]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[48]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[49]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[50]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[51]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[52]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[53]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[54]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[55]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[56]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[57]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[58]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[59]
Half Maximal Inhibitory Concentration (IC50) <10 nM
BT-20 cells
Invasive breast carcinoma of no special type
CVCL_0178 
[38]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
[39]
Half Maximal Inhibitory Concentration (IC50) <10 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[38]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
Hep 3B2.1-7 cells
Childhood hepatocellular carcinoma
CVCL_0326 
[60]
Half Maximal Inhibitory Concentration (IC50) <10 nM
MDA-MB-453 cells
Breast adenocarcinoma
CVCL_0418 
[38]
Half Maximal Inhibitory Concentration (IC50) <10 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[38]
Half Maximal Cell Growth Inhibitory Concentration (GI50) <10 nM
SF539 cells
Gliosarcoma
CVCL_1691 
[61]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
SF539 cells
Gliosarcoma
CVCL_1691 
[42]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
SF539 cells
Gliosarcoma
CVCL_1691 
[45]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
SF539 cells
Gliosarcoma
CVCL_1691 
[48]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
SF539 cells
Gliosarcoma
CVCL_1691 
[49]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
SF539 cells
Gliosarcoma
CVCL_1691 
[50]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
SF539 cells
Gliosarcoma
CVCL_1691 
[52]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
SF539 cells
Gliosarcoma
CVCL_1691 
[53]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
SF539 cells
Gliosarcoma
CVCL_1691 
[54]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
SF539 cells
Gliosarcoma
CVCL_1691 
[55]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
SF539 cells
Gliosarcoma
CVCL_1691 
[56]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
SF539 cells
Gliosarcoma
CVCL_1691 
[57]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
SF539 cells
Gliosarcoma
CVCL_1691 
[58]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
SF539 cells
Gliosarcoma
CVCL_1691 
[59]
Half Maximal Inhibitory Concentration (IC50) <10 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[38]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
SF268 cells
Astrocytoma
CVCL_1689 
[46]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
SF268 cells
Astrocytoma
CVCL_1689 
[47]
Half Maximal Inhibitory Concentration (IC50) <10 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[38]
Half Maximal Inhibitory Concentration (IC50) <10 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[37]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[41]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[41]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[60]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[52]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[62]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[53]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[63]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[57]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[58]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
Panel NCI-60 cells
Normal
Undisclosed [64]
Half Maximal Inhibitory Concentration (IC50) <10 nM
Hs 683 cells
Glioma
CVCL_0844 
[37]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
DMS-273 cells
Small cell lung carcinoma
CVCL_1176 
[39]
Half Maximal Cell Growth Inhibitory Concentration (GI50) <10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[61]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[42]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[43]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[44]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[45]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[46]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[47]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[48]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[49]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[50]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[51]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[52]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[53]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[54]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[55]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[57]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[58]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[59]
Half Maximal Cell Growth Inhibitory Concentration (GI50) <10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[61]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[42]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[43]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[44]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[45]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[46]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[47]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[65]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[48]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[49]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[50]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[52]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[53]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[54]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[55]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[56]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[57]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[58]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10 nM
UACC-62 cells
Melanoma
CVCL_1780 
[59]
Half Maximal Inhibitory Concentration (IC50) <10 nM
MCF-12A cells
Normal
CVCL_3744 
[38]
Half Maximal Inhibitory Concentration (IC50) 10 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[66]
Half Maximal Inhibitory Concentration (IC50) 10 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[37]
Half Maximal Inhibitory Concentration (IC50) 10 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[67]
Half Maximal Inhibitory Concentration (IC50) 10 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[68]
Half Maximal Inhibitory Concentration (IC50) 10 nM
SK-MES-1 cells
Lung squamous cell carcinoma
CVCL_0630 
[68]
Half Maximal Inhibitory Concentration (IC50) 10 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[69]
Half Maximal Inhibitory Concentration (IC50) 10 nM
Human umbilical vein endothelial cells(HUVEC)
Normal
Undisclosed [70]
Half Maximal Inhibitory Concentration (IC50) 10 nM
HEK293 cells
Normal
CVCL_0045 
[71]
Half Maximal Inhibitory Concentration (IC50) 10 nM
GLC4 cells
Lung small cell carcinoma
CVCL_0279 
[72]
Half Maximal Inhibitory Concentration (IC50) 10 nM
KB 3-1 cells
Cervical epithelial carcinoma
CVCL_2088 
[73]
Half Maximal Inhibitory Concentration (IC50) 10 nM
P388 cells
Lymphoma
CVCL_7222 
[73]
Half Maximal Inhibitory Concentration (IC50) 10.12 nM
A388 cells
Skin squamous cell carcinoma
CVCL_1063 
Half Maximal Inhibitory Concentration (IC50) 10.51 nM
Ramos-2G6-4C10 cells
Burkitt lymphoma
CVCL_1646 
Half Maximal Inhibitory Concentration (IC50) 10.56 nM
IST-MES1 cells
Pleural epithelioid mesothelioma
CVCL_1311 
Half Maximal Inhibitory Concentration (IC50) 10.59 nM
KGN cells
Ovarian granulosa cell tumor
CVCL_0375 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10.64 nM
UACC-62 cells
Melanoma
CVCL_1780 
[39]
Half Maximal Inhibitory Concentration (IC50) 10.78 nM
SK-MES-1 cells
Lung squamous cell carcinoma
CVCL_0630 
Half Maximal Inhibitory Concentration (IC50) <100 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[74]
Half Maximal Inhibitory Concentration (IC50) <100 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[74]
Half Maximal Inhibitory Concentration (IC50) <100 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[75]
Half Maximal Inhibitory Concentration (IC50) <100 nM
Huh-7 cells
Adult hepatocellular carcinoma
CVCL_0336 
[74]
Half Maximal Inhibitory Concentration (IC50) <100 nM
Huh-7 cells
Adult hepatocellular carcinoma
CVCL_0336 
[75]
Half Maximal Inhibitory Concentration (IC50) <100 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[74]
Half Maximal Inhibitory Concentration (IC50) <100 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[75]
Half Maximal Inhibitory Concentration (IC50) <100 nM
Mahlavu cells
Hepatoma
CVCL_0405 
[74]
Half Maximal Inhibitory Concentration (IC50) <100 nM
FOCUS cells
Hepatocellular carcinoma
CVCL_7955 
[74]
Half Maximal Inhibitory Concentration (IC50) 100 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[76]
Half Maximal Inhibitory Concentration (IC50) 100 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[77]
Half Maximal Inhibitory Concentration (IC50) 100 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[78]
Half Maximal Inhibitory Concentration (IC50) 100 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[79]
Half Maximal Inhibitory Concentration (IC50) 100 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[80]
Half Maximal Inhibitory Concentration (IC50) 100 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[80]
Half Maximal Inhibitory Concentration (IC50) 100 nM
Huh-7 cells
Adult hepatocellular carcinoma
CVCL_0336 
[81]
Half Maximal Inhibitory Concentration (IC50) 100 nM
CNE-2 cells
Normal
CVCL_6889 
[82]
Half Maximal Inhibitory Concentration (IC50) <1000 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[83]
Half Maximal Inhibitory Concentration (IC50) <1000 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[75]
Half Maximal Inhibitory Concentration (IC50) <1000 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[67]
Half Maximal Inhibitory Concentration (IC50) <1000 nM
Hep 3B2.1-7 cells
Childhood hepatocellular carcinoma
CVCL_0326 
[75]
Half Maximal Inhibitory Concentration (IC50) <1000 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[67]
Half Maximal Inhibitory Concentration (IC50) <1000 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[67]
Half Maximal Inhibitory Concentration (IC50) <1000 nM
Mahlavu cells
Hepatoma
CVCL_0405 
[75]
Half Maximal Inhibitory Concentration (IC50) <1000 nM
SNU-475 cells
Hepatocellular carcinoma
CVCL_0497 
[75]
Half Maximal Inhibitory Concentration (IC50) <1000 nM
MFE-296 cells
Endometrial adenocarcinoma
CVCL_1406 
[67]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 1000 nM
CEM/C2 cells
T acute lymphoblastic leukemia
CVCL_3497 
[84]
Half Maximal Inhibitory Concentration (IC50) <1000 nM
FOCUS cells
Hepatocellular carcinoma
CVCL_7955 
[67]
Half Maximal Inhibitory Concentration (IC50) <1000 nM
FOCUS cells
Hepatocellular carcinoma
CVCL_7955 
[75]
Half Maximal Inhibitory Concentration (IC50) <1000 nM
QSG-7701 cells
Endocervical adenocarcinoma
CVCL_6944 
[83]
Half Maximal Inhibitory Concentration (IC50) 1000 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[85]
Half Maximal Inhibitory Concentration (IC50) 1000 nM
Raji cells
EBV-related Burkitt lymphoma
CVCL_0511 
[86]
Half Maximal Inhibitory Concentration (IC50) 1000 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[87]
Half Maximal Inhibitory Concentration (IC50) 1000 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[88]
Half Maximal Inhibitory Concentration (IC50) 1000 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[76]
Half Maximal Inhibitory Concentration (IC50) >1000 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[31]
Half Maximal Cell Growth Inhibitory Concentration (GI50) >1000 nM
CEM/C2 cells
T acute lymphoblastic leukemia
CVCL_3497 
[41]
Half Maximal Inhibitory Concentration (IC50) 10000 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[89]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
MIA PaCa-2 cells (MSLN expression)
Pancreatic ductal adenocarcinoma
CVCL_0428 
[90]
Half Maximal Inhibitory Concentration (IC50) 10000 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[91]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
Peripheral blood mononuclear cells
Normal
Undisclosed [90]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
SMMC-7721 cells
Hepatocellular carcinoma
CVCL_0534 
[92]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
RPMI-8402 cells
T acute lymphoblastic leukemia
CVCL_1667 
[73]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
P388 cells
Lymphoma
CVCL_7222 
[93]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
P388 cells
Lymphoma
CVCL_7222 
[94]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
P388 cells
Lymphoma
CVCL_7222 
[95]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
P388CPT45 cells
Lymphoma
CVCL_D638 
[96]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
P388CPT45 cells
Lymphoma
CVCL_D638 
[97]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
CPT-K5 cells
T acute lymphoblastic leukemia
CVCL_2878 
[96]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
CPT-K5 cells
T acute lymphoblastic leukemia
CVCL_2878 
[93]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
CPT-K5 cells
T acute lymphoblastic leukemia
CVCL_2878 
[94]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
CPT-K5 cells
T acute lymphoblastic leukemia
CVCL_2878 
[97]
Half Maximal Inhibitory Concentration (IC50) >100000 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[70]
Half Maximal Inhibitory Concentration (IC50) >100000 nM
SH-SY5Y cells
Bone marrow neuroblastoma
CVCL_0019 
[98]
Half Maximal Inhibitory Concentration (IC50) 10070 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[99]
Half Maximal Inhibitory Concentration (IC50) 1009.34 nM
NCI-H727 cells
Lung carcinoid tumor
CVCL_1584 
Half Maximal Inhibitory Concentration (IC50) 1010 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[100]
Half Maximal Inhibitory Concentration (IC50) 1010 nM
HEK293 cells
Normal
CVCL_0045 
[101]
Half Maximal Inhibitory Concentration (IC50) 10100 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[102]
Half Maximal Inhibitory Concentration (IC50) 102.32 nM
WM-115 cells
Melanoma
CVCL_0040 
Half Maximal Inhibitory Concentration (IC50) 102.97 nM
KP-N-YN cells
Adrenal gland neuroblastoma
CVCL_1341 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 1030 nM
BT-483 cells
Ductal carcinoma
CVCL_2319 
[103]
Half Maximal Inhibitory Concentration (IC50) 1040 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[104]
Half Maximal Inhibitory Concentration (IC50) 105.42 nM
NCI-H358 cells
Minimally invasive lung adenocarcinoma
CVCL_1559 
Half Maximal Inhibitory Concentration (IC50) 106.62 nM
SK-N-FI cells
Neuroblastoma
CVCL_1702 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 106.66 nM
NCI-H322M cells
Minimally invasive lung adenocarcinoma
CVCL_1557 
[39]
Half Maximal Inhibitory Concentration (IC50) 1060 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[101]
Half Maximal Inhibitory Concentration (IC50) 1060 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[105]
Half Maximal Inhibitory Concentration (IC50) 1060 nM
HFL1 cells
Normal
CVCL_0298 
[106]
Half Maximal Inhibitory Concentration (IC50) 107.08 nM
BEN cells
Lung non-small cell carcinoma
CVCL_1082 
Half Maximal Inhibitory Concentration (IC50) 1070 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[87]
Half Maximal Inhibitory Concentration (IC50) 1077.74 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
Half Maximal Inhibitory Concentration (IC50) 108.94 nM
BALL-1 cells
B acute lymphoblastic leukemia
CVCL_1075 
Half Maximal Inhibitory Concentration (IC50) 1080 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[88]
Half Maximal Inhibitory Concentration (IC50) 1080 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[107]
Half Maximal Inhibitory Concentration (IC50) 1080 nM
SMMC-7721 cells
Hepatocellular carcinoma
CVCL_0534 
[108]
Half Maximal Inhibitory Concentration (IC50) 109.27 nM
COLO-741 cells
Melanoma
CVCL_1133 
Half Maximal Inhibitory Concentration (IC50) 109.97 nM
TGBC1TKB cells
Gallbladder undifferentiated carcinoma
CVCL_1769 
Half Maximal Inhibitory Concentration (IC50) 1093.19 nM
HT-1197 cells
Recurrent bladder carcinoma
CVCL_1291 
Half Maximal Inhibitory Concentration (IC50) 11 nM
A-431 cells
Skin squamous cell carcinoma
CVCL_0037 
[109]
Half Maximal Inhibitory Concentration (IC50) 11 nM
ADR5000 cells
Leukemia
CVCL_D544 
[110]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 11.07 nM
U-251MG cells
Astrocytoma
CVCL_0021 
[39]
Half Maximal Inhibitory Concentration (IC50) 11.26 nM
KMOE-2 cells
Erythroleukemia
CVCL_1332 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 11.35 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[39]
Half Maximal Inhibitory Concentration (IC50) 11.5 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[111]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 11.51 nM
SF268 cells
Astrocytoma
CVCL_1689 
[39]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 11.53 nM
SF-295 cells
Glioblastoma
CVCL_1690 
[39]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 11.56 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[39]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 11.64 nM
ACHN cells
Renal adenocarcinoma
CVCL_1067 
[39]
Half Maximal Inhibitory Concentration (IC50) 11.65 nM
YH-13 cells
Glioblastoma
CVCL_1795 
Half Maximal Inhibitory Concentration (IC50) 11.67 nM
COLO-829 cells
Cutaneous melanoma
CVCL_1137 
Half Maximal Inhibitory Concentration (IC50) 11.7 nM
HSC-2 cells
Oral cavity squamous cell carcinoma
CVCL_1287 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 11.8 nM
Caki-1 cells
Clear cell renal cell carcinoma
CVCL_0234 
[39]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 11.97 nM
NCI-ADR-RES cells
High grade ovarian serous adenocarcinoma
CVCL_1452 
[39]
Half Maximal Inhibitory Concentration (IC50) 110 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[77]
Half Maximal Inhibitory Concentration (IC50) 110 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[112]
Half Maximal Inhibitory Concentration (IC50) 110 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[113]
Half Maximal Inhibitory Concentration (IC50) 110 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[106]
Half Maximal Inhibitory Concentration (IC50) 110 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[114]
Half Maximal Inhibitory Concentration (IC50) 110 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[115]
Half Maximal Inhibitory Concentration (IC50) 110.1 nM
NCI-H1395 cells
Lung adenocarcinoma
CVCL_1467 
Half Maximal Inhibitory Concentration (IC50) 1100 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[116]
Half Maximal Inhibitory Concentration (IC50) 11120 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[117]
Half Maximal Inhibitory Concentration (IC50) 11170 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[118]
Half Maximal Inhibitory Concentration (IC50) 113.08 nM
no-11 cells
Glioblastoma
CVCL_3076 
Half Maximal Inhibitory Concentration (IC50) 113.62 nM
RCC10RGB cells
Renal cell carcinoma
CVCL_1647 
Half Maximal Inhibitory Concentration (IC50) 11360 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[119]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 114.82 nM
BT-549 cells
Breast ductal carcinoma
CVCL_1092 
[39]
Half Maximal Inhibitory Concentration (IC50) 115.84 nM
Huh-7 cells
Adult hepatocellular carcinoma
CVCL_0336 
Half Maximal Inhibitory Concentration (IC50) 115.96 nM
UACC-257 cells
Melanoma
CVCL_1779 
Half Maximal Inhibitory Concentration (IC50) 116.78 nM
BxPC-3 CDX model cells
Pancreatic ductal adenocarcinoma
CVCL_0186 
Half Maximal Inhibitory Concentration (IC50) 11620 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[120]
Half Maximal Inhibitory Concentration (IC50) 117.2 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[121]
Half Maximal Inhibitory Concentration (IC50) 1170 nM
KATO III cells
Down syndrome
CVCL_0371 
Half Maximal Inhibitory Concentration (IC50) 1180 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[100]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 12 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[122]
Half Maximal Inhibitory Concentration (IC50) 12 nM
IA-LM cells
Lung large cell carcinoma
CVCL_1302 
Half Maximal Inhibitory Concentration (IC50) 12 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[31]
Half Maximal Inhibitory Concentration (IC50) 12 nM
Human umbilical vein endothelial cells(HUVEC)
Normal
Undisclosed [123]
Half Maximal Inhibitory Concentration (IC50) 12.24 nM
TGBC11TKB cells
Gastric carcinoma
CVCL_1768 
Half Maximal Inhibitory Concentration (IC50) 12.49 nM
GP5d cells
Colon adenocarcinoma
CVCL_1235 
Half Maximal Inhibitory Concentration (IC50) 12.65 nM
HuO-3N1 cells
Osteosarcoma
CVCL_1297 
Half Maximal Inhibitory Concentration (IC50) 12.76 nM
A-172 cells
Glioblastoma
CVCL_0131 
Half Maximal Inhibitory Concentration (IC50) 12.86 nM
HCC38 cells
Breast ductal carcinoma
CVCL_1267 
Half Maximal Inhibitory Concentration (IC50) 12.98 nM
NCI-H2122 cells
Lung adenocarcinoma
CVCL_1531 
Half Maximal Inhibitory Concentration (IC50) 120 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[98]
Half Maximal Inhibitory Concentration (IC50) 120 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[124]
Half Maximal Inhibitory Concentration (IC50) 120 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[125]
Half Maximal Inhibitory Concentration (IC50) 120 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[126]
Half Maximal Inhibitory Concentration (IC50) 120 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[70]
Half Maximal Inhibitory Concentration (IC50) 120 nM
LX-1 cells
Lung carcinoma
CVCL_5791 
[127]
Half Maximal Inhibitory Concentration (IC50) 120.28 nM
BB49-HNC cells
Floor of mouth squamous cell carcinoma
CVCL_1077 
Half Maximal Inhibitory Concentration (IC50) 1200 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[128]
Half Maximal Inhibitory Concentration (IC50) 1200 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[129]
Half Maximal Inhibitory Concentration (IC50) 1200 nM
NCI-H1975 cells
Lung adenocarcinoma
CVCL_1511 
[130]
Half Maximal Inhibitory Concentration (IC50) 12000 nM
NIH3T3 cells
Normal
CVCL_0594 
[131]
Half Maximal Inhibitory Concentration (IC50) 121 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[132]
Half Maximal Inhibitory Concentration (IC50) 121.91 nM
CAS-1 cells
Glioblastoma
CVCL_1117 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 122.18 nM
HOP-18 cells
Non-small cell lung adenocarcinoma
CVCL_H642 
[39]
Half Maximal Inhibitory Concentration (IC50) 1220 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[133]
Half Maximal Inhibitory Concentration (IC50) 1220 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[133]
Half Maximal Inhibitory Concentration (IC50) 1220 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[133]
Half Maximal Inhibitory Concentration (IC50) 1220 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[133]
Half Maximal Inhibitory Concentration (IC50) 124.47 nM
LAN-6 cells
Neuroblastoma
CVCL_1363 
Half Maximal Inhibitory Concentration (IC50) 1240 nM
RD cells
Rhabdomyosarcoma
CVCL_1649 
[134]
Half Maximal Inhibitory Concentration (IC50) 1240 nM
RD cells
Rhabdomyosarcoma
CVCL_1649 
[135]
Half Maximal Inhibitory Concentration (IC50) 12500 nM
Bel-7402 cells
Hepatoma
CVCL_5492 
[136]
Half Maximal Inhibitory Concentration (IC50) 12500 nM
Bel-7402 cells
Hepatoma
CVCL_5492 
[137]
Half Maximal Inhibitory Concentration (IC50) 126 nM
L1210 cells
Lymphoblastic leukemia
CVCL_0382 
Half Maximal Inhibitory Concentration (IC50) 126.89 nM
EFM-19 cells
Breast ductal carcinoma
CVCL_0253 
Half Maximal Inhibitory Concentration (IC50) 1270 nM
BGC-823 cells
Stomach adenocarcinoma
CVCL_3360 
[138]
Half Maximal Inhibitory Concentration (IC50) 127000 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[139]
Half Maximal Inhibitory Concentration (IC50) 12750 nM
BT474-M1 cells
Invasive breast carcinoma
CVCL_0179 
[38]
Half Maximal Inhibitory Concentration (IC50) 128.79 nM
SNU-423 cells
Hepatocellular carcinoma
CVCL_0366 
Half Maximal Inhibitory Concentration (IC50) 1290 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[118]
Half Maximal Inhibitory Concentration (IC50) <13 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[140]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 13 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[54]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 13 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[55]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 13 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[56]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 13 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[61]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 13 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[59]
Half Maximal Inhibitory Concentration (IC50) <13 nM
HCT-8 cells
Ileocecal adenocarcinoma
CVCL_2478 
[140]
Half Maximal Inhibitory Concentration (IC50) 13 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[88]
Half Maximal Inhibitory Concentration (IC50) 13 nM
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
[19]
Half Maximal Inhibitory Concentration (IC50) 13 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[31]
Half Maximal Inhibitory Concentration (IC50) 13 nM
A375 cells
Amelanotic melanoma
CVCL_0132 
[141]
Half Maximal Inhibitory Concentration (IC50) 13 nM
P388 cells
Lymphoma
CVCL_7222 
[142]
Half Maximal Inhibitory Concentration (IC50) 13 nM
P388 cells
Lymphoma
CVCL_7222 
[143]
Half Maximal Inhibitory Concentration (IC50) 13.12 nM
JEG-3 cells
Gestational choriocarcinoma
CVCL_0363 
Half Maximal Inhibitory Concentration (IC50) 13.18 nM
KYSE-180 cells
Esophageal squamous cell carcinoma
CVCL_1349 
Half Maximal Inhibitory Concentration (IC50) 13.34 nM
Detroit 562 cells
Pharyngeal squamous cell carcinoma
CVCL_1171 
Half Maximal Inhibitory Concentration (IC50) 13.37 nM
C32 cells
Amelanotic melanoma
CVCL_1097 
Half Maximal Inhibitory Concentration (IC50) 13.52 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
Half Maximal Inhibitory Concentration (IC50) 13.52 nM
HH cells
T-cell non-Hodgkin lymphoma
CVCL_1280 
Half Maximal Inhibitory Concentration (IC50) 13.54 nM
U2OS cells
Osteosarcoma
CVCL_0042 
Half Maximal Inhibitory Concentration (IC50) 13.55 nM
NCI-H661 cells
Lung large cell carcinoma
CVCL_1577 
Half Maximal Inhibitory Concentration (IC50) 13.58 nM
PC-14 cells
Lung adenocarcinoma
CVCL_1640 
Half Maximal Inhibitory Concentration (IC50) 13.71 nM
NCI-H2170 cells
Lung squamous cell carcinoma
CVCL_1535 
Half Maximal Inhibitory Concentration (IC50) 13.82 nM
COLO-684 cells
Endometrial adenocarcinoma
CVCL_1132 
Half Maximal Inhibitory Concentration (IC50) 130 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[144]
Half Maximal Inhibitory Concentration (IC50) 130 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[24]
Half Maximal Inhibitory Concentration (IC50) 130 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[33]
Half Maximal Inhibitory Concentration (IC50) 130 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[145]
Half Maximal Inhibitory Concentration (IC50) 130 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[146]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 1300 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[147]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 1300 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[148]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 1300 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[149]
Half Maximal Inhibitory Concentration (IC50) 1300 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[22]
Half Maximal Inhibitory Concentration (IC50) 1300 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[150]
Half Maximal Inhibitory Concentration (IC50) 130000 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[151]
Half Maximal Inhibitory Concentration (IC50) 1310 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[152]
Half Maximal Inhibitory Concentration (IC50) 13200 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[82]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 1324.34 nM
TK-10 cells
Renal carcinoma
CVCL_1773 
[39]
Half Maximal Inhibitory Concentration (IC50) 134.42 nM
MDA-MB-415 cells
Breast adenocarcinoma
CVCL_0621 
Half Maximal Inhibitory Concentration (IC50) 134.47 nM
KARPAS-45 cells
T acute lymphoblastic leukemia
CVCL_1326 
Half Maximal Inhibitory Concentration (IC50) 1360 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[108]
Half Maximal Inhibitory Concentration (IC50) 13620 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[153]
Half Maximal Inhibitory Concentration (IC50) 13640 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[102]
Half Maximal Inhibitory Concentration (IC50) 1367.35 nM
HCC1395 cells
Breast ductal carcinoma
CVCL_1249 
Half Maximal Inhibitory Concentration (IC50) 1370 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[154]
Half Maximal Inhibitory Concentration (IC50) 1370 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[155]
Half Maximal Inhibitory Concentration (IC50) 1370 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[156]
Half Maximal Inhibitory Concentration (IC50) 13700 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[106]
Half Maximal Inhibitory Concentration (IC50) 1380 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[101]
Half Maximal Inhibitory Concentration (IC50) 14 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[157]
Half Maximal Inhibitory Concentration (IC50) 14 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[158]
Half Maximal Inhibitory Concentration (IC50) 14 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[159]
Half Maximal Inhibitory Concentration (IC50) 14 nM
L1210 cells
Lymphoblastic leukemia
CVCL_0382 
[160]
Half Maximal Inhibitory Concentration (IC50) 14 nM
Bel-7402 cells
Hepatoma
CVCL_5492 
[161]
Half Maximal Inhibitory Concentration (IC50) 14 nM
P388 cells
Lymphoma
CVCL_7222 
[162]
Half Maximal Inhibitory Concentration (IC50) 14 nM
P388 cells
Lymphoma
CVCL_7222 
[96]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 14.03 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[39]
Half Maximal Inhibitory Concentration (IC50) 14.09 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
Half Maximal Inhibitory Concentration (IC50) 14.11 nM
MZ2-MEL cells
Melanoma
CVCL_1435 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 14.49 nM
SF539 cells
Gliosarcoma
CVCL_1691 
[39]
Half Maximal Inhibitory Concentration (IC50) 14.54 nM
JAR cells
Gestational choriocarcinoma
CVCL_0360 
Half Maximal Inhibitory Concentration (IC50) 14.55 nM
TI-73 cells
Normal
CVCL_3605 
Half Maximal Inhibitory Concentration (IC50) 14.75 nM
CFPAC-1 cells
Pancreatic ductal adenocarcinoma
CVCL_1119 
Half Maximal Inhibitory Concentration (IC50) 14.88 nM
RT-112 cells
Bladder carcinoma
CVCL_1670 
Half Maximal Inhibitory Concentration (IC50) 14.91 nM
RO82-W-1 cells
Thyroid gland follicular carcinoma
CVCL_0582 
Half Maximal Inhibitory Concentration (IC50) 14.93 nM
LoVo cells
Colon adenocarcinoma
CVCL_0399 
Half Maximal Inhibitory Concentration (IC50) 14.95 nM
Capan-1 cells
Pancreatic ductal adenocarcinoma
CVCL_0237 
Half Maximal Inhibitory Concentration (IC50) 14.95 nM
NCI-H1651 cells
Lung adenocarcinoma
CVCL_1484 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 14.96 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[39]
Half Maximal Inhibitory Concentration (IC50) 140 nM
A-172 cells
Glioblastoma
CVCL_0131 
Half Maximal Inhibitory Concentration (IC50) 140 nM
BEL-7404 tumor cells
Endocervical adenocarcinoma
CVCL_6568 
[76]
Half Maximal Inhibitory Concentration (IC50) 140 nM
L02 cells
Cervical carcinoma
CVCL_6926 
[163]
Half Maximal Inhibitory Concentration (IC50) 1400 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[164]
Half Maximal Inhibitory Concentration (IC50) 14000 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[165]
Half Maximal Inhibitory Concentration (IC50) 14000000 nM
DLD-1 cells
Colon adenocarcinoma
CVCL_0248 
[166]
Half Maximal Inhibitory Concentration (IC50) 1410 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[138]
Half Maximal Inhibitory Concentration (IC50) 1414.4 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[121]
Half Maximal Inhibitory Concentration (IC50) 14200 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[116]
Half Maximal Inhibitory Concentration (IC50) 144.23 nM
MKN7 cells
Gastric tubular adenocarcinoma
CVCL_1417 
Half Maximal Inhibitory Concentration (IC50) 144.69 nM
Hs 578T cells
Invasive breast carcinoma
CVCL_0332 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 145.21 nM
MDA-N cells
Breast carcinoma
CVCL_1910 
[39]
Half Maximal Inhibitory Concentration (IC50) 1460 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[167]
Half Maximal Inhibitory Concentration (IC50) 147.61 nM
TE-10 cells
Esophageal squamous cell carcinoma
CVCL_1760 
Half Maximal Inhibitory Concentration (IC50) 14760 nM
MDA-MB-468 cells
Breast adenocarcinoma
CVCL_0419 
[168]
Half Maximal Inhibitory Concentration (IC50) 148.3 nM
L-428 cells
Hodgkin lymphoma
CVCL_1361 
Half Maximal Inhibitory Concentration (IC50) 149.39 nM
NCI-H1650 cells
Lung adenocarcinoma
CVCL_1483 
Half Maximal Inhibitory Concentration (IC50) 15 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[169]
Half Maximal Inhibitory Concentration (IC50) 15 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[170]
Half Maximal Inhibitory Concentration (IC50) 15 nM
786-O cells
Renal cell carcinoma
CVCL_1051 
[171]
Half Maximal Inhibitory Concentration (IC50) 15 nM
L1210 cells
Lymphoblastic leukemia
CVCL_0382 
[172]
Half Maximal Inhibitory Concentration (IC50) 15 nM
KB 3-1 cells
Cervical epithelial carcinoma
CVCL_2088 
[93]
Half Maximal Inhibitory Concentration (IC50) 15 nM
KB 3-1 cells
Cervical epithelial carcinoma
CVCL_2088 
[95]
Half Maximal Inhibitory Concentration (IC50) 15 nM
U-373MG ATCC cells
Astrocytoma
CVCL_2219 
[37]
Half Maximal Inhibitory Concentration (IC50) 15.35 nM
A704 cells
Renal carcinoma
CVCL_1065 
Half Maximal Inhibitory Concentration (IC50) 15.74 nM
RD cells
Rhabdomyosarcoma
CVCL_1649 
Half Maximal Inhibitory Concentration (IC50) 15.75 nM
DSH1 cells
Bladder carcinoma
CVCL_1182 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 15.78 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[39]
Half Maximal Inhibitory Concentration (IC50) 15.8 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[132]
Half Maximal Inhibitory Concentration (IC50) 15.86 nM
MC116 cells
B-cell non-Hodgkin lymphoma
CVCL_1399 
Half Maximal Inhibitory Concentration (IC50) 150 nM
Huh-7 cells
Adult hepatocellular carcinoma
CVCL_0336 
[67]
Half Maximal Inhibitory Concentration (IC50) 150.08 nM
EW-18 cells
Ewing sarcoma
CVCL_1213 
Half Maximal Inhibitory Concentration (IC50) 150.28 nM
HCC 2998 cells
Colon adenocarcinoma
CVCL_1266 
Half Maximal Inhibitory Concentration (IC50) 150.37 nM
NCI-H1563 cells
Lung adenocarcinoma
CVCL_1475 
Half Maximal Inhibitory Concentration (IC50) 150.57 nM
CAL-72 cells
Osteosarcoma
CVCL_1113 
Half Maximal Inhibitory Concentration (IC50) 1500 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[173]
Half Maximal Inhibitory Concentration (IC50) >150000 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[174]
Half Maximal Inhibitory Concentration (IC50) >150000 nM
HGC-27 cells
Gastric carcinoma
CVCL_1279 
[174]
Half Maximal Inhibitory Concentration (IC50) >150000 nM
MGC-803 cells
Gastric cancer
CVCL_5334 
[174]
Half Maximal Inhibitory Concentration (IC50) >150000 nM
L02 cells
Cervical carcinoma
CVCL_6926 
[174]
Half Maximal Inhibitory Concentration (IC50) >150000 nM
HCCLM9 cells
Adult hepatocellular carcinoma
CVCL_A5CU 
[174]
Half Maximal Inhibitory Concentration (IC50) 151.26 nM
IGR-1 cells
Cutaneous melanoma
CVCL_1303 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 151.71 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[39]
Half Maximal Inhibitory Concentration (IC50) 1520 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[138]
Half Maximal Inhibitory Concentration (IC50) 15200 nM
FHCC-98 cells
Hepatocellular carcinoma
CVCL_L437 
[175]
Half Maximal Inhibitory Concentration (IC50) 1530 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[101]
Half Maximal Inhibitory Concentration (IC50) 1540 nM
LoVo cells
Colon adenocarcinoma
CVCL_0399 
[77]
Half Maximal Inhibitory Concentration (IC50) 1543.63 nM
SHP-77 cells
Small cell lung carcinoma
CVCL_1693 
Half Maximal Inhibitory Concentration (IC50) 1552.36 nM
A-431 cells
Skin squamous cell carcinoma
CVCL_0037 
Half Maximal Inhibitory Concentration (IC50) 1560 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[70]
Half Maximal Inhibitory Concentration (IC50) 157.32 nM
NCI-H1770 cells
Lung non-small cell carcinoma
CVCL_1493 
Half Maximal Inhibitory Concentration (IC50) 1570 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[176]
Half Maximal Inhibitory Concentration (IC50) 1570 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[177]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 158.85 nM
HCC 2998 cells
Colon adenocarcinoma
CVCL_1266 
[39]
Half Maximal Inhibitory Concentration (IC50) 159 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[178]
Half Maximal Inhibitory Concentration (IC50) 159 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[179]
Half Maximal Inhibitory Concentration (IC50) 1590 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[180]
Half Maximal Inhibitory Concentration (IC50) 16 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[181]
Half Maximal Inhibitory Concentration (IC50) 16 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[182]
Half Maximal Inhibitory Concentration (IC50) 16 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[183]
Half Maximal Inhibitory Concentration (IC50) 16.13 nM
AGS cells
Gastric adenocarcinoma
CVCL_0139 
Half Maximal Inhibitory Concentration (IC50) 16.33 nM
TE-11 cells
Esophageal squamous cell carcinoma
CVCL_1761 
Half Maximal Inhibitory Concentration (IC50) 16.44 nM
LU-139 cells
Lung small cell carcinoma
CVCL_1390 
Half Maximal Inhibitory Concentration (IC50) 16.8 nM
NB7 cells
Neuroblastoma
CVCL_8824 
Half Maximal Inhibitory Concentration (IC50) 160 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[115]
Half Maximal Inhibitory Concentration (IC50) 1600 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[165]
Half Maximal Inhibitory Concentration (IC50) 1600 nM
KG-1 cells
Adult acute myeloid leukemia
CVCL_0374 
[184]
Half Maximal Inhibitory Concentration (IC50) 162 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[19]
Half Maximal Inhibitory Concentration (IC50) 162.01 nM
NCI-H520 cells
Lung squamous cell carcinoma
CVCL_1566 
Half Maximal Inhibitory Concentration (IC50) 1620 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[180]
Half Maximal Inhibitory Concentration (IC50) 16240 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[185]
Half Maximal Inhibitory Concentration (IC50) 16440 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[186]
Half Maximal Inhibitory Concentration (IC50) 165 nM
SK-MEL-2 cells (MEK inhibitor-resistant)
Melanoma
CVCL_0069 
[159]
Half Maximal Inhibitory Concentration (IC50) 166 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[187]
Half Maximal Inhibitory Concentration (IC50) 166 nM
HGC-27 cells
Gastric carcinoma
CVCL_1279 
[156]
Half Maximal Inhibitory Concentration (IC50) 1660 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[188]
Half Maximal Inhibitory Concentration (IC50) 1670 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[70]
Half Maximal Inhibitory Concentration (IC50) 168.37 nM
AsPC-1 cells
Pancreatic ductal adenocarcinoma
CVCL_0152 
Half Maximal Inhibitory Concentration (IC50) 169.17 nM
COLO-792 cells
Melanoma
CVCL_1134 
Half Maximal Inhibitory Concentration (IC50) 17 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[109]
Half Maximal Inhibitory Concentration (IC50) 17 nM
MKN45 cells
Gastric adenocarcinoma
CVCL_0434 
[157]
Half Maximal Inhibitory Concentration (IC50) 17 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[189]
Half Maximal Inhibitory Concentration (IC50) 17 nM
WiDr cells
Colon adenocarcinoma
CVCL_2760 
[157]
Half Maximal Inhibitory Concentration (IC50) 17.13 nM
SK-MEL-28 cells (BRAF inhibitor resistant)
Cutaneous melanoma
CVCL_0526 
Half Maximal Inhibitory Concentration (IC50) 17.34 nM
SNB-75 cells
Glioblastoma
CVCL_1706 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 17.38 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[56]
Half Maximal Inhibitory Concentration (IC50) 17.64 nM
BT-549 cells
Breast ductal carcinoma
CVCL_1092 
Half Maximal Inhibitory Concentration (IC50) 17.73 nM
D-392MG cells
Glioblastoma
CVCL_1158 
Half Maximal Inhibitory Concentration (IC50) 17.77 nM
SAOS-2 cells
Osteosarcoma
CVCL_0548 
Half Maximal Inhibitory Concentration (IC50) 17.86 nM
HT-144 cells
Melanoma
CVCL_0318 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 17.95 nM
NCI-H226 cells
Pleural epithelioid mesothelioma
CVCL_1544 
[39]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 170 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[190]
Half Maximal Inhibitory Concentration (IC50) 170 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[189]
Half Maximal Inhibitory Concentration (IC50) 170 nM
MDA-MB-361 cells
Breast adenocarcinoma
CVCL_0620 
[38]
Half Maximal Inhibitory Concentration (IC50) 170 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[191]
Half Maximal Inhibitory Concentration (IC50) 170 nM
4T1 cells
Mammary carcinoma
CVCL_0125 
[77]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 1700 nM
WiDr cells
Colon adenocarcinoma
CVCL_2760 
[147]
Half Maximal Inhibitory Concentration (IC50) 1700 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[184]
Half Maximal Inhibitory Concentration (IC50) 1700 nM
MRC5 cells
Normal
CVCL_0440 
[85]
Half Maximal Inhibitory Concentration (IC50) 1700 nM
MX1 cells
Breast carcinoma
CVCL_4774 
[192]
Half Maximal Inhibitory Concentration (IC50) 1710 nM
MDA-MB-468 cells
Breast adenocarcinoma
CVCL_0419 
[193]
Half Maximal Inhibitory Concentration (IC50) 1720 nM
RD cells
Rhabdomyosarcoma
CVCL_1649 
[152]
Half Maximal Inhibitory Concentration (IC50) 173.4 nM
NCI-H1573 cells
Lung adenocarcinoma
CVCL_1478 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 173.78 nM
Malme-3M cells
Melanoma
CVCL_1438 
[39]
Half Maximal Inhibitory Concentration (IC50) 174.04 nM
no-10 cells
Glioblastoma
CVCL_3075 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 176.6 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[39]
Half Maximal Inhibitory Concentration (IC50) 178.42 nM
NCI-H2126 cells
Lung large cell carcinoma
CVCL_1532 
Half Maximal Inhibitory Concentration (IC50) 178.5 nM
TE-6 cells
Esophageal squamous cell carcinoma
CVCL_1765 
Half Maximal Inhibitory Concentration (IC50) 178.95 nM
Calu-6 cells
Lung adenocarcinoma
CVCL_0236 
Half Maximal Inhibitory Concentration (IC50) 1780.55 nM
HT-1376 cells
Bladder carcinoma
CVCL_1292 
Half Maximal Inhibitory Concentration (IC50) 18 nM
SJSA-1 cells
Osteosarcoma
CVCL_1697 
Half Maximal Inhibitory Concentration (IC50) 18 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[194]
Half Maximal Inhibitory Concentration (IC50) 18 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[195]
Half Maximal Inhibitory Concentration (IC50) 18 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[196]
Half Maximal Inhibitory Concentration (IC50) 18 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[197]
Half Maximal Inhibitory Concentration (IC50) 18 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[198]
Half Maximal Inhibitory Concentration (IC50) 18 nM
NCI-H128 cells
Lung carcinoma
CVCL_1460 
[157]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 18.11 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[39]
Half Maximal Inhibitory Concentration (IC50) 18.13 nM
HEC-1 cells
Endometrial adenocarcinoma
CVCL_1274 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 18.16 nM
SNB-19 cells
Astrocytoma
CVCL_0535 
[39]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 18.2 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[56]
Half Maximal Inhibitory Concentration (IC50) 18.37 nM
LB831-BLC cells
Bladder carcinoma
CVCL_1370 
Half Maximal Inhibitory Concentration (IC50) 18.57 nM
SCC-15 cells
Squamous carcinoma
CVCL_1681 
Half Maximal Inhibitory Concentration (IC50) 18.71 nM
NCI-H1666 cells
Lung adenocarcinoma
CVCL_1485 
Half Maximal Inhibitory Concentration (IC50) 18.92 nM
DOK cells
Oral epithelial dysplasia
CVCL_1180 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 180 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[199]
Half Maximal Inhibitory Concentration (IC50) 180 nM
L1210 cells
Lymphoblastic leukemia
CVCL_0382 
Half Maximal Inhibitory Concentration (IC50) 180 nM
PANC-1 cells
Pancreatic ductal adenocarcinoma
CVCL_0480 
[200]
Half Maximal Inhibitory Concentration (IC50) 180 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[201]
Half Maximal Inhibitory Concentration (IC50) 180 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[202]
Half Maximal Inhibitory Concentration (IC50) 180 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[171]
Half Maximal Inhibitory Concentration (IC50) 180 nM
MIA PaCa-2 cells (MSLN expression)
Pancreatic ductal adenocarcinoma
CVCL_0428 
[203]
Half Maximal Inhibitory Concentration (IC50) 180.87 nM
SK-LMS-1 cells
Vulvar leiomyosarcoma
CVCL_0628 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 1800 nM
WiDr cells
Colon adenocarcinoma
CVCL_2760 
[204]
Half Maximal Inhibitory Concentration (IC50) 1800 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[205]
Half Maximal Inhibitory Concentration (IC50) 1800 nM
Ca-Ski cells
Cervical squamous cell carcinoma
CVCL_1100 
[206]
Half Maximal Inhibitory Concentration (IC50) 182.71 nM
NB6 cells
Neuroblastoma
CVCL_8823 
Half Maximal Inhibitory Concentration (IC50) 18240 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[186]
Half Maximal Inhibitory Concentration (IC50) 18300 nM
QSG-7701 cells
Endocervical adenocarcinoma
CVCL_6944 
[175]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 184.08 nM
IGROV-1 cells
Ovarian endometrioid adenocarcinoma
CVCL_1304 
[39]
Half Maximal Inhibitory Concentration (IC50) 184.93 nM
COR-L105 cells
Lung adenocarcinoma
CVCL_1138 
Half Maximal Inhibitory Concentration (IC50) 1840 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[201]
Half Maximal Inhibitory Concentration (IC50) 1840 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[202]
Half Maximal Inhibitory Concentration (IC50) 1840 nM
MS cells
Diffuse large B-cell lymphoma
CVCL_ZC25 
[134]
Half Maximal Inhibitory Concentration (IC50) 185.61 nM
NCI-H2347 cells
Lung adenocarcinoma
CVCL_1550 
Half Maximal Inhibitory Concentration (IC50) <1850 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[174]
Half Maximal Inhibitory Concentration (IC50) <1850 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[174]
Half Maximal Inhibitory Concentration (IC50) <1850 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[174]
Half Maximal Inhibitory Concentration (IC50) <1850 nM
Huh-7 cells
Adult hepatocellular carcinoma
CVCL_0336 
[174]
Half Maximal Inhibitory Concentration (IC50) <1850 nM
RKO cells
Colon carcinoma
CVCL_0504 
[174]
Half Maximal Inhibitory Concentration (IC50) <1850 nM
U-87MG ATCC cells
Glioblastoma
CVCL_0022 
[174]
Half Maximal Inhibitory Concentration (IC50) <1850 nM
C6 cells
Glioma
CVCL_0194 
[174]
Half Maximal Inhibitory Concentration (IC50) <1850 nM
SGC-7901 cells
Gastric carcinoma
CVCL_0520 
[174]
Half Maximal Inhibitory Concentration (IC50) 1850 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[167]
Half Maximal Inhibitory Concentration (IC50) 188.55 nM
OVCAR-4 cells
Ovarian adenocarcinoma
CVCL_1627 
Half Maximal Inhibitory Concentration (IC50) 1880 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[135]
Half Maximal Inhibitory Concentration (IC50) 1880 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[152]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 19 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[207]
Half Maximal Inhibitory Concentration (IC50) 19 nM
U-118-MG cells
Astrocytoma
CVCL_0633 
Half Maximal Inhibitory Concentration (IC50) 19 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[178]
Half Maximal Inhibitory Concentration (IC50) 19 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[179]
Half Maximal Inhibitory Concentration (IC50) 19.16 nM
G-401 cells
Kidney Wilm's tumor
CVCL_0270 
Half Maximal Inhibitory Concentration (IC50) 19.16 nM
CAL-39 cells
Vulvar squamous cell carcinoma
CVCL_1109 
Half Maximal Inhibitory Concentration (IC50) 19.26 nM
SCC-4 cells
Tongue squamous cell carcinoma
CVCL_1684 
Half Maximal Inhibitory Concentration (IC50) 19.37 nM
LS-513 cells
Cecum adenocarcinoma
CVCL_1386 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 19.41 nM
NCI-H23 cells
Lung adenocarcinoma
CVCL_1547 
[39]
Half Maximal Inhibitory Concentration (IC50) 19.42 nM
KNS-81-FD cells
Glioblastoma
CVCL_1336 
Half Maximal Inhibitory Concentration (IC50) 19.46 nM
23132-87 cells
Gastric adenocarcinoma
CVCL_1046 
Half Maximal Inhibitory Concentration (IC50) 19.68 nM
Panc1005 cells
Pancreatic carcinoma
CVCL_1639 
Half Maximal Inhibitory Concentration (IC50) 19.82 nM
NMC-G1 cells
Astrocytoma
CVCL_1608 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 190 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[40]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 190 nM
SF268 cells
Astrocytoma
CVCL_1689 
[208]
Half Maximal Inhibitory Concentration (IC50) 190 nM
MIA PaCa-2 cells (MSLN expression)
Pancreatic ductal adenocarcinoma
CVCL_0428 
[128]
Half Maximal Inhibitory Concentration (IC50) 190 nM
MIA PaCa-2 cells (MSLN expression)
Pancreatic ductal adenocarcinoma
CVCL_0428 
[129]
Half Maximal Inhibitory Concentration (IC50) 190 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[209]
Half Maximal Inhibitory Concentration (IC50) 190 nM
SF268 cells
Astrocytoma
CVCL_1689 
[117]
Half Maximal Inhibitory Concentration (IC50) 190 nM
PC-3M cells
Bone metastasis of prostate carcinoma
CVCL_9555 
[210]
Half Maximal Inhibitory Concentration (IC50) 190.35 nM
SW1116 cells
Colon adenocarcinoma
CVCL_0544 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 1900 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[147]
Half Maximal Inhibitory Concentration (IC50) 192.44 nM
HT55 cells
Rectal adenocarcinoma
CVCL_1294 
Half Maximal Inhibitory Concentration (IC50) 194.29 nM
SNU-449 cells
Hepatocellular carcinoma
CVCL_0454 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 195 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[40]
Half Maximal Inhibitory Concentration (IC50) 196.84 nM
LB771-HNC cells
Head and neck squamous cell carcinoma
CVCL_1369 
Half Maximal Inhibitory Concentration (IC50) 1980 nM
U-937 cells
Adult acute monocytic leukemia
CVCL_0007 
[211]
Half Maximal Inhibitory Concentration (IC50) 1980 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[212]
Half Maximal Inhibitory Concentration (IC50) 19800 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[213]
Half Maximal Inhibitory Concentration (IC50) 1985.76 nM
BT474-M1 cells
Invasive breast carcinoma
CVCL_0179 
Half Maximal Inhibitory Concentration (IC50) >19952.62 nM
Vero C1008 cells
Normal
CVCL_0574 
[214]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2 nM
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
[41]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2 nM
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
[84]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2 nM
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
[207]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[215]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[216]
Half Maximal Inhibitory Concentration (IC50) 2 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[86]
Half Maximal Inhibitory Concentration (IC50) 2 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[217]
Half Maximal Inhibitory Concentration (IC50) 2 nM
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
[182]
Half Maximal Inhibitory Concentration (IC50) 2 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[69]
Half Maximal Inhibitory Concentration (IC50) 2 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[218]
Half Maximal Inhibitory Concentration (IC50) 2.01 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[219]
Half Maximal Inhibitory Concentration (IC50) 2.018 nM
CAL-27 cells
Tongue adenosquamous carcinom
CVCL_1107 
Half Maximal Inhibitory Concentration (IC50) 2.029 nM
697 cells
Childhood B acute lymphoblastic leukemia
CVCL_0079 
Half Maximal Inhibitory Concentration (IC50) 2.043 nM
ATN-1 cells
T acute lymphoblastic leukemia
CVCL_1073 
Half Maximal Inhibitory Concentration (IC50) 2.076 nM
LB2241-RCC cells
Renal cell carcinoma
CVCL_1365 
Half Maximal Inhibitory Concentration (IC50) 2.082 nM
BPH-1 cells
Benign prostatic hyperplasia
CVCL_1091 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2.1 nM
MSTO-211H cells
Pleural biphasic mesothelioma
CVCL_1430 
[215]
Half Maximal Inhibitory Concentration (IC50) 2.165 nM
ML-2 cells
Acute myeloid leukemia
CVCL_1418 
Half Maximal Inhibitory Concentration (IC50) 2.175 nM
NB17 cells
Neuroblastoma
CVCL_1445 
Half Maximal Inhibitory Concentration (IC50) 2.21 nM
VM-CUB-1 cells
Bladder carcinoma
CVCL_1786 
Half Maximal Inhibitory Concentration (IC50) 2.21 nM
IMR-32 cells
Neuroblastoma
CVCL_0346 
[220]
Half Maximal Inhibitory Concentration (IC50) 2.211 nM
Ca9-22 cells
Gingival squamous cell carcinoma
CVCL_1102 
Half Maximal Inhibitory Concentration (IC50) 2.217 nM
RPMI-2650 cells
Head and neck squamous cell carcinoma
CVCL_1664 
Half Maximal Inhibitory Concentration (IC50) 2.24 nM
NCI-H292 cells
Lung mucoepidermoid carcinoma
CVCL_0455 
Half Maximal Inhibitory Concentration (IC50) 2.3 nM
Huh-7 cells
Adult hepatocellular carcinoma
CVCL_0336 
[182]
Half Maximal Inhibitory Concentration (IC50) 2.348 nM
SW1573 cells
Lung carcinoma
CVCL_1720 
Half Maximal Inhibitory Concentration (IC50) 2.381 nM
BV-173 cells
Chronic myelogenous leukemia
CVCL_0181 
Half Maximal Inhibitory Concentration (IC50) 2.406 nM
ONS-76 cells
Medulloblastoma
CVCL_1624 
Half Maximal Inhibitory Concentration (IC50) 2.438 nM
C2BBe1 cells
Colon adenocarcinoma
CVCL_1096 
Half Maximal Inhibitory Concentration (IC50) 2.504 nM
JVM-3 cells
B-cell prolymphocytic leukemia
CVCL_1320 
Half Maximal Inhibitory Concentration (IC50) 2.506 nM
OC-314 cells
Ovarian serous adenocarcinoma
CVCL_1616 
Half Maximal Inhibitory Concentration (IC50) 2.551 nM
D-423MG cells
Glioblastoma
CVCL_1160 
Half Maximal Inhibitory Concentration (IC50) 2.551 nM
HAL-01 cells
B acute lymphoblastic leukemia
CVCL_1242 
Half Maximal Inhibitory Concentration (IC50) 2.579 nM
J-RT3-T3-5 cells
T acute lymphoblastic leukemi
CVCL_1316 
Half Maximal Inhibitory Concentration (IC50) 2.659 nM
EW-11 cells
Ewing sarcoma
CVCL_1209 
Half Maximal Inhibitory Concentration (IC50) 2.692 nM
ME-180 cells
Cervical squamous cell carcinoma
CVCL_1401 
Half Maximal Inhibitory Concentration (IC50) 2.733 nM
MHH-PREB-1 cells
B-cell non-Hodgkin lymphoma
CVCL_1413 
Half Maximal Inhibitory Concentration (IC50) 2.759 nM
MIA PaCa-2 cells (MSLN expression)
Pancreatic ductal adenocarcinoma
CVCL_0428 
Half Maximal Inhibitory Concentration (IC50) 2.774 nM
MS-1 cells
Lung small cell carcinoma
CVCL_1429 
Half Maximal Inhibitory Concentration (IC50) 2.792 nM
P30-OHK cells
B acute lymphoblastic leukemia
CVCL_1631 
Half Maximal Inhibitory Concentration (IC50) 2.806 nM
LC-2-ad cells
Lung adenocarcinoma
CVCL_1373 
Half Maximal Inhibitory Concentration (IC50) 2.835 nM
SF-126 cells
Glioblastoma
CVCL_1688 
Half Maximal Inhibitory Concentration (IC50) 2.881 nM
HuO9 cells
Osteosarcoma
CVCL_1298 
Half Maximal Inhibitory Concentration (IC50) 2.902 nM
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
Half Maximal Inhibitory Concentration (IC50) 2.993 nM
SW13 cells
Adrenal cortex carcinoma
CVCL_0542 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[42]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[43]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[44]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[46]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[47]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[65]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[48]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[49]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[50]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[51]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[52]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[53]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[54]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[57]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[58]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[61]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[59]
Half Maximal Inhibitory Concentration (IC50) 20 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[221]
Half Maximal Inhibitory Concentration (IC50) 20 nM
SK-BR-3 cells
Breast adenocarcinoma
CVCL_0033 
[157]
Half Maximal Inhibitory Concentration (IC50) 20 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[169]
Half Maximal Inhibitory Concentration (IC50) 20 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[222]
Half Maximal Inhibitory Concentration (IC50) 20 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[201]
Half Maximal Inhibitory Concentration (IC50) 20 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[202]
Half Maximal Inhibitory Concentration (IC50) 20 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[223]
Half Maximal Inhibitory Concentration (IC50) 20 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[145]
Half Maximal Inhibitory Concentration (IC50) 20 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[73]
Half Maximal Inhibitory Concentration (IC50) 20 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[24]
Half Maximal Inhibitory Concentration (IC50) 20 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[157]
Half Maximal Inhibitory Concentration (IC50) 20 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[140]
Half Maximal Inhibitory Concentration (IC50) 20 nM
SMMC-7721 cells
Hepatocellular carcinoma
CVCL_0534 
[185]
Half Maximal Inhibitory Concentration (IC50) 20 nM
MDA-MB-157 cells
Breast carcinoma
CVCL_0618 
[38]
Half Maximal Inhibitory Concentration (IC50) 20 nM
KB 3-1 cells
Cervical epithelial carcinoma
CVCL_2088 
[73]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20.18 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[39]
Half Maximal Inhibitory Concentration (IC50) 20.32 nM
EFO-21 cells
Ovarian serous cystadenocarcinoma
CVCL_0029 
Half Maximal Inhibitory Concentration (IC50) 20.33 nM
MZ1-PC cells
Pancreatic ductal adenocarcinoma
CVCL_1434 
Half Maximal Inhibitory Concentration (IC50) 20.35 nM
SW 954 cells
Vulva squamous carcinoma
CVCL_1732 
Half Maximal Inhibitory Concentration (IC50) 20.49 nM
LCLC-103H cells
Lung large cell carcinoma
CVCL_1375 
Half Maximal Inhibitory Concentration (IC50) 20.51 nM
SW 962 cells
Vulva lymphoid carcinoma
CVCL_1733 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20.56 nM
DMS 114 cells
Lung small cell carcinoma
CVCL_1174 
[39]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 20.65 nM
M14 cells
Melanoma
CVCL_1395 
[39]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 200 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[148]
Half Maximal Inhibitory Concentration (IC50) 200 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[60]
Half Maximal Inhibitory Concentration (IC50) 200 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[128]
Half Maximal Inhibitory Concentration (IC50) 200 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[129]
Half Maximal Inhibitory Concentration (IC50) 200 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[60]
Half Maximal Inhibitory Concentration (IC50) 200 nM
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
[66]
Half Maximal Inhibitory Concentration (IC50) 200 nM
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
[224]
Half Maximal Inhibitory Concentration (IC50) 200 nM
SW1990 cells
Pancreatic adenocarcinoma
CVCL_1723 
[225]
Half Maximal Inhibitory Concentration (IC50) 200 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[66]
Half Maximal Inhibitory Concentration (IC50) 200 nM
Human umbilical vein endothelial cells(HUVEC)
Normal
Undisclosed [144]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2000 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[149]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2000 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[204]
Half Maximal Inhibitory Concentration (IC50) 2000 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[91]
Half Maximal Inhibitory Concentration (IC50) >20000 nM
Vero C1008 cells
Normal
CVCL_0574 
[214]
Half Maximal Inhibitory Concentration (IC50) >200000 nM
NCI-H446 cells
Lung small cell carcinoma
CVCL_1562 
[76]
Half Maximal Inhibitory Concentration (IC50) >200000 nM
NCI-H446 cells
Lung small cell carcinoma
CVCL_1562 
[223]
Half Maximal Inhibitory Concentration (IC50) 207 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[226]
Half Maximal Inhibitory Concentration (IC50) 208.15 nM
CP66-MEL cells
Melanoma
CVCL_1144 
Half Maximal Inhibitory Concentration (IC50) 208.78 nM
NCI-H1755 cells
Lung adenocarcinoma
CVCL_1492 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 209.41 nM
OVCAR-4 cells
Ovarian adenocarcinoma
CVCL_1627 
[39]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 21 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[227]
Half Maximal Inhibitory Concentration (IC50) 21 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[123]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 21.38 nM
786-O cells
Renal cell carcinoma
CVCL_1051 
[39]
Half Maximal Inhibitory Concentration (IC50) 21.55 nM
BB30-HNC cells
Head and neck squamous cell carcinoma
CVCL_1076 
Half Maximal Inhibitory Concentration (IC50) 21.56 nM
MFE-280 cells
Endometrial adenocarcinoma
CVCL_1405 
Half Maximal Inhibitory Concentration (IC50) 21.69 nM
SK-N-DZ cells
Neuroblastoma
CVCL_1701 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 210 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[227]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 210 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[122]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 210 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[228]
Half Maximal Inhibitory Concentration (IC50) 210 nM
DLD-1 cells
Colon adenocarcinoma
CVCL_0248 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 210 nM
SW1573 cells
Lung carcinoma
CVCL_1720 
[147]
Half Maximal Inhibitory Concentration (IC50) 210 nM
SK-BR-3 cells
Breast adenocarcinoma
CVCL_0033 
[105]
Half Maximal Inhibitory Concentration (IC50) 210 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[229]
Half Maximal Inhibitory Concentration (IC50) 210 nM
Capan-1 cells
Pancreatic ductal adenocarcinoma
CVCL_0237 
[200]
Half Maximal Inhibitory Concentration (IC50) 210 nM
SW480 cells
Colon adenocarcinoma
CVCL_0546 
[197]
Half Maximal Inhibitory Concentration (IC50) 210 nM
BGC-823 cells
Stomach adenocarcinoma
CVCL_3360 
[230]
Half Maximal Inhibitory Concentration (IC50) 210 nM
HPDE6c7 cells
Normal
CVCL_0P38 
[203]
Half Maximal Inhibitory Concentration (IC50) 2100 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[231]
Half Maximal Inhibitory Concentration (IC50) 2100 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[232]
Half Maximal Inhibitory Concentration (IC50) 2110 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[171]
Half Maximal Inhibitory Concentration (IC50) 2150 nM
L02 cells
Cervical carcinoma
CVCL_6926 
[233]
Half Maximal Inhibitory Concentration (IC50) 218.07 nM
GAK cells
Vulvar melanoma
CVCL_1225 
Half Maximal Inhibitory Concentration (IC50) 2190 nM
MCF-10A cells
Normal
CVCL_0598 
[77]
Half Maximal Inhibitory Concentration (IC50) 22.03 nM
KU-19-19 cells
Bladder carcinoma
CVCL_1344 
Half Maximal Inhibitory Concentration (IC50) 22.32 nM
COLO-668 cells
Lung small cell carcinoma
CVCL_1128 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 22.34 nM
NCI-H522 cells
Non-small cell lung carcinoma
CVCL_1567 
[39]
Half Maximal Inhibitory Concentration (IC50) 22.49 nM
NCI-H226 cells
Pleural epithelioid mesothelioma
CVCL_1544 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 22.54 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[39]
Half Maximal Inhibitory Concentration (IC50) 22.59 nM
D-502MG cells
Glioblastoma
CVCL_1162 
Half Maximal Inhibitory Concentration (IC50) 22.87 nM
RERF-LC-MS cells
Lung adenocarcinoma
CVCL_1655 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[42]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[43]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[45]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[46]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[48]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[49]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[50]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[52]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[53]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[54]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[55]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[56]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[57]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[58]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[61]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[59]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
SK-HEP1 cells
Hepatoma
CVCL_0525 
[199]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 220 nM
SK-HEP1 cells
Hepatoma
CVCL_0525 
[103]
Half Maximal Inhibitory Concentration (IC50) 220 nM
SK-HEP1 cells
Hepatoma
CVCL_0525 
[171]
Half Maximal Inhibitory Concentration (IC50) 220 nM
RPMI-7951 cells
Malignant melanoma
CVCL_1666 
[234]
Half Maximal Inhibitory Concentration (IC50) 22000 nM
Jurkat cells
T acute lymphoblastic leukemia
CVCL_0065 
[235]
Half Maximal Inhibitory Concentration (IC50) 2210 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[186]
Half Maximal Inhibitory Concentration (IC50) 2260 nM
SK-MEL-28 cells (BRAF inhibitor resistant)
Cutaneous melanoma
CVCL_0526 
[236]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 227.51 nM
SK-MEL-28 cells (BRAF inhibitor resistant)
Cutaneous melanoma
CVCL_0526 
[39]
Half Maximal Inhibitory Concentration (IC50) 2281.94 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
Half Maximal Inhibitory Concentration (IC50) 2281.97 nM
SK-MEL-30 cells
Cutaneous melanoma
CVCL_0039 
Half Maximal Inhibitory Concentration (IC50) 229.98 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
Half Maximal Inhibitory Concentration (IC50) 23 nM
L1210 cells
Lymphoblastic leukemia
CVCL_0382 
[237]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 23.01 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[39]
Half Maximal Inhibitory Concentration (IC50) 23.34 nM
Becker cells
Astrocytoma
CVCL_1093 
Half Maximal Inhibitory Concentration (IC50) 23.65 nM
TE-9 cells
Esophageal squamous cell carcinoma
CVCL_1767 
Half Maximal Inhibitory Concentration (IC50) 23.73 nM
KYSE-450 cells
Esophageal squamous cell carcinoma
CVCL_1353 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 230 nM
HBL-100 cells
Normal
CVCL_4362 
[147]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 230 nM
HBL-100 cells
Normal
CVCL_4362 
[204]
Half Maximal Inhibitory Concentration (IC50) 230 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[229]
Half Maximal Inhibitory Concentration (IC50) 230 nM
WI-38 cells
Normal
CVCL_0579 
[238]
Half Maximal Inhibitory Concentration (IC50) 230 nM
MS cells
Diffuse large B-cell lymphoma
CVCL_ZC25 
[239]
Half Maximal Inhibitory Concentration (IC50) 2300 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[116]
Half Maximal Inhibitory Concentration (IC50) 2310 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[240]
Half Maximal Inhibitory Concentration (IC50) 2320 nM
NCI-N87 cells
Gastric tubular adenocarcinoma
CVCL_1603 
[105]
Half Maximal Inhibitory Concentration (IC50) 2370 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[100]
Half Maximal Inhibitory Concentration (IC50) 23760 nM
AGS cells
Gastric adenocarcinoma
CVCL_0139 
[171]
Half Maximal Inhibitory Concentration (IC50) 23980 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[241]
Half Maximal Inhibitory Concentration (IC50) 24 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[19]
Half Maximal Inhibitory Concentration (IC50) 24 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[242]
Half Maximal Inhibitory Concentration (IC50) 24 nM
A-427 cells
Lung carcinoma
CVCL_1055 
[243]
Half Maximal Inhibitory Concentration (IC50) 24 nM
HCT-8 cells
Ileocecal adenocarcinoma
CVCL_2478 
[161]
Half Maximal Inhibitory Concentration (IC50) 24.12 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
Half Maximal Inhibitory Concentration (IC50) 24.16 nM
SW872 cells
Liposarcoma
CVCL_1730 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 24.49 nM
SN12K1 cells
Lung metastasis of renal carcinoma
CVCL_D106 
[39]
Half Maximal Inhibitory Concentration (IC50) 24.5 nM
G-402 cells
Kidney neoplasm
CVCL_1221 
Half Maximal Inhibitory Concentration (IC50) 24.57 nM
SW1783 cells
Anaplastic astrocytoma
CVCL_1722 
Half Maximal Inhibitory Concentration (IC50) 240 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[244]
Half Maximal Inhibitory Concentration (IC50) 240 nM
BxPC-3 CDX model cells
Pancreatic ductal adenocarcinoma
CVCL_0186 
[66]
Half Maximal Inhibitory Concentration (IC50) 240 nM
ZR-75-30 cells
Breast carcinoma
CVCL_1661 
[125]
Half Maximal Inhibitory Concentration (IC50) 241 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[189]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 242.66 nM
DLD-1 cells
Colon adenocarcinoma
CVCL_0248 
[39]
Half Maximal Inhibitory Concentration (IC50) 2430 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[245]
Half Maximal Inhibitory Concentration (IC50) 244.5 nM
RMG-I cells
Ovarian clear cell adenocarcinoma
CVCL_1662 
Half Maximal Inhibitory Concentration (IC50) 245.96 nM
KYSE-150 cells
Esophageal squamous cell carcinoma
CVCL_1348 
Half Maximal Inhibitory Concentration (IC50) 24770 nM
MCF10 cells
Normal
Undisclosed [246]
Half Maximal Inhibitory Concentration (IC50) 25 nM
Sf9 cells
Normal
CVCL_0549 
[247]
Half Maximal Inhibitory Concentration (IC50) 25 nM
Sf9 cells
Normal
CVCL_0549 
[248]
Half Maximal Inhibitory Concentration (IC50) 25 nM
KB-V1 cells
Cervical carcinoma
CVCL_2089 
[93]
Half Maximal Inhibitory Concentration (IC50) 25 nM
KB-V1 cells
Cervical carcinoma
CVCL_2089 
[95]
Half Maximal Inhibitory Concentration (IC50) 25.07 nM
EGI-1 cells
Cholangiocarcinoma
CVCL_1193 
Half Maximal Inhibitory Concentration (IC50) 25.34 nM
769-P cells
Renal cell carcinom
CVCL_1050 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 25.35 nM
P388/ADR cells
Lymphoma
CVCL_IZ75 
[39]
Half Maximal Inhibitory Concentration (IC50) 25.55 nM
OE33 cells
Barrett adenocarcinoma
CVCL_0471 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 25.64 nM
RXF 393 cells
Renal carcinoma
CVCL_1673 
[39]
Half Maximal Inhibitory Concentration (IC50) 25.78 nM
SW780 cells
Bladder carcinoma
CVCL_1728 
Half Maximal Inhibitory Concentration (IC50) 25.99 nM
BT-20 cells
Invasive breast carcinoma of no special type
CVCL_0178 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 250 nM
SW1573 cells
Lung carcinoma
CVCL_1720 
[204]
Half Maximal Inhibitory Concentration (IC50) 250 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[249]
Half Maximal Inhibitory Concentration (IC50) 250 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[241]
Half Maximal Inhibitory Concentration (IC50) 2500 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[76]
Half Maximal Inhibitory Concentration (IC50) 2500 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[247]
Half Maximal Inhibitory Concentration (IC50) 2500 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[248]
Half Maximal Inhibitory Concentration (IC50) 2500 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[248]
Half Maximal Inhibitory Concentration (IC50) >25000 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[250]
Half Maximal Inhibitory Concentration (IC50) >25000 nM
GLC-82 cells
Endocervical adenocarcinoma
CVCL_3371 
[250]
Half Maximal Inhibitory Concentration (IC50) 2511.11 nM
UMC-11 cells
Lung carcinoid tumor
CVCL_1784 
Half Maximal Inhibitory Concentration (IC50) 253.14 nM
NCI-H1838 cells
Lung adenocarcinoma
CVCL_1499 
Half Maximal Inhibitory Concentration (IC50) 2530 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[164]
Half Maximal Inhibitory Concentration (IC50) 2544 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[187]
Half Maximal Inhibitory Concentration (IC50) 2544.45 nM
G-361 cells
Melanoma
CVCL_1220 
Half Maximal Inhibitory Concentration (IC50) 256.33 nM
SNU-387 cells
Hepatocellular carcinoma
CVCL_0250 
Half Maximal Inhibitory Concentration (IC50) 257.84 nM
A101D cells
Melanoma
CVCL_1057 
Half Maximal Inhibitory Concentration (IC50) 2580 nM
MCF-10A cells
Normal
CVCL_0598 
[105]
Half Maximal Inhibitory Concentration (IC50) 26 nM
Jurkat cells
T acute lymphoblastic leukemia
CVCL_0065 
[211]
Half Maximal Inhibitory Concentration (IC50) 26 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[19]
Half Maximal Inhibitory Concentration (IC50) 26 nM
KBH5.0 cells
Endocervical adenocarcinoma
CVCL_D644 
[93]
Half Maximal Inhibitory Concentration (IC50) 26 nM
KBH5.0 cells
Endocervical adenocarcinoma
CVCL_D644 
[95]
Half Maximal Inhibitory Concentration (IC50) 26.03 nM
PFSK-1 cells
Primitive neuroectodermal tumor
CVCL_1642 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 26.06 nM
LOX IMVI cells
Melanoma
CVCL_1381 
[39]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 26.67 nM
P388 cells
Lymphoma
CVCL_7222 
[39]
Half Maximal Inhibitory Concentration (IC50) 26.69 nM
NCI-H1693 cells
Lung adenocarcinoma
CVCL_1488 
Half Maximal Inhibitory Concentration (IC50) 260 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[251]
Half Maximal Inhibitory Concentration (IC50) 260 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[125]
Half Maximal Inhibitory Concentration (IC50) 260 nM
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
[251]
Half Maximal Inhibitory Concentration (IC50) 260 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[100]
Half Maximal Inhibitory Concentration (IC50) 260 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[112]
Half Maximal Inhibitory Concentration (IC50) 260 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[232]
Half Maximal Inhibitory Concentration (IC50) 260 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[31]
Half Maximal Inhibitory Concentration (IC50) 260 nM
HCT-8 cells
Ileocecal adenocarcinoma
CVCL_2478 
[251]
Half Maximal Inhibitory Concentration (IC50) 260 nM
Bel-7402 cells
Hepatoma
CVCL_5492 
[251]
Half Maximal Inhibitory Concentration (IC50) 260.2 nM
SW948 cells
Colon adenocarcinoma
CVCL_0632 
Half Maximal Inhibitory Concentration (IC50) 2600 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[205]
Half Maximal Inhibitory Concentration (IC50) 261 nM
ZR-75-30 cells
Breast carcinoma
CVCL_1661 
Half Maximal Inhibitory Concentration (IC50) 2610 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[114]
Half Maximal Inhibitory Concentration (IC50) 262.05 nM
CAL-12T cells
Lung non-small cell carcinoma
CVCL_1105 
Half Maximal Inhibitory Concentration (IC50) 2620 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[240]
Half Maximal Inhibitory Concentration (IC50) 264 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[77]
Half Maximal Inhibitory Concentration (IC50) 26450 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[120]
Half Maximal Inhibitory Concentration (IC50) 265.25 nM
TE-12 cells
Esophageal squamous cell carcinoma
CVCL_1762 
Half Maximal Inhibitory Concentration (IC50) 266.61 nM
HCC1954 cells
Breast ductal carcinoma
CVCL_1259 
Half Maximal Inhibitory Concentration (IC50) 267.54 nM
HCC1569 cells
Breast ductal carcinoma
CVCL_1255 
Half Maximal Inhibitory Concentration (IC50) 269.5 nM
COLO-824 cells
Breast carcinoma
CVCL_1136 
Half Maximal Inhibitory Concentration (IC50) 27.08 nM
MFH-ino cells
Pleomorphic sarcoma
CVCL_1407 
Half Maximal Inhibitory Concentration (IC50) 27.15 nM
T98G cells
Glioblastoma
CVCL_0556 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 27.16 nM
SK-MEL-5 cells
Cutaneous melanoma
CVCL_0527 
[39]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 27.16 nM
SNB-75 cells
Glioblastoma
CVCL_1706 
[39]
Half Maximal Inhibitory Concentration (IC50) 27.23 nM
NCI-H1793 cells
Lung adenocarcinoma
CVCL_1496 
Half Maximal Inhibitory Concentration (IC50) 27.24 nM
MPP-89 cells
Pleural epithelioid mesothelioma
CVCL_1427 
Half Maximal Inhibitory Concentration (IC50) 27.5 nM
MKN45 cells
Gastric adenocarcinoma
CVCL_0434 
Half Maximal Inhibitory Concentration (IC50) 27.77 nM
SW1088 cells
Astrocytoma
CVCL_1715 
Half Maximal Inhibitory Concentration (IC50) 27.79 nM
SBC-1 cells
Lung small cell carcinoma
CVCL_1676 
Half Maximal Inhibitory Concentration (IC50) 270 nM
MCF-10A cells
Normal
CVCL_0598 
[99]
Half Maximal Inhibitory Concentration (IC50) 2700 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[223]
Half Maximal Inhibitory Concentration (IC50) 2700 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[205]
Half Maximal Inhibitory Concentration (IC50) 27000 nM
Vero cells
Normal
CVCL_0059 
[131]
Half Maximal Inhibitory Concentration (IC50) 27200 nM
TERT-RPE1 cells
Normal
CVCL_4388 
[221]
Half Maximal Inhibitory Concentration (IC50) 276.33 nM
Lu-65 cells
Lung giant cell carcinoma
CVCL_1392 
Half Maximal Inhibitory Concentration (IC50) 2770 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[167]
Half Maximal Inhibitory Concentration (IC50) 2780 nM
B16-F10 cells
Mouse melanoma
CVCL_0159 
[252]
Half Maximal Inhibitory Concentration (IC50) 28.16 nM
LU-135 cells
Lung small cell carcinoma
CVCL_1389 
Half Maximal Inhibitory Concentration (IC50) 28.34 nM
NCI-H2052 cells
Pleural mesothelioma
CVCL_1518 
Half Maximal Inhibitory Concentration (IC50) 28.4 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[253]
Half Maximal Inhibitory Concentration (IC50) 28.66 nM
RCM-1 cells
Rectal adenocarcinoma
CVCL_1648 
Half Maximal Inhibitory Concentration (IC50) 28.7 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[132]
Half Maximal Inhibitory Concentration (IC50) 28.7 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[254]
Half Maximal Inhibitory Concentration (IC50) 28.7 nM
Lu1 cells
Lung carcinoma
Undisclosed [254]
Half Maximal Inhibitory Concentration (IC50) 28.7 nM
SW626 cells
Colon adenocarcinoma
CVCL_1725 
[254]
Half Maximal Inhibitory Concentration (IC50) 28.8 nM
NB13 cells
Neuroblastoma
CVCL_1443 
Half Maximal Inhibitory Concentration (IC50) 280 nM
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
[136]
Half Maximal Inhibitory Concentration (IC50) 280 nM
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
[230]
Half Maximal Inhibitory Concentration (IC50) 280 nM
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
[255]
Half Maximal Inhibitory Concentration (IC50) 280 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[99]
Half Maximal Inhibitory Concentration (IC50) 280 nM
HEK293 cells
Normal
CVCL_0045 
[212]
Half Maximal Inhibitory Concentration (IC50) 280 nM
SNU-638 cells
Gastric carcinoma
CVCL_0102 
[256]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2800 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[103]
Half Maximal Inhibitory Concentration (IC50) 2800 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[223]
Half Maximal Inhibitory Concentration (IC50) 282.32 nM
NCI-H630 cells
Colon carcinoma
CVCL_1572 
Half Maximal Inhibitory Concentration (IC50) 2820 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[201]
Half Maximal Inhibitory Concentration (IC50) 2820 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[202]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 285.76 nM
COLO 205 cells
Colon adenocarcinoma
CVCL_0218 
[39]
Half Maximal Inhibitory Concentration (IC50) 28660 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[102]
Half Maximal Cell Growth Inhibitory Concentration (GI50) >287000 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[190]
Half Maximal Cell Growth Inhibitory Concentration (GI50) >287000 nM
U2OS cells
Osteosarcoma
CVCL_0042 
[190]
Half Maximal Inhibitory Concentration (IC50) 2892.53 nM
Karpas-299 cells/Karpas BVR cells
ALK-positive anaplastic large cell lymphoma
CVCL_1324 
Half Maximal Inhibitory Concentration (IC50) 29 nM
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
[161]
Half Maximal Inhibitory Concentration (IC50) 29.49 nM
RPMI-8226 cells
Plasma cell myeloma
CVCL_0014 
Half Maximal Inhibitory Concentration (IC50) 29.6 nM
YAPC cells
Pancreas carincoma
CVCL_1794 
Half Maximal Inhibitory Concentration (IC50) 29.71 nM
HT cells
Diffuse large B-cell lymphoma
CVCL_1290 
Half Maximal Inhibitory Concentration (IC50) 29.74 nM
CAL-51 cells
Breast carcinoma
CVCL_1110 
Half Maximal Inhibitory Concentration (IC50) 290 nM
SW480 cells
Colon adenocarcinoma
CVCL_0546 
[257]
Half Maximal Inhibitory Concentration (IC50) 2900000 nM
Caov-3 cells
Ovarian serous adenocarcinoma
CVCL_0201 
[166]
Half Maximal Inhibitory Concentration (IC50) 291 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[158]
Half Maximal Inhibitory Concentration (IC50) 291.41 nM
D-542MG cells
Glioblastoma
CVCL_1164 
Half Maximal Inhibitory Concentration (IC50) 296.49 nM
NCI-H747 cells
Cecum adenocarcinoma
CVCL_1587 
Half Maximal Inhibitory Concentration (IC50) 2960 nM
MGC-803 cells
Gastric cancer
CVCL_5334 
[258]
Half Maximal Inhibitory Concentration (IC50) 2968.73 nM
NCI-H596 cells
Lung adenosquamous carcinoma
CVCL_1571 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 297.85 nM
SK-MEL-2 cells (MEK inhibitor-resistant)
Melanoma
CVCL_0069 
[39]
Half Maximal Inhibitory Concentration (IC50) 298.06 nM
SJRH30 cells
Alveolar rhabdomyosarcoma
CVCL_0041 
Half Maximal Inhibitory Concentration (IC50) 29810 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[98]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 3 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[207]
Half Maximal Inhibitory Concentration (IC50) <3 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[76]
Half Maximal Inhibitory Concentration (IC50) <3 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[223]
Half Maximal Inhibitory Concentration (IC50) <3 nM
MV3 cells
Amelanotic melanoma
CVCL_W280 
[76]
Half Maximal Inhibitory Concentration (IC50) 3 nM
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
[68]
Half Maximal Inhibitory Concentration (IC50) 3 nM
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
[110]
Half Maximal Inhibitory Concentration (IC50) 3 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[141]
Half Maximal Inhibitory Concentration (IC50) 3 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[69]
Half Maximal Inhibitory Concentration (IC50) 3 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[66]
Half Maximal Inhibitory Concentration (IC50) 3 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[259]
Half Maximal Inhibitory Concentration (IC50) 3 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[69]
Half Maximal Inhibitory Concentration (IC50) 3 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[22]
Half Maximal Inhibitory Concentration (IC50) 3 nM
SMMC-7721 cells
Hepatocellular carcinoma
CVCL_0534 
[260]
Half Maximal Inhibitory Concentration (IC50) 3.015 nM
HSC-3 cells
Oral squamous cell carcinoma
CVCL_1288 
Half Maximal Inhibitory Concentration (IC50) 3.017 nM
SW48 cells
Colon adenocarcinoma
CVCL_1724 
Half Maximal Inhibitory Concentration (IC50) 3.041 nM
BCPAP cells
Thyroid carcinoma
CVCL_0153 
Half Maximal Inhibitory Concentration (IC50) 3.067 nM
SK-UT-1 cells
Uterine corpus leiomyosarcoma
CVCL_0533 
Half Maximal Inhibitory Concentration (IC50) 3.067 nM
DU-4475 cells
Breast adenocarcinoma
CVCL_1183 
Half Maximal Inhibitory Concentration (IC50) 3.069 nM
PSN1 cells
Pancreatic adenocarcinoma
CVCL_1644 
Half Maximal Inhibitory Concentration (IC50) 3.093 nM
UM-UC-3 cells
Bladder carcinoma
CVCL_1783 
Half Maximal Inhibitory Concentration (IC50) 3.1 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[243]
Half Maximal Inhibitory Concentration (IC50) 3.108 nM
NEC8 cells
Testicular embryonal carcinoma
CVCL_1604 
Half Maximal Inhibitory Concentration (IC50) 3.136 nM
NUGC-3 cells
Gastric carcinoma
CVCL_1612 
Half Maximal Inhibitory Concentration (IC50) 3.143 nM
HCC1806 cells
Breast squamous cell carcinoma
CVCL_1258 
Half Maximal Inhibitory Concentration (IC50) 3.162 nM
KP-4 cells
Pancreatic carcinoma
CVCL_1338 
Half Maximal Inhibitory Concentration (IC50) 3.198 nM
D283 Med cells
Medulloblastoma
CVCL_1155 
Half Maximal Inhibitory Concentration (IC50) 3.267 nM
EW-13 cells
Ewing sarcoma
CVCL_1211 
Half Maximal Inhibitory Concentration (IC50) 3.275 nM
CGTH-W-1 cells
Thyroid gland squamous cell carcinoma
CVCL_1120 
Half Maximal Inhibitory Concentration (IC50) 3.3 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[24]
Half Maximal Inhibitory Concentration (IC50) 3.301 nM
8505C cells
Thyroid gland anaplastic carcinoma
CVCL_1054 
Half Maximal Inhibitory Concentration (IC50) 3.344 nM
HC-1 cells
Hairy cell leukemia
CVCL_1243 
Half Maximal Inhibitory Concentration (IC50) 3.365 nM
GI-1 cells
Gliosarcoma
CVCL_1231 
Half Maximal Inhibitory Concentration (IC50) 3.379 nM
SF268 cells
Astrocytoma
CVCL_1689 
Half Maximal Inhibitory Concentration (IC50) 3.382 nM
HuTu 80 cells
Duodenal adenocarcinoma
CVCL_1301 
Half Maximal Inhibitory Concentration (IC50) 3.468 nM
ABC-1 cells
Lung adenocarcinoma
CVCL_1066 
Half Maximal Inhibitory Concentration (IC50) 3.469 nM
VA-ES-BJ cells
Epithelioid sarcoma
CVCL_1785 
Half Maximal Inhibitory Concentration (IC50) 3.599 nM
A2058 cells
Melanoma
CVCL_1059 
Half Maximal Inhibitory Concentration (IC50) 3.68 nM
AU565 cells
Breast adenocarcinoma
CVCL_1074 
Half Maximal Inhibitory Concentration (IC50) 3.688 nM
A375 cells
Amelanotic melanoma
CVCL_0132 
Half Maximal Inhibitory Concentration (IC50) 3.72 nM
LOX IMVI cells
Melanoma
CVCL_1381 
Half Maximal Inhibitory Concentration (IC50) 3.734 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
Half Maximal Inhibitory Concentration (IC50) 3.793 nM
NH-12 cells
Adrenal gland neuroblastoma
CVCL_1605 
Half Maximal Inhibitory Concentration (IC50) 3.81 nM
IST-MEL1 cells
Melanoma
CVCL_1308 
Half Maximal Inhibitory Concentration (IC50) 3.853 nM
ECC10 cells
Gastric small cell carcinoma
CVCL_1188 
Half Maximal Inhibitory Concentration (IC50) 3.854 nM
LU-99A cells
Lung giant cell carcinoma
CVCL_1393 
Half Maximal Inhibitory Concentration (IC50) 3.86 nM
RH-1 cells
Ewing sarcoma
CVCL_1658 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[41]
Half Maximal Inhibitory Concentration (IC50) 30 nM
Caov-3 cells
Ovarian serous adenocarcinoma
CVCL_0201 
Half Maximal Inhibitory Concentration (IC50) 30 nM
Caov-3 cells
Ovarian serous adenocarcinoma
CVCL_0201 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[42]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[43]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[46]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[47]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[48]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[49]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[50]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[52]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[53]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[54]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[55]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[56]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[57]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[58]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[59]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[208]
Half Maximal Inhibitory Concentration (IC50) 30 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[222]
Half Maximal Inhibitory Concentration (IC50) 30 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[261]
Half Maximal Inhibitory Concentration (IC50) 30 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[222]
Half Maximal Inhibitory Concentration (IC50) 30 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[68]
Half Maximal Inhibitory Concentration (IC50) 30 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[261]
Half Maximal Inhibitory Concentration (IC50) 30 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[198]
Half Maximal Inhibitory Concentration (IC50) 30 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[261]
Half Maximal Inhibitory Concentration (IC50) 30 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[104]
Half Maximal Inhibitory Concentration (IC50) 30 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[117]
Half Maximal Inhibitory Concentration (IC50) 30 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[261]
Half Maximal Inhibitory Concentration (IC50) 30 nM
L1210 cells
Lymphoblastic leukemia
CVCL_0382 
[262]
Half Maximal Inhibitory Concentration (IC50) 30 nM
WI-38 cells
Normal
CVCL_0579 
[263]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 30.27 nM
UO-31 cells
Renal carcinoma
CVCL_1911 
[39]
Half Maximal Inhibitory Concentration (IC50) 300 nM
U-937 cells
Adult acute monocytic leukemia
CVCL_0007 
[60]
Half Maximal Inhibitory Concentration (IC50) 300 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[91]
Half Maximal Inhibitory Concentration (IC50) 300 nM
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
[137]
Half Maximal Inhibitory Concentration (IC50) 300 nM
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
[264]
Half Maximal Inhibitory Concentration (IC50) 300 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[113]
Half Maximal Inhibitory Concentration (IC50) 300 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[265]
Half Maximal Inhibitory Concentration (IC50) 300 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[78]
Half Maximal Inhibitory Concentration (IC50) >300 nM
H69AR cells
Lung small cell carcinoma
CVCL_3513 
[31]
Half Maximal Inhibitory Concentration (IC50) 300 nM
ADR5000 cells
Leukemia
CVCL_D544 
[90]
Half Maximal Inhibitory Concentration (IC50) 3010 nM
HEp-2 cells
Laryngeal carcinoma
CVCL_1906 
[152]
Half Maximal Inhibitory Concentration (IC50) 3029.5 nM
JVM-2 cells
Mantle cell lymphoma
CVCL_1319 
Half Maximal Inhibitory Concentration (IC50) 304 nM
Renca cells
Renal carcinoma
CVCL_2174 
[198]
Half Maximal Inhibitory Concentration (IC50) 304.67 nM
ChaGo-K-1 cells
Bronchogenic carcinoma
CVCL_1121 
Half Maximal Inhibitory Concentration (IC50) 3040 nM
HEp-2 cells
Laryngeal carcinoma
CVCL_1906 
[134]
Half Maximal Inhibitory Concentration (IC50) 3040 nM
HEp-2 cells
Laryngeal carcinoma
CVCL_1906 
[135]
Half Maximal Inhibitory Concentration (IC50) 307 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[266]
Half Maximal Inhibitory Concentration (IC50) 307 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[267]
Half Maximal Inhibitory Concentration (IC50) 3090 nM
T24 cells
Bladder carcinoma
CVCL_0554 
[233]
Half Maximal Inhibitory Concentration (IC50) 31 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[19]
Half Maximal Inhibitory Concentration (IC50) 31.03 nM
LNCaP-Clone-FGC cells
Prostate carcinoma
CVCL_1379 
Half Maximal Inhibitory Concentration (IC50) 31.03 nM
UACC-62 cells
Melanoma
CVCL_1780 
Half Maximal Inhibitory Concentration (IC50) 31.47 nM
HTC-C3 cells
Thyroid gland anaplastic carcinoma
CVCL_1295 
Half Maximal Inhibitory Concentration (IC50) 31.84 nM
SW900 cells
Lung squamous cell carcinoma
CVCL_1731 
Half Maximal Inhibitory Concentration (IC50) 31.85 nM
DMS-79 cells
Small cell lung carcinoma
CVCL_1178 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 310 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[228]
Half Maximal Inhibitory Concentration (IC50) 310 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[107]
Half Maximal Inhibitory Concentration (IC50) 310 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[106]
Half Maximal Inhibitory Concentration (IC50) 310 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[77]
Half Maximal Inhibitory Concentration (IC50) 310 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[268]
Half Maximal Inhibitory Concentration (IC50) 3100 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[137]
Half Maximal Inhibitory Concentration (IC50) 3100 nM
LoVo cells
Colon adenocarcinoma
CVCL_0399 
[269]
Half Maximal Inhibitory Concentration (IC50) 311.44 nM
NCI-H69 cells
Small cell lung carcinoma
CVCL_1579 
Half Maximal Inhibitory Concentration (IC50) 3120 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[136]
Half Maximal Inhibitory Concentration (IC50) 314.07 nM
HCC1187 cells
Breast ductal carcinoma
CVCL_1247 
Half Maximal Inhibitory Concentration (IC50) 3140 nM
NCI-H1299 cells (MMAE resistant)
Lung large cell carcinoma
CVCL_0060 
[171]
Half Maximal Inhibitory Concentration (IC50) 3150 nM
HCT-8 cells
Ileocecal adenocarcinoma
CVCL_2478 
[136]
Half Maximal Inhibitory Concentration (IC50) 31860 nM
MDA-MB-436 cells
Metastasis of ductal carcinoma
CVCL_0623 
[241]
Half Maximal Inhibitory Concentration (IC50) 32 nM
U-937 cells
Adult acute monocytic leukemia
CVCL_0007 
[270]
Half Maximal Inhibitory Concentration (IC50) 32 nM
P388 cells
Lymphoma
CVCL_7222 
[271]
Half Maximal Inhibitory Concentration (IC50) 32.1 nM
P388 cells
Lymphoma
CVCL_7222 
[272]
Half Maximal Inhibitory Concentration (IC50) 32.15 nM
SBC-5 cells
Lung small cell carcinoma
CVCL_1679 
Half Maximal Inhibitory Concentration (IC50) 32.8 nM
Calu-3 cells
Lung adenocarcinoma
CVCL_0609 
Half Maximal Inhibitory Concentration (IC50) 320 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[70]
Half Maximal Inhibitory Concentration (IC50) 320 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[273]
Half Maximal Inhibitory Concentration (IC50) 3200 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[88]
Half Maximal Inhibitory Concentration (IC50) 3200 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[116]
Half Maximal Inhibitory Concentration (IC50) 3200 nM
HCT-8 cells
Ileocecal adenocarcinoma
CVCL_2478 
[137]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 3210 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[228]
Half Maximal Inhibitory Concentration (IC50) 32110 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[235]
Half Maximal Inhibitory Concentration (IC50) 32300 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[274]
Half Maximal Inhibitory Concentration (IC50) 3270 nM
Raji cells
EBV-related Burkitt lymphoma
CVCL_0511 
[186]
Half Maximal Inhibitory Concentration (IC50) 3273.33 nM
OE19 cells
Esophageal adenocarcinoma
CVCL_1622 
Half Maximal Inhibitory Concentration (IC50) 329.41 nM
SK-MEL3 cells
Melanoma
CVCL_0550 
Half Maximal Inhibitory Concentration (IC50) 3293.6 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 33 nM
U-373MG ATCC cells
Astrocytoma
CVCL_2219 
[148]
Half Maximal Inhibitory Concentration (IC50) 33 nM
Lewis lung carcinoma cells
Lung carcinoma
CVCL_4358 
[275]
Half Maximal Inhibitory Concentration (IC50) 33 nM
Lewis lung carcinoma cells
Lung carcinoma
CVCL_4358 
[142]
Half Maximal Inhibitory Concentration (IC50) 33 nM
Lewis lung carcinoma cells
Lung carcinoma
CVCL_4358 
[143]
Half Maximal Inhibitory Concentration (IC50) 33.14 nM
KNS-42 cells
Glioblastoma
CVCL_0378 
Half Maximal Inhibitory Concentration (IC50) 33.19 nM
SCC-9 cells
Tongue squamous cell carcinoma
CVCL_1685 
Half Maximal Inhibitory Concentration (IC50) 33.5 nM
NCI-H1581 cells
Lung large cell carcinoma
CVCL_1479 
Half Maximal Inhibitory Concentration (IC50) 33.57 nM
SW1710 cells
Bladder carcinoma
CVCL_1721 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 33.65 nM
RPMI-8226 cells
Plasma cell myeloma
CVCL_0014 
[39]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 33.73 nM
HOP-92 cells
Non-small cell lung carcinoma
CVCL_1286 
[39]
Half Maximal Inhibitory Concentration (IC50) 33.89 nM
GI-ME-N cells
Neuroblastoma
CVCL_1232 
Half Maximal Inhibitory Concentration (IC50) 33.98 nM
AN3-CA cells
Endometrial adenocarcinoma
CVCL_0028 
Half Maximal Inhibitory Concentration (IC50) 330 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[276]
Half Maximal Inhibitory Concentration (IC50) 330 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[185]
Half Maximal Inhibitory Concentration (IC50) 330 nM
Carcinoma cells
Carcinoma
Undisclosed [277]
Half Maximal Inhibitory Concentration (IC50) 330 nM
L1210 cells
Lymphoblastic leukemia
CVCL_0382 
[278]
Half Maximal Inhibitory Concentration (IC50) 330000 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[166]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 332.66 nM
SNB-78 cells
Glioblastoma
CVCL_B321 
[39]
Half Maximal Inhibitory Concentration (IC50) 332.9 nM
KINGS-1 cells
Anaplastic astrocytoma
CVCL_1328 
Half Maximal Inhibitory Concentration (IC50) 3320 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[279]
Half Maximal Inhibitory Concentration (IC50) 334.48 nM
NCI-H1975 cells
Lung adenocarcinoma
CVCL_1511 
Half Maximal Inhibitory Concentration (IC50) 34 nM
CT26 cells
Colon carcinoma
CVCL_7254 
[198]
Half Maximal Inhibitory Concentration (IC50) 34.07 nM
UO-31 cells
Renal carcinoma
CVCL_1911 
Half Maximal Inhibitory Concentration (IC50) 34.38 nM
IST-SL1 cells
Lung small cell carcinoma
CVCL_1313 
Half Maximal Inhibitory Concentration (IC50) 34.43 nM
MDA-MB-361 cells
Breast adenocarcinoma
CVCL_0620 
Half Maximal Inhibitory Concentration (IC50) 34.89 nM
ETK-1 cells
Cholangiocarcinoma
CVCL_1206 
Half Maximal Inhibitory Concentration (IC50) 34.93 nM
NCI-H1437 cells
Lung adenocarcinoma
CVCL_1472 
Half Maximal Inhibitory Concentration (IC50) 340 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[221]
Half Maximal Inhibitory Concentration (IC50) 340 nM
CNE cells
Nasopharyngeal carcinoma
CVCL_6888 
[108]
Half Maximal Inhibitory Concentration (IC50) 342 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[280]
Half Maximal Inhibitory Concentration (IC50) 349.21 nM
HCC1937 cells
Breast ductal carcinoma
CVCL_0290 
Half Maximal Inhibitory Concentration (IC50) 35 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[141]
Half Maximal Inhibitory Concentration (IC50) 35 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[104]
Half Maximal Inhibitory Concentration (IC50) 35.11 nM
TF-1 cells
Esophageal squamous cell carcinoma
CVCL_1759 
Half Maximal Inhibitory Concentration (IC50) 35.38 nM
SNU-C2B cells
Cecum adenocarcinoma
CVCL_1710 
Half Maximal Inhibitory Concentration (IC50) 35.45 nM
CW-2 cells
Colon adenocarcinoma
CVCL_1151 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 35.48 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[56]
Half Maximal Inhibitory Concentration (IC50) 35.53 nM
LK-2 cells
Lung squamous cell carcinoma
CVCL_1377 
Half Maximal Inhibitory Concentration (IC50) 35.62 nM
MEL-JUSO cells
Cutaneous melanoma
CVCL_1403 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 350 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[228]
Half Maximal Inhibitory Concentration (IC50) 350 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[209]
Half Maximal Inhibitory Concentration (IC50) 350 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[281]
Half Maximal Inhibitory Concentration (IC50) 350 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[163]
Half Maximal Inhibitory Concentration (IC50) 3500 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[92]
Half Maximal Inhibitory Concentration (IC50) 3570 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[282]
Half Maximal Inhibitory Concentration (IC50) 36.34 nM
IGROV-1 cells
Ovarian endometrioid adenocarcinoma
CVCL_1304 
Half Maximal Inhibitory Concentration (IC50) 36.35 nM
HuP-T3 cells
Pancreatic adenocarcinoma
CVCL_1299 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 36.64 nM
SW620 cells
Colon adenocarcinoma
CVCL_0547 
[39]
Half Maximal Inhibitory Concentration (IC50) 3600 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[224]
Half Maximal Inhibitory Concentration (IC50) 3600 nM
HCT-8 cells
Ileocecal adenocarcinoma
CVCL_2478 
[26]
Half Maximal Inhibitory Concentration (IC50) 3634.01 nM
KURAMOCHI cells
Ovarian serous adenocarcinoma
CVCL_1345 
Half Maximal Inhibitory Concentration (IC50) 3670 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[193]
Half Maximal Inhibitory Concentration (IC50) 3682.73 nM
COLO-678 cells
Colon carcinoma
CVCL_1129 
Half Maximal Inhibitory Concentration (IC50) 37 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[283]
Half Maximal Inhibitory Concentration (IC50) 37 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[181]
Half Maximal Inhibitory Concentration (IC50) 37 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[226]
Half Maximal Inhibitory Concentration (IC50) 37.88 nM
SW1990 cells
Pancreatic adenocarcinoma
CVCL_1723 
Half Maximal Inhibitory Concentration (IC50) 37.91 nM
MKN-1 cells
Gastric carcinoma
CVCL_1415 
Half Maximal Inhibitory Concentration (IC50) 370 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[163]
Half Maximal Inhibitory Concentration (IC50) 370 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[284]
Half Maximal Inhibitory Concentration (IC50) 37050 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[239]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 372.39 nM
LXFL 529 cells
Non-small cell lung carcinoma
CVCL_D085 
[39]
Half Maximal Inhibitory Concentration (IC50) 375 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[170]
Half Maximal Inhibitory Concentration (IC50) 3750 nM
SW480 cells
Colon adenocarcinoma
CVCL_0546 
[285]
Half Maximal Inhibitory Concentration (IC50) 38 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[69]
Half Maximal Inhibitory Concentration (IC50) 38.07 nM
NCI-H1648 cells
Lung adenocarcinoma
CVCL_1482 
Half Maximal Inhibitory Concentration (IC50) 38.13 nM
OCUB-M cells
Breast carcinoma
CVCL_1621 
Half Maximal Inhibitory Concentration (IC50) 38.4 nM
MMAC-SF cells
Melanoma
CVCL_1420 
Half Maximal Inhibitory Concentration (IC50) 38.51 nM
SK-MEL-24 cells
Melanoma
CVCL_0599 
Half Maximal Inhibitory Concentration (IC50) 38.68 nM
NCI-H28 cells
Pleural mesothelioma
CVCL_1555 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 38.82 nM
OVCAR-8 cells
High grade ovarian serous adenocarcinoma
CVCL_1629 
[39]
Half Maximal Inhibitory Concentration (IC50) 380 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[281]
Half Maximal Inhibitory Concentration (IC50) 3800 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[83]
Half Maximal Inhibitory Concentration (IC50) 3820 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[105]
Half Maximal Inhibitory Concentration (IC50) 383.65 nM
UACC-893 cells
Breast carcinoma
CVCL_1782 
Half Maximal Inhibitory Concentration (IC50) 389.64 nM
RH-18 cells
Alveolar rhabdomyosarcoma
CVCL_1659 
Half Maximal Inhibitory Concentration (IC50) 39 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[286]
Half Maximal Inhibitory Concentration (IC50) 39.04 nM
TCCSUP cells
Bladder carcinoma
CVCL_1738 
Half Maximal Inhibitory Concentration (IC50) 39.51 nM
MEG-01 cells
Chronic myeloid leukemia
CVCL_0425 
Half Maximal Inhibitory Concentration (IC50) 39.54 nM
D-247MG cells
Gliosarcoma
CVCL_1153 
Half Maximal Inhibitory Concentration (IC50) 390 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[265]
Half Maximal Inhibitory Concentration (IC50) 3910 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[100]
Half Maximal Inhibitory Concentration (IC50) 3960 nM
CAKI-2 cells
Renal carcinoma
CVCL_0235 
[164]
Half Maximal Inhibitory Concentration (IC50) 3970 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[107]
Half Maximal Inhibitory Concentration (IC50) 4 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[159]
Half Maximal Inhibitory Concentration (IC50) 4 nM
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
[127]
Half Maximal Inhibitory Concentration (IC50) 4 nM
Huh-7 cells
Adult hepatocellular carcinoma
CVCL_0336 
[20]
Half Maximal Inhibitory Concentration (IC50) 4 nM
RPMI-8402 cells
T acute lymphoblastic leukemia
CVCL_1667 
[93]
Half Maximal Inhibitory Concentration (IC50) 4 nM
RPMI-8402 cells
T acute lymphoblastic leukemia
CVCL_1667 
[94]
Half Maximal Inhibitory Concentration (IC50) 4 nM
RPMI-8402 cells
T acute lymphoblastic leukemia
CVCL_1667 
[97]
Half Maximal Inhibitory Concentration (IC50) 4 nM
MT4 cells
Normal
CVCL_2632 
[68]
Half Maximal Inhibitory Concentration (IC50) 4 nM
MT4 cells
Normal
CVCL_2632 
[169]
Half Maximal Inhibitory Concentration (IC50) 4 nM
P388 cells
Lymphoma
CVCL_7222 
[93]
Half Maximal Inhibitory Concentration (IC50) 4 nM
P388 cells
Lymphoma
CVCL_7222 
[94]
Half Maximal Inhibitory Concentration (IC50) 4 nM
P388 cells
Lymphoma
CVCL_7222 
[97]
Half Maximal Inhibitory Concentration (IC50) 4.032 nM
DoTc2-4510 cells
Cervix uteri
CVCL_1181 
Half Maximal Inhibitory Concentration (IC50) 4.033 nM
EW-24 cells
Ewing sarcoma
CVCL_1215 
Half Maximal Inhibitory Concentration (IC50) 4.062 nM
SW982 cells
Biphasic synovial sarcoma
CVCL_1734 
Half Maximal Inhibitory Concentration (IC50) 4.066 nM
Kasumi-1 cells
Myeloid leukemia with maturation
CVCL_0589 
Half Maximal Inhibitory Concentration (IC50) 4.073 nM
HGC-27 cells
Gastric carcinoma
CVCL_1279 
Half Maximal Inhibitory Concentration (IC50) 4.08 nM
EM-2 cells
Chronic myeloid leukemia
CVCL_1196 
Half Maximal Inhibitory Concentration (IC50) 4.082 nM
SW620 cells
Colon adenocarcinoma
CVCL_0547 
Half Maximal Inhibitory Concentration (IC50) 4.095 nM
M059J cells
Glioblastoma
CVCL_0400 
Half Maximal Inhibitory Concentration (IC50) 4.17 nM
TE-8 cells
Esophageal squamous cell carcinoma
CVCL_1766 
Half Maximal Inhibitory Concentration (IC50) 4.183 nM
5637 cells
Bladder carcinoma
CVCL_0126 
Half Maximal Inhibitory Concentration (IC50) 4.211 nM
SW756 cells
Cervical squamous cell carcinoma
CVCL_1727 
Half Maximal Inhibitory Concentration (IC50) 4.23 nM
RKO cells
Colon carcinoma
CVCL_0504 
Half Maximal Inhibitory Concentration (IC50) 4.251 nM
A-427 cells
Lung carcinoma
CVCL_1055 
Half Maximal Inhibitory Concentration (IC50) 4.393 nM
KOSC-2 cells
Floor of mouth squamous cell carcinoma
CVCL_1337 
Half Maximal Inhibitory Concentration (IC50) 4.408 nM
AM-38 cells
Glioblastoma
CVCL_1070 
Half Maximal Inhibitory Concentration (IC50) 4.503 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
Half Maximal Inhibitory Concentration (IC50) 4.525 nM
A204 cells
Rhabdomyosarcoma
CVCL_1058 
Half Maximal Inhibitory Concentration (IC50) 4.564 nM
BE-13 cells
T acute lymphoblastic leukemia
CVCL_1081 
Half Maximal Inhibitory Concentration (IC50) 4.567 nM
FTC-133 cells
Thyroid gland follicular carcinoma
CVCL_1219 
Half Maximal Inhibitory Concentration (IC50) 4.582 nM
SKG-IIIa cells
Cervical squamous cell carcinoma
CVCL_1704 
Half Maximal Inhibitory Concentration (IC50) 4.662 nM
RXF 393 cells
Renal carcinoma
CVCL_1673 
Half Maximal Inhibitory Concentration (IC50) 4.677 nM
GB-1 cells
Glioblastoma
CVCL_1227 
Half Maximal Inhibitory Concentration (IC50) 4.713 nM
SK-LU-1 cells
Lung adenocarcinoma
CVCL_0629 
Half Maximal Inhibitory Concentration (IC50) 4.722 nM
J82 cells
Bladder carcinoma
CVCL_0359 
Half Maximal Inhibitory Concentration (IC50) 4.753 nM
RPMI-7951 cells
Malignant melanoma
CVCL_1666 
Half Maximal Inhibitory Concentration (IC50) 4.758 nM
CAL-54 cells
Renal cell carcinoma
CVCL_1111 
Half Maximal Inhibitory Concentration (IC50) 4.94 nM
TYK-nu cells
Ovarian serous adenocarcinoma
CVCL_1776 
Half Maximal Inhibitory Concentration (IC50) 4.97 nM
Ca-Ski cells
Cervical squamous cell carcinoma
CVCL_1100 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 40 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[42]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 40 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[43]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 40 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[44]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 40 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[45]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 40 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[46]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 40 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[48]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 40 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[49]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 40 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[50]
Half Maximal Inhibitory Concentration (IC50) <40 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[287]
Half Maximal Inhibitory Concentration (IC50) 40 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[182]
Half Maximal Inhibitory Concentration (IC50) 40 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[288]
Half Maximal Inhibitory Concentration (IC50) 40 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[289]
Half Maximal Inhibitory Concentration (IC50) 40 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[290]
Half Maximal Inhibitory Concentration (IC50) 40 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[70]
Half Maximal Inhibitory Concentration (IC50) 40 nM
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
[291]
Half Maximal Inhibitory Concentration (IC50) 40 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[123]
Half Maximal Inhibitory Concentration (IC50) 40 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[104]
Half Maximal Inhibitory Concentration (IC50) 40 nM
SK-MEL-28 cells (BRAF inhibitor resistant)
Cutaneous melanoma
CVCL_0526 
[68]
Half Maximal Inhibitory Concentration (IC50) 40 nM
SF268 cells
Astrocytoma
CVCL_1689 
[287]
Half Maximal Inhibitory Concentration (IC50) 40 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[152]
Half Maximal Inhibitory Concentration (IC50) 40 nM
Panel (56 tumour cells)
Tumour
Undisclosed [292]
Half Maximal Inhibitory Concentration (IC50) 40 nM
BGC-823 cells
Stomach adenocarcinoma
CVCL_3360 
[26]
Half Maximal Inhibitory Concentration (IC50) 40.12 nM
NCI-H1792 cells
Lung adenocarcinoma
CVCL_1495 
Half Maximal Inhibitory Concentration (IC50) 40.69 nM
NCI-H23 cells
Lung adenocarcinoma
CVCL_1547 
Half Maximal Inhibitory Concentration (IC50) 40.86 nM
DBTRG-05MG cells
Anaplastic astrocytoma
CVCL_1169 
Half Maximal Inhibitory Concentration (IC50) 40.93 nM
COR-L88 cells
Lung small cell carcinoma
CVCL_1141 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 400 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[40]
Half Maximal Inhibitory Concentration (IC50) 400 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[221]
Half Maximal Inhibitory Concentration (IC50) 400 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[293]
Half Maximal Inhibitory Concentration (IC50) 400 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[225]
Half Maximal Inhibitory Concentration (IC50) 400 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[78]
Half Maximal Inhibitory Concentration (IC50) 400 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[79]
Half Maximal Inhibitory Concentration (IC50) 400 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[176]
Half Maximal Inhibitory Concentration (IC50) 400 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[177]
Half Maximal Inhibitory Concentration (IC50) 400 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[112]
Half Maximal Inhibitory Concentration (IC50) 400 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[106]
Half Maximal Inhibitory Concentration (IC50) 400 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[78]
Half Maximal Inhibitory Concentration (IC50) 400 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[79]
Half Maximal Inhibitory Concentration (IC50) 400 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[268]
Half Maximal Inhibitory Concentration (IC50) 400 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[225]
Half Maximal Inhibitory Concentration (IC50) 400 nM
MIA PaCa-2 cells (MSLN expression)
Pancreatic ductal adenocarcinoma
CVCL_0428 
[294]
Half Maximal Inhibitory Concentration (IC50) 400 nM
L2987 cells
Lung adenocarcinoma
CVCL_H586 
[295]
Half Maximal Inhibitory Concentration (IC50) 400 nM
BEL-7404 tumor cells
Endocervical adenocarcinoma
CVCL_6568 
[223]
Half Maximal Inhibitory Concentration (IC50) 4000 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[131]
Half Maximal Inhibitory Concentration (IC50) >40000 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[221]
Half Maximal Inhibitory Concentration (IC50) >40000 nM
BJ cells
Normal
CVCL_3653 
[221]
Half Maximal Inhibitory Concentration (IC50) >40000 nM
TERT-RPE1 cells
Normal
CVCL_4388 
[221]
Half Maximal Inhibitory Concentration (IC50) 4010 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[99]
Half Maximal Inhibitory Concentration (IC50) 41 nM
SK-VLB cells
Ovarian carcinoma
Undisclosed [226]
Half Maximal Inhibitory Concentration (IC50) 41.48 nM
C8166 cells
Leukemia
CVCL_1099 
Half Maximal Inhibitory Concentration (IC50) 410 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[268]
Half Maximal Inhibitory Concentration (IC50) 4100 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[296]
Half Maximal Inhibitory Concentration (IC50) 411.5 nM
KLE cells
Endometrial adenocarcinoma
CVCL_1329 
Half Maximal Inhibitory Concentration (IC50) 4155.69 nM
HCC1419 cells
Breast ductal carcinoma
CVCL_1251 
Half Maximal Inhibitory Concentration (IC50) 4160 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[88]
Half Maximal Inhibitory Concentration (IC50) 42.71 nM
SNU-5 cells
Gastric adenocarcinoma
CVCL_0078 
Half Maximal Inhibitory Concentration (IC50) 420 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[186]
Half Maximal Inhibitory Concentration (IC50) 420 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[265]
Half Maximal Inhibitory Concentration (IC50) 420 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[77]
Half Maximal Inhibitory Concentration (IC50) 420 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[108]
Half Maximal Inhibitory Concentration (IC50) 4200 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[116]
Half Maximal Inhibitory Concentration (IC50) 4270 nM
MGC-803 cells
Gastric cancer
CVCL_5334 
[233]
Half Maximal Inhibitory Concentration (IC50) 43.18 nM
NCI-H1092 cells
Lung small cell carcinoma
CVCL_1454 
Half Maximal Inhibitory Concentration (IC50) 43.33 nM
OVCAR-5 cells
Ovarian serous adenocarcinoma
CVCL_1628 
Half Maximal Inhibitory Concentration (IC50) 43.6 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[114]
Half Maximal Inhibitory Concentration (IC50) 430 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[221]
Half Maximal Inhibitory Concentration (IC50) 430 nM
IMR-90 cells
Normal
CVCL_0347 
[218]
Half Maximal Inhibitory Concentration (IC50) 430 nM
CT26.WT cells
Colon adenocarcinoma
CVCL_7256 
[156]
Half Maximal Inhibitory Concentration (IC50) 4356.62 nM
NY cells
Osteosarcoma
CVCL_1613 
Half Maximal Inhibitory Concentration (IC50) 436.37 nM
EKVX cells
Non-small cell lung carcinoma
CVCL_1195 
Half Maximal Inhibitory Concentration (IC50) 436.47 nM
DJM-1 cells
Skin squamous cell carcinoma
CVCL_1172 
Half Maximal Inhibitory Concentration (IC50) 4370 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[221]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 44 nM
Tumor cells
Tumour
Undisclosed [170]
Half Maximal Inhibitory Concentration (IC50) 44 nM
HCC70 cells
Breast ductal carcinoma
CVCL_1270 
[241]
Half Maximal Inhibitory Concentration (IC50) 44.02 nM
NB12 cells
Neuroblastoma
CVCL_1442 
Half Maximal Inhibitory Concentration (IC50) 44.69 nM
NCI-H720 cells
Lung carcinoid tumor
CVCL_1583 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 44.87 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[39]
Half Maximal Inhibitory Concentration (IC50) 44.89 nM
PANC-08-13 cells
Pancreatic ductal adenocarcinoma
CVCL_1638 
Half Maximal Inhibitory Concentration (IC50) 4430 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[258]
Half Maximal Inhibitory Concentration (IC50) 4470 nM
RD cells
Rhabdomyosarcoma
CVCL_1649 
[239]
Half Maximal Inhibitory Concentration (IC50) 4490 nM
RD cells
Rhabdomyosarcoma
CVCL_1649 
[153]
Half Maximal Inhibitory Concentration (IC50) 45 nM
Col2 cells
Colon carcinoma
CVCL_D645 
[194]
Half Maximal Inhibitory Concentration (IC50) 45 nM
Col2 cells
Colon carcinoma
CVCL_D645 
[196]
Half Maximal Inhibitory Concentration (IC50) 45.46 nM
HCC70 cells
Breast ductal carcinoma
CVCL_1270 
Half Maximal Inhibitory Concentration (IC50) 450 nM
SMMC-7721 cells
Hepatocellular carcinoma
CVCL_0534 
[257]
Half Maximal Inhibitory Concentration (IC50) 452.29 nM
Capan-2 cells
Pancreatic ductal adenocarcinoma
CVCL_0026 
Half Maximal Inhibitory Concentration (IC50) 4540 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[281]
Half Maximal Inhibitory Concentration (IC50) 455 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[69]
Half Maximal Inhibitory Concentration (IC50) 459.3 nM
Fibroblast cells
Normal
Undisclosed [34]
Half Maximal Inhibitory Concentration (IC50) 46 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[226]
Half Maximal Inhibitory Concentration (IC50) 46.97 nM
MeWo cells
Melanoma
CVCL_0445 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 460 nM
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
[147]
Half Maximal Inhibitory Concentration (IC50) 460 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[138]
Half Maximal Inhibitory Concentration (IC50) 460 nM
SK-MEL-24 cells
Melanoma
CVCL_0599 
[234]
Half Maximal Inhibitory Concentration (IC50) 46000000 nM
KATO III cells
Down syndrome
CVCL_0371 
[166]
Half Maximal Inhibitory Concentration (IC50) 4602.33 nM
T84 cells
Colon adenocarcinoma
CVCL_0555 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 47 nM
SK-MEL cells
Melanoma
Undisclosed [148]
Half Maximal Inhibitory Concentration (IC50) 47.35 nM
VMRC-RCZ cells
Renal cell carcinoma
CVCL_1791 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 47.97 nM
M19-MEL cells
Melanoma
CVCL_B415 
[39]
Half Maximal Inhibitory Concentration (IC50) 470 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[236]
Half Maximal Inhibitory Concentration (IC50) 474 nM
ID8 cells
Normal
CVCL_IU14 
[192]
Half Maximal Inhibitory Concentration (IC50) 4750 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[285]
Half Maximal Inhibitory Concentration (IC50) 4790 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[258]
Half Maximal Inhibitory Concentration (IC50) 4791.52 nM
COLO-679 cells
Cutaneous melanoma
CVCL_1130 
Half Maximal Inhibitory Concentration (IC50) 48 nM
LOX IMVI cells
Melanoma
CVCL_1381 
[226]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 48.31 nM
XF498 cells
Glioma
CVCL_8928 
[39]
Half Maximal Inhibitory Concentration (IC50) 48.53 nM
NCI-H2030 cells
Lung adenocarcinoma
CVCL_1517 
Half Maximal Inhibitory Concentration (IC50) 48.92 nM
SW837 cells
Rectal adenocarcinoma
CVCL_1729 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 480 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[148]
Half Maximal Inhibitory Concentration (IC50) 480 nM
PC-3M cells
Bone metastasis of prostate carcinoma
CVCL_9555 
[210]
Half Maximal Inhibitory Concentration (IC50) 486.07 nM
HDLM-2 cells
Hodgkin lymphoma
CVCL_0009 
Half Maximal Inhibitory Concentration (IC50) 49 nM
NCI-H2228 cells
Lung adenocarcinoma
CVCL_1543 
Half Maximal Inhibitory Concentration (IC50) 49 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[241]
Half Maximal Inhibitory Concentration (IC50) 490 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[145]
Half Maximal Inhibitory Concentration (IC50) 490 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[163]
Half Maximal Inhibitory Concentration (IC50) 491.21 nM
NCI-H2029 cells
Lung small cell carcinoma
CVCL_1516 
Half Maximal Inhibitory Concentration (IC50) 4920 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[83]
Half Maximal Inhibitory Concentration (IC50) 4950 nM
VACO 241 cells
Colon carcinoma
CVCL_5396 
[285]
Half Maximal Inhibitory Concentration (IC50) 4960 nM
184B5 cells
Normal
CVCL_4688 
[168]
Half Maximal Inhibitory Concentration (IC50) 5 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
Half Maximal Inhibitory Concentration (IC50) 5 nM
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
[297]
Half Maximal Inhibitory Concentration (IC50) 5 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[72]
Half Maximal Inhibitory Concentration (IC50) 5 nM
RPMI-8402 cells
T acute lymphoblastic leukemia
CVCL_1667 
[298]
Half Maximal Inhibitory Concentration (IC50) 5 nM
RPMI-8402 cells
T acute lymphoblastic leukemia
CVCL_1667 
[95]
Half Maximal Inhibitory Concentration (IC50) 5.021 nM
786-O cells
Renal cell carcinoma
CVCL_1051 
Half Maximal Inhibitory Concentration (IC50) 5.023 nM
GCT cells
Pleomorphic sarcoma
CVCL_1229 
Half Maximal Inhibitory Concentration (IC50) 5.051 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
Half Maximal Inhibitory Concentration (IC50) 5.074 nM
NCI-H2087 cells
Lung adenocarcinoma
CVCL_1524 
Half Maximal Inhibitory Concentration (IC50) 5.083 nM
MN-60 cells
Burkitt lymphoma
CVCL_1421 
Half Maximal Inhibitory Concentration (IC50) 5.205 nM
D-336MG cells
Glioblastoma
CVCL_1156 
Half Maximal Inhibitory Concentration (IC50) 5.223 nM
KYSE-270 cells
Esophageal squamous cell carcinoma
CVCL_1350 
Half Maximal Inhibitory Concentration (IC50) 5.31 nM
BHY cells
Head and neck squamous cell carcinoma
CVCL_1086 
Half Maximal Inhibitory Concentration (IC50) 5.354 nM
Caki-1 cells
Clear cell renal cell carcinoma
CVCL_0234 
Half Maximal Inhibitory Concentration (IC50) 5.377 nM
SK-N-AS cells
Neuroblastoma
CVCL_1700 
Half Maximal Inhibitory Concentration (IC50) 5.379 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[299]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 5.4 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[215]
Half Maximal Inhibitory Concentration (IC50) 5.4 nM
COLO 205 cells
Colon adenocarcinoma
CVCL_0218 
[300]
Half Maximal Inhibitory Concentration (IC50) 5.453 nM
YKG-1 cells
Glioblastoma
CVCL_1796 
Half Maximal Inhibitory Concentration (IC50) 5.469 nM
HCE-T cells
Nornal
CVCL_1272 
Half Maximal Inhibitory Concentration (IC50) 5.5 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[27]
Half Maximal Inhibitory Concentration (IC50) 5.5 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[23]
Half Maximal Inhibitory Concentration (IC50) 5.5 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[28]
Half Maximal Inhibitory Concentration (IC50) 5.5 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[29]
Half Maximal Inhibitory Concentration (IC50) 5.5 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[30]
Half Maximal Inhibitory Concentration (IC50) 5.547 nM
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
Half Maximal Inhibitory Concentration (IC50) 5.6 nM
Jurkat cells
T acute lymphoblastic leukemia
CVCL_0065 
[142]
Half Maximal Inhibitory Concentration (IC50) 5.6 nM
Jurkat cells
T acute lymphoblastic leukemia
CVCL_0065 
[143]
Half Maximal Inhibitory Concentration (IC50) 5.6 nM
HEK293 cells
Normal
CVCL_0045 
[30]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 5.7 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[40]
Half Maximal Inhibitory Concentration (IC50) 5.753 nM
HLE cells
Hepatocellular carcinoma
CVCL_1281 
Half Maximal Inhibitory Concentration (IC50) 5.997 nM
CAL-33 cells
Tongue squamous cell carcinoma
CVCL_1108 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 50 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[216]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 50 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[40]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 50 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[228]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 50 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[62]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 50 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[63]
Half Maximal Inhibitory Concentration (IC50) 50 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[290]
Half Maximal Inhibitory Concentration (IC50) 50 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[241]
Half Maximal Inhibitory Concentration (IC50) 50 nM
COLO 205 cells
Colon adenocarcinoma
CVCL_0218 
[128]
Half Maximal Inhibitory Concentration (IC50) 50 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[70]
Half Maximal Inhibitory Concentration (IC50) 50 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[154]
Half Maximal Inhibitory Concentration (IC50) 50 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[155]
Half Maximal Inhibitory Concentration (IC50) 50 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[266]
Half Maximal Inhibitory Concentration (IC50) 50 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[267]
Half Maximal Inhibitory Concentration (IC50) 50.3 nM
NCI-H810 cells
Lung large cell carcinoma
CVCL_1590 
Half Maximal Inhibitory Concentration (IC50) 500 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[150]
Half Maximal Inhibitory Concentration (IC50) 500 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[301]
Half Maximal Inhibitory Concentration (IC50) 500 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[293]
Half Maximal Inhibitory Concentration (IC50) 500 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[241]
Half Maximal Inhibitory Concentration (IC50) 500 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[78]
Half Maximal Inhibitory Concentration (IC50) 500 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[79]
Half Maximal Inhibitory Concentration (IC50) 500 nM
U-87MG ATCC cells
Glioblastoma
CVCL_0022 
[173]
Half Maximal Inhibitory Concentration (IC50) 500 nM
CRL-7065 cells
Normal
CVCL_1041 
[68]
Half Maximal Inhibitory Concentration (IC50) >50000 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[186]
Half Maximal Inhibitory Concentration (IC50) 50880 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[235]
Half Maximal Inhibitory Concentration (IC50) 51 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[302]
Half Maximal Inhibitory Concentration (IC50) 51.21 nM
MKN-28 cells
Gastric epithelial carcinoma
CVCL_1416 
Half Maximal Inhibitory Concentration (IC50) 51.29 nM
SK-MEL-1 cells
Metastatic melanoma
CVCL_0068 
Half Maximal Inhibitory Concentration (IC50) 51.69 nM
SW1463 cells
Rectal adenocarcinoma
CVCL_1718 
Half Maximal Inhibitory Concentration (IC50) 510 nM
L1210 cells
Lymphoblastic leukemia
CVCL_0382 
[192]
Half Maximal Inhibitory Concentration (IC50) 51500 nM
Jurkat cells
T acute lymphoblastic leukemia
CVCL_0065 
[235]
Half Maximal Inhibitory Concentration (IC50) 517.64 nM
LN-405 cells
Glioblastoma
CVCL_1378 
Half Maximal Inhibitory Concentration (IC50) 52 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[198]
Half Maximal Inhibitory Concentration (IC50) 52 nM
MES-SA/Dx5 cells
Uterine sarcoma
CVCL_2598 
[31]
Half Maximal Inhibitory Concentration (IC50) 52.7 nM
SW1417 cells
Colon adenocarcinoma
CVCL_1717 
Half Maximal Inhibitory Concentration (IC50) 520 nM
CA46 cells
Burkitt lymphoma
CVCL_1101 
[165]
Half Maximal Inhibitory Concentration (IC50) 520 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[268]
Half Maximal Inhibitory Concentration (IC50) 5270.72 nM
MFM-223 cells
Breast carcinoma
CVCL_1408 
Half Maximal Inhibitory Concentration (IC50) 53 nM
SK-VLB cells
Ovarian carcinoma
Undisclosed [302]
Half Maximal Inhibitory Concentration (IC50) 53.71 nM
TGBC24TKB cells
Gallbladder carcinoma
CVCL_1770 
Half Maximal Inhibitory Concentration (IC50) 5300 nM
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
[303]
Half Maximal Inhibitory Concentration (IC50) 5370 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[120]
Half Maximal Inhibitory Concentration (IC50) 5370 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[233]
Half Maximal Inhibitory Concentration (IC50) 5380 nM
NHDF cells
Normal
Undisclosed [188]
Half Maximal Inhibitory Concentration (IC50) 5385 nM
CEM/C2 cells
T acute lymphoblastic leukemia
CVCL_3497 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 54.33 nM
UACC-257 cells
Melanoma
CVCL_1779 
[39]
Half Maximal Inhibitory Concentration (IC50) 54.75 nM
SK-MEL-2 cells (MEK inhibitor-resistant)
Melanoma
CVCL_0069 
Half Maximal Inhibitory Concentration (IC50) 54.96 nM
NCI-H650 cells
Lung adenocarcinoma
CVCL_1575 
Half Maximal Inhibitory Concentration (IC50) 540 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[115]
Half Maximal Inhibitory Concentration (IC50) 540 nM
H22 cells
Hepatoma
CVCL_H613 
[77]
Half Maximal Inhibitory Concentration (IC50) 54690 nM
HEK293 cells
Normal
CVCL_0045 
[153]
Half Maximal Inhibitory Concentration (IC50) 55.12 nM
HPAF-II cells
Pancreatic ductal adenocarcinoma
CVCL_0313 
Half Maximal Inhibitory Concentration (IC50) 55.5 nM
HCC2218 cells
Breast ductal carcinoma
CVCL_1263 
Half Maximal Inhibitory Concentration (IC50) 55.67 nM
KM-H2 cells
Hodgkin lymphoma
CVCL_1330 
Half Maximal Inhibitory Concentration (IC50) 55.79 nM
TK-10 cells
Renal carcinoma
CVCL_1773 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 550 nM
SiHa cells
Cervical squamous cell carcinoma
CVCL_0032 
[40]
Half Maximal Inhibitory Concentration (IC50) 5500 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[82]
Half Maximal Inhibitory Concentration (IC50) 5500 nM
M059J cells
Glioblastoma
CVCL_0400 
[213]
Half Maximal Inhibitory Concentration (IC50) 5500 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[85]
Half Maximal Inhibitory Concentration (IC50) 56 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[304]
Half Maximal Inhibitory Concentration (IC50) 56.63 nM
NCI-H446 cells
Lung small cell carcinoma
CVCL_1562 
Half Maximal Inhibitory Concentration (IC50) 56.73 nM
SCC-25 cells
Squamous carcinoma
CVCL_1682 
Half Maximal Inhibitory Concentration (IC50) 56.87 nM
C3A cells
Hepatoblastoma
CVCL_1098 
Half Maximal Inhibitory Concentration (IC50) 560 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[77]
Half Maximal Inhibitory Concentration (IC50) 5650 nM
HEK-293T cells
Normal
CVCL_0063 
[70]
Half Maximal Inhibitory Concentration (IC50) 5690 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[233]
Half Maximal Inhibitory Concentration (IC50) 57 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[269]
Half Maximal Inhibitory Concentration (IC50) 57 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[243]
Half Maximal Inhibitory Concentration (IC50) 57 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[243]
Half Maximal Inhibitory Concentration (IC50) 57 nM
MES-SA cells
Uterine sarcoma
CVCL_1404 
[31]
Half Maximal Inhibitory Concentration (IC50) 57 nM
BGC-823 cells
Stomach adenocarcinoma
CVCL_3360 
[161]
Half Maximal Inhibitory Concentration (IC50) 57.87 nM
KS-1 cells
Glioblastoma
CVCL_1343 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 570 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[208]
Half Maximal Inhibitory Concentration (IC50) 5770 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[168]
Half Maximal Inhibitory Concentration (IC50) 58 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[305]
Half Maximal Inhibitory Concentration (IC50) 58.08 nM
LS-411N cells
Cecum adenocarcinoma
CVCL_1385 
Half Maximal Inhibitory Concentration (IC50) 58.48 nM
NCI-H2405 cells
Pleural mesothelioma
CVCL_1551 
Half Maximal Inhibitory Concentration (IC50) 580 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[87]
Half Maximal Inhibitory Concentration (IC50) 5800 nM
SGC-7901 cells
Gastric carcinoma
CVCL_0520 
[156]
Half Maximal Inhibitory Concentration (IC50) 588.29 nM
NCI-H82 cells
Lung small cell carcinoma
CVCL_1591 
Half Maximal Inhibitory Concentration (IC50) 59.28 nM
NCI-H1304 cells
Lung small cell carcinoma
CVCL_1462 
Half Maximal Inhibitory Concentration (IC50) 59.8 nM
SH-4 cells
Melanoma
CVCL_1692 
Half Maximal Inhibitory Concentration (IC50) 590 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[306]
Half Maximal Inhibitory Concentration (IC50) 590 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[245]
Half Maximal Inhibitory Concentration (IC50) 590 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[118]
Half Maximal Inhibitory Concentration (IC50) 590 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[281]
Half Maximal Inhibitory Concentration (IC50) 59130 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[98]
Half Maximal Inhibitory Concentration (IC50) 5930 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[134]
Half Maximal Inhibitory Concentration (IC50) 5930 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[135]
Half Maximal Inhibitory Concentration (IC50) 594.73 nM
CAL-120 cells
Breast carcinoma
CVCL_1104 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 6 nM
Huh-7 cells
Adult hepatocellular carcinoma
CVCL_0336 
[207]
Half Maximal Inhibitory Concentration (IC50) 6 nM
DC3F cells
Normal
CVCL_4704 
Half Maximal Inhibitory Concentration (IC50) 6 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[161]
Half Maximal Inhibitory Concentration (IC50) 6 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[69]
Half Maximal Inhibitory Concentration (IC50) 6 nM
RPMI-8226 cells
Plasma cell myeloma
CVCL_0014 
[162]
Half Maximal Inhibitory Concentration (IC50) 6 nM
T24 cells
Bladder carcinoma
CVCL_0554 
[158]
Half Maximal Inhibitory Concentration (IC50) 6 nM
RPMI-8402 cells
T acute lymphoblastic leukemia
CVCL_1667 
[73]
Half Maximal Inhibitory Concentration (IC50) 6 nM
RPMI-8402 cells
T acute lymphoblastic leukemia
CVCL_1667 
[96]
Half Maximal Inhibitory Concentration (IC50) 6.072 nM
DMS-273 cells
Small cell lung carcinoma
CVCL_1176 
Half Maximal Inhibitory Concentration (IC50) 6.091 nM
CHL-1 cells
Melanoma
CVCL_1122 
Half Maximal Inhibitory Concentration (IC50) 6.3 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[300]
Half Maximal Inhibitory Concentration (IC50) 6.311 nM
HEL cells
Erythroleukemia
CVCL_0001 
Half Maximal Inhibitory Concentration (IC50) 6.427 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
Half Maximal Inhibitory Concentration (IC50) 6.427 nM
CaR-1 cells
Rectal adenocarcinoma
CVCL_1116 
Half Maximal Inhibitory Concentration (IC50) 6.477 nM
C-33-A cells
Cervical squamous cell carcinoma
CVCL_1094 
Half Maximal Inhibitory Concentration (IC50) 6.515 nM
NCI-H1703 cells
Lung squamous cell carcinoma
CVCL_1490 
Half Maximal Inhibitory Concentration (IC50) 6.632 nM
U-87MG ATCC cells
Glioblastoma
CVCL_0022 
Half Maximal Inhibitory Concentration (IC50) 6.663 nM
ACHN cells
Renal adenocarcinoma
CVCL_1067 
Half Maximal Inhibitory Concentration (IC50) 6.7 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[307]
Half Maximal Inhibitory Concentration (IC50) 6.754 nM
KYSE-510 cells
Esophageal squamous cell carcinoma
CVCL_1354 
Half Maximal Inhibitory Concentration (IC50) 6.849 nM
COR-L23 cells
Lung carcinoma
CVCL_1139 
Half Maximal Inhibitory Concentration (IC50) 6.925 nM
BFTC-909 cells
Renal pelvis urothelial carcinoma
CVCL_1084 
Half Maximal Inhibitory Concentration (IC50) 6.965 nM
MDA-MB-453 cells
Breast adenocarcinoma
CVCL_0418 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 60 nM
Jurkat cells
T acute lymphoblastic leukemia
CVCL_0065 
[40]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 60 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[62]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 60 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[208]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 60 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[62]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 60 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[40]
Half Maximal Inhibitory Concentration (IC50) 60 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[128]
Half Maximal Inhibitory Concentration (IC50) 60 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[232]
Half Maximal Inhibitory Concentration (IC50) 60 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[290]
Half Maximal Inhibitory Concentration (IC50) 60 nM
Huh-7 cells
Adult hepatocellular carcinoma
CVCL_0336 
[38]
Half Maximal Inhibitory Concentration (IC50) 60 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[308]
Half Maximal Inhibitory Concentration (IC50) 60 nM
HEC-1B cells
Endometrial adenocarcinoma
CVCL_0294 
[166]
Half Maximal Inhibitory Concentration (IC50) 60 nM
L1210 cells
Lymphoblastic leukemia
CVCL_0382 
[273]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 600 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[309]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 600 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[204]
Half Maximal Inhibitory Concentration (IC50) 600 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[211]
Half Maximal Inhibitory Concentration (IC50) 600 nM
NCI-N87 cells
Gastric tubular adenocarcinoma
CVCL_1603 
[33]
Half Maximal Inhibitory Concentration (IC50) 600 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[293]
Half Maximal Inhibitory Concentration (IC50) 600 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[163]
Half Maximal Inhibitory Concentration (IC50) 600 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[231]
Half Maximal Inhibitory Concentration (IC50) 600 nM
HEK293 cells
Normal
CVCL_0045 
[225]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 6000 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[148]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 6000 nM
SAS cells
Tongue squamous cell carcinoma
CVCL_1675 
[103]
Half Maximal Inhibitory Concentration (IC50) 6000 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[213]
Half Maximal Inhibitory Concentration (IC50) 6000 nM
SAS cells
Tongue squamous cell carcinoma
CVCL_1675 
[171]
Half Maximal Inhibitory Concentration (IC50) 60010 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[244]
Half Maximal Inhibitory Concentration (IC50) 6080 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[108]
Half Maximal Inhibitory Concentration (IC50) 6080 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[180]
Half Maximal Inhibitory Concentration (IC50) 61.7 nM
RKO cells
Colon carcinoma
CVCL_0504 
[156]
Half Maximal Inhibitory Concentration (IC50) 610 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[245]
Half Maximal Inhibitory Concentration (IC50) 610 nM
SH-SY5Y cells
Bone marrow neuroblastoma
CVCL_0019 
[163]
Half Maximal Inhibitory Concentration (IC50) 61000 nM
CPT-K5 cells
T acute lymphoblastic leukemia
CVCL_2878 
[95]
Half Maximal Inhibitory Concentration (IC50) 6130 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[168]
Half Maximal Inhibitory Concentration (IC50) 618.33 nM
NCI-H2342 cells
Lung adenocarcinoma
CVCL_1549 
Half Maximal Inhibitory Concentration (IC50) 62.09 nM
COLO 320HSR cells
Colon adenocarcinoma
CVCL_0220 
Half Maximal Inhibitory Concentration (IC50) 620 nM
Macrophage cells
Normal
Undisclosed [310]
Half Maximal Inhibitory Concentration (IC50) 628.09 nM
SCH cells
Gastric choriocarcinoma
CVCL_1687 
Half Maximal Inhibitory Concentration (IC50) 630 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[308]
Half Maximal Inhibitory Concentration (IC50) 6300 nM
Bel-7402 cells
Hepatoma
CVCL_5492 
[26]
Half Maximal Inhibitory Concentration (IC50) <64 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[257]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 64.42 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[39]
Half Maximal Inhibitory Concentration (IC50) 640 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[311]
Half Maximal Inhibitory Concentration (IC50) 6400 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[175]
Half Maximal Inhibitory Concentration (IC50) >6400 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[77]
Half Maximal Inhibitory Concentration (IC50) 65 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[282]
Half Maximal Inhibitory Concentration (IC50) 65 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[107]
Half Maximal Inhibitory Concentration (IC50) 65.1 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[192]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 65.77 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[39]
Half Maximal Inhibitory Concentration (IC50) 650 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[312]
Half Maximal Inhibitory Concentration (IC50) 650 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[173]
Half Maximal Inhibitory Concentration (IC50) 6510 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[258]
Half Maximal Inhibitory Concentration (IC50) 66 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[164]
Half Maximal Inhibitory Concentration (IC50) 66.1 nM
NCI-H1355 cells
Lung adenocarcinoma
CVCL_1464 
Half Maximal Inhibitory Concentration (IC50) 66.15 nM
GCIY cells
Gastric adenocarcinoma
CVCL_1228 
Half Maximal Inhibitory Concentration (IC50) 660 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[313]
Half Maximal Inhibitory Concentration (IC50) 660 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[108]
Half Maximal Inhibitory Concentration (IC50) 660 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[308]
Half Maximal Inhibitory Concentration (IC50) 660 nM
A375 cells
Amelanotic melanoma
CVCL_0132 
[163]
Half Maximal Inhibitory Concentration (IC50) 67 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[87]
Half Maximal Inhibitory Concentration (IC50) 67 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[222]
Half Maximal Inhibitory Concentration (IC50) 6700 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[134]
Half Maximal Inhibitory Concentration (IC50) 68.13 nM
NCI-H2009 cells
Lung adenocarcinoma
CVCL_1514 
Half Maximal Inhibitory Concentration (IC50) 680 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[314]
Half Maximal Inhibitory Concentration (IC50) 680 nM
U-937 cells
Adult acute monocytic leukemia
CVCL_0007 
[270]
Half Maximal Inhibitory Concentration (IC50) 680 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[87]
Half Maximal Inhibitory Concentration (IC50) 680 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[313]
Half Maximal Inhibitory Concentration (IC50) 680 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[257]
Half Maximal Inhibitory Concentration (IC50) 6800 nM
T24 cells
Bladder carcinoma
CVCL_0554 
[258]
Half Maximal Inhibitory Concentration (IC50) 69 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[194]
Half Maximal Inhibitory Concentration (IC50) 69 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[196]
Half Maximal Inhibitory Concentration (IC50) 69.51 nM
U266B1 cells
Plasma cell myeloma
CVCL_0566 
Half Maximal Inhibitory Concentration (IC50) 69.74 nM
KYSE-140 cells
Esophageal squamous cell carcinoma
CVCL_1347 
Half Maximal Inhibitory Concentration (IC50) 69.89 nM
KALS-1 cells
Glioblastoma
CVCL_1323 
Half Maximal Inhibitory Concentration (IC50) 690 nM
HEK-293T cells
Normal
CVCL_0063 
[163]
Half Maximal Inhibitory Concentration (IC50) 6960 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[315]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 7 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[216]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 7 nM
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
[227]
Half Maximal Inhibitory Concentration (IC50) 7 nM
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
[72]
Half Maximal Inhibitory Concentration (IC50) 7 nM
HCT-8 cells
Ileocecal adenocarcinoma
CVCL_2478 
[316]
Half Maximal Inhibitory Concentration (IC50) 7 nM
Bel-7402 cells
Hepatoma
CVCL_5492 
[316]
Half Maximal Inhibitory Concentration (IC50) 7 nM
P388 cells
Lymphoma
CVCL_7222 
[317]
Half Maximal Inhibitory Concentration (IC50) 7.02 nM
LAMA-84 cells
Chronic myeloid leukemia
CVCL_0388 
Half Maximal Inhibitory Concentration (IC50) 7.054 nM
LXF-289 cells
Lung adenocarcinoma
CVCL_1394 
Half Maximal Inhibitory Concentration (IC50) 7.077 nM
A498 cells
Renal carcinoma
CVCL_1056 
Half Maximal Inhibitory Concentration (IC50) 7.079 nM
ESS-1 cells
Endometrioid stromal sarcoma
CVCL_1205 
Half Maximal Inhibitory Concentration (IC50) 7.103 nM
Panc 03.27 cells
Pancreatic adenocarcinoma
CVCL_1635 
Half Maximal Inhibitory Concentration (IC50) 7.253 nM
SK-HEP1 cells
Hepatoma
CVCL_0525 
Half Maximal Inhibitory Concentration (IC50) 7.263 nM
OAW-28 cells
Ovarian serous cystadenocarcinoma
CVCL_1614 
Half Maximal Inhibitory Concentration (IC50) 7.272 nM
OVCAR-8 cells
High grade ovarian serous adenocarcinoma
CVCL_1629 
Half Maximal Inhibitory Concentration (IC50) 7.311 nM
GMS-10 cells
Glioblastoma
CVCL_1233 
Half Maximal Inhibitory Concentration (IC50) 7.38 nM
TE-5 cells
Esophageal squamous cell carcinoma
CVCL_1764 
Half Maximal Inhibitory Concentration (IC50) 7.569 nM
MDA-MB-157 cells
Breast carcinoma
CVCL_0618 
Half Maximal Inhibitory Concentration (IC50) 7.628 nM
MEL-HO cells
Melanoma
CVCL_1402 
Half Maximal Inhibitory Concentration (IC50) 7.654 nM
MG-63 cells
Osteosarcoma
CVCL_0426 
Half Maximal Inhibitory Concentration (IC50) 7.701 nM
KNS-62 cells
Lung squamous cell carcinoma
CVCL_1335 
Half Maximal Inhibitory Concentration (IC50) 7.8 nM
NCI-H928 cells
Normal
Undisclosed [300]
Half Maximal Inhibitory Concentration (IC50) 7.897 nM
LB1047-RCC cells
Renal cell carcinoma
CVCL_1364 
Half Maximal Inhibitory Concentration (IC50) 7.904 nM
EC-GI-10 cells
Esophageal squamous cell carcinoma
CVCL_1187 
Half Maximal Inhibitory Concentration (IC50) 7.909 nM
SF-295 cells
Glioblastoma
CVCL_1690 
Half Maximal Inhibitory Concentration (IC50) 70 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[120]
Half Maximal Inhibitory Concentration (IC50) 70 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[221]
Half Maximal Inhibitory Concentration (IC50) 70 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[284]
Half Maximal Inhibitory Concentration (IC50) 70 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[318]
Half Maximal Inhibitory Concentration (IC50) 70 nM
BT-20 cells
Invasive breast carcinoma of no special type
CVCL_0178 
[67]
Half Maximal Inhibitory Concentration (IC50) 70 nM
BT-20 cells
Invasive breast carcinoma of no special type
CVCL_0178 
[27]
Half Maximal Inhibitory Concentration (IC50) 70 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[312]
Half Maximal Inhibitory Concentration (IC50) 70 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[104]
Half Maximal Inhibitory Concentration (IC50) 70 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[256]
Half Maximal Inhibitory Concentration (IC50) 70 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[154]
Half Maximal Inhibitory Concentration (IC50) 70 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[155]
Half Maximal Inhibitory Concentration (IC50) 70 nM
CAMA-1 cells
Breast adenocarcinoma
CVCL_1115 
[67]
Half Maximal Inhibitory Concentration (IC50) 70 nM
CAMA-1 cells
Breast adenocarcinoma
CVCL_1115 
[38]
Half Maximal Inhibitory Concentration (IC50) 70 nM
NCI-H23 cells
Lung adenocarcinoma
CVCL_1547 
[209]
Half Maximal Inhibitory Concentration (IC50) 70 nM
SF268 cells
Astrocytoma
CVCL_1689 
[218]
Half Maximal Inhibitory Concentration (IC50) 70 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[287]
Half Maximal Inhibitory Concentration (IC50) 700 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[130]
Half Maximal Inhibitory Concentration (IC50) 700 nM
HEp-2 cells
Laryngeal carcinoma
CVCL_1906 
[222]
Half Maximal Inhibitory Concentration (IC50) 7000 nM
BT474-M1 cells
Invasive breast carcinoma
CVCL_0179 
[296]
Half Maximal Inhibitory Concentration (IC50) 71 nM
THP-1 cells
Childhood acute monocytic leukemia
CVCL_0006 
[211]
Half Maximal Inhibitory Concentration (IC50) 71.47 nM
RVH-421 cells
Melanoma
CVCL_1672 
Half Maximal Inhibitory Concentration (IC50) 710 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[269]
Half Maximal Inhibitory Concentration (IC50) 710 nM
SW579 cells
Thyroid carcinoma
CVCL_3603 
[76]
Half Maximal Inhibitory Concentration (IC50) 7100 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[296]
Half Maximal Inhibitory Concentration (IC50) 711 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[221]
Half Maximal Inhibitory Concentration (IC50) 711.49 nM
SW684 cells
Fibrosarcoma
CVCL_1726 
Half Maximal Inhibitory Concentration (IC50) 71300 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[244]
Half Maximal Inhibitory Concentration (IC50) 72 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[305]
Half Maximal Inhibitory Concentration (IC50) 72.08 nM
CP50-MEL-B cells
Melanoma
CVCL_1143 
Half Maximal Inhibitory Concentration (IC50) 72.45 nM
COLO-680N cells
Esophageal squamous cell carcinoma
CVCL_1131 
Half Maximal Inhibitory Concentration (IC50) 72.8 nM
EPLC-272H cells
Lung mucoepidermoid carcinoma
CVCL_1197 
Half Maximal Inhibitory Concentration (IC50) 7210.91 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
Half Maximal Inhibitory Concentration (IC50) 7325.59 nM
LS-123 cells
Colon adenocarcinoma
CVCL_1383 
Half Maximal Inhibitory Concentration (IC50) 736.29 nM
KP-N-YS cells
Adrenal gland neuroblastoma
CVCL_1342 
Half Maximal Inhibitory Concentration (IC50) 74 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[123]
Half Maximal Inhibitory Concentration (IC50) 74.99 nM
KM12 cells
Colon adenocarcinoma
CVCL_1331 
Half Maximal Inhibitory Concentration (IC50) 7420 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[167]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 75 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[207]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 75 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[227]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 75 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[122]
Half Maximal Inhibitory Concentration (IC50) 750 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[212]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 76.38 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[39]
Half Maximal Inhibitory Concentration (IC50) 76.9 nM
SW626 cells
Colon adenocarcinoma
CVCL_1725 
Half Maximal Inhibitory Concentration (IC50) 760 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[308]
Half Maximal Inhibitory Concentration (IC50) 760 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[240]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 77.62 nM
KM-20L2 cells
Colon carcinoma
CVCL_D889 
[39]
Half Maximal Inhibitory Concentration (IC50) 776.97 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
Half Maximal Inhibitory Concentration (IC50) 78 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[19]
Half Maximal Inhibitory Concentration (IC50) 78.11 nM
KYSE-410 cells
Esophageal squamous cell carcinoma
CVCL_1352 
Half Maximal Inhibitory Concentration (IC50) 78.21 nM
OMC-1 cells
Cervical squamous cell carcinoma
CVCL_1623 
Half Maximal Inhibitory Concentration (IC50) 780 nM
HEK293 cells
Normal
CVCL_0045 
[265]
Half Maximal Inhibitory Concentration (IC50) 786 nM
WI-38 cells
Normal
CVCL_0579 
[192]
Half Maximal Inhibitory Concentration (IC50) 7860 nM
SK-MEL-2 cells (MEK inhibitor-resistant)
Melanoma
CVCL_0069 
[187]
Half Maximal Inhibitory Concentration (IC50) 7923.68 nM
CAL-85-1 cells
Breast carcinoma
CVCL_1114 
Half Maximal Inhibitory Concentration (IC50) 7940 nM
HEK293 cells
Normal
CVCL_0045 
[319]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 8 nM
LoVo cells
Colon adenocarcinoma
CVCL_0399 
[148]
Half Maximal Inhibitory Concentration (IC50) 8 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[316]
Half Maximal Inhibitory Concentration (IC50) 8 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[211]
Half Maximal Inhibitory Concentration (IC50) 8 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[302]
Half Maximal Inhibitory Concentration (IC50) 8.123 nM
KY821 cells
Acute myelomonocytic leukemia
CVCL_1346 
Half Maximal Inhibitory Concentration (IC50) 8.136 nM
LCLC-97TM1 cells
Lung large cell carcinoma
CVCL_1376 
Half Maximal Inhibitory Concentration (IC50) 8.238 nM
MSTO-211H cells
Pleural biphasic mesothelioma
CVCL_1430 
Half Maximal Inhibitory Concentration (IC50) 8.365 nM
KU812 cells
Chronic myeloid leukemia
CVCL_0379 
Half Maximal Inhibitory Concentration (IC50) 8.5 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[253]
Half Maximal Inhibitory Concentration (IC50) 8.612 nM
MZ7-mel cells
Melanoma
CVCL_1436 
Half Maximal Inhibitory Concentration (IC50) 8.63 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[266]
Half Maximal Inhibitory Concentration (IC50) 8.63 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[267]
Half Maximal Inhibitory Concentration (IC50) 8.743 nM
NCI-N87 cells
Gastric tubular adenocarcinoma
CVCL_1603 
Half Maximal Inhibitory Concentration (IC50) 8.787 nM
HOP-92 cells
Non-small cell lung carcinoma
CVCL_1286 
Half Maximal Inhibitory Concentration (IC50) 8.8 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[320]
Half Maximal Inhibitory Concentration (IC50) 8.887 nM
HMV-2 cells
Vaginal melanoma
CVCL_1282 
Half Maximal Inhibitory Concentration (IC50) 8.99 nM
OAW-42 cells
Ovarian serous cystadenocarcinoma
CVCL_1615 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 80 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[103]
Half Maximal Inhibitory Concentration (IC50) 80 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[311]
Half Maximal Inhibitory Concentration (IC50) 80 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[308]
Half Maximal Inhibitory Concentration (IC50) 80 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[263]
Half Maximal Inhibitory Concentration (IC50) 80 nM
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
[90]
Half Maximal Inhibitory Concentration (IC50) 80 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[229]
Half Maximal Inhibitory Concentration (IC50) 80 nM
HT-1080 cells (FAP expression)
Fibrosarcoma
CVCL_0317 
[194]
Half Maximal Inhibitory Concentration (IC50) 80 nM
HT-1080 cells (FAP expression)
Fibrosarcoma
CVCL_0317 
[195]
Half Maximal Inhibitory Concentration (IC50) 80 nM
HT-1080 cells (FAP expression)
Fibrosarcoma
CVCL_0317 
[196]
Half Maximal Inhibitory Concentration (IC50) 80 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[113]
Half Maximal Inhibitory Concentration (IC50) 80 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[33]
Half Maximal Inhibitory Concentration (IC50) 80 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[218]
Half Maximal Inhibitory Concentration (IC50) 80 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[112]
Half Maximal Inhibitory Concentration (IC50) 80 nM
IMR-32 cells
Neuroblastoma
CVCL_0346 
[222]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 80.91 nM
OVCAR-5 cells
Ovarian serous adenocarcinoma
CVCL_1628 
[39]
Half Maximal Inhibitory Concentration (IC50) 80.99 nM
EFO-27 cells
Ovarian mucinous adenocarcinoma
CVCL_1192 
Half Maximal Inhibitory Concentration (IC50) 800 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[321]
Half Maximal Inhibitory Concentration (IC50) 800 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[293]
Half Maximal Inhibitory Concentration (IC50) 800 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[245]
Half Maximal Inhibitory Concentration (IC50) 800 nM
NCI-H1299 cells (MMAE resistant)
Lung large cell carcinoma
CVCL_0060 
[130]
Half Maximal Inhibitory Concentration (IC50) 800 nM
MRC5 cells
Normal
CVCL_0440 
[30]
Half Maximal Inhibitory Concentration (IC50) 81.1 nM
DMS 114 cells
Lung small cell carcinoma
CVCL_1174 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 816.58 nM
Hs 578T cells
Invasive breast carcinoma
CVCL_0332 
[39]
Half Maximal Inhibitory Concentration (IC50) 82.56 nM
KYSE-520 cells
Esophageal squamous cell carcinoma
CVCL_1355 
Half Maximal Inhibitory Concentration (IC50) 8280 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[92]
Half Maximal Inhibitory Concentration (IC50) 83 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[159]
Half Maximal Inhibitory Concentration (IC50) 83.02 nM
MDA-MB-175-VII cells
Breast carcinoma
CVCL_1400 
Half Maximal Inhibitory Concentration (IC50) 830 nM
HEK293 cells
Normal
CVCL_0045 
[106]
Half Maximal Inhibitory Concentration (IC50) 8370 nM
WI-38 cells
Normal
CVCL_0579 
[258]
Half Maximal Inhibitory Concentration (IC50) 84 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[286]
Half Maximal Inhibitory Concentration (IC50) 84.75 nM
DK-MG cells
Glioblastoma
CVCL_1173 
Half Maximal Inhibitory Concentration (IC50) 85 nM
Jurkat cells
T acute lymphoblastic leukemia
CVCL_0065 
[322]
Half Maximal Inhibitory Concentration (IC50) 85.52 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
Half Maximal Inhibitory Concentration (IC50) 85.66 nM
ACN cells
Melanoma
CVCL_1068 
Half Maximal Inhibitory Concentration (IC50) 850 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[282]
Half Maximal Inhibitory Concentration (IC50) 86.1 nM
LNCaP cells
Prostate carcinoma
CVCL_0395 
[254]
Half Maximal Inhibitory Concentration (IC50) 86.88 nM
SiHa cells
Cervical squamous cell carcinoma
CVCL_0032 
Half Maximal Inhibitory Concentration (IC50) 860 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[282]
Half Maximal Inhibitory Concentration (IC50) 8640 nM
HEC-1B cells
Endometrial adenocarcinoma
CVCL_0294 
[164]
Half Maximal Inhibitory Concentration (IC50) 87.25 nM
LB2518-MEL cells
Melanoma
CVCL_1366 
Half Maximal Inhibitory Concentration (IC50) 87.43 nM
CAMA-1 cells
Breast adenocarcinoma
CVCL_1115 
Half Maximal Inhibitory Concentration (IC50) 87.5 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[266]
Half Maximal Inhibitory Concentration (IC50) 87.8 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[302]
Half Maximal Inhibitory Concentration (IC50) 8750 nM
HEK293 cells
Normal
CVCL_0045 
[248]
Half Maximal Inhibitory Concentration (IC50) 88 nM
T24 cells
Bladder carcinoma
CVCL_0554 
[323]
Half Maximal Inhibitory Concentration (IC50) 88.05 nM
ES6 cells
Ewing sarcoma
CVCL_1202 
Half Maximal Inhibitory Concentration (IC50) 8830 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[193]
Half Maximal Inhibitory Concentration (IC50) 8870 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[153]
Half Maximal Inhibitory Concentration (IC50) 89 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[305]
Half Maximal Inhibitory Concentration (IC50) 890 nM
HEK293 cells
Normal
CVCL_0045 
[134]
Half Maximal Inhibitory Concentration (IC50) 890 nM
MRC5 cells
Normal
CVCL_0440 
[117]
Half Maximal Inhibitory Concentration (IC50) 8900 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[92]
Half Maximal Inhibitory Concentration (IC50) 8930 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[324]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 9 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[207]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 9 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[227]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 9 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[122]
Half Maximal Inhibitory Concentration (IC50) 9 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[141]
Half Maximal Inhibitory Concentration (IC50) 9 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[127]
Half Maximal Inhibitory Concentration (IC50) 9 nM
P388 cells
Lymphoma
CVCL_7222 
[95]
Half Maximal Inhibitory Concentration (IC50) 9.009 nM
SF539 cells
Gliosarcoma
CVCL_1691 
Half Maximal Inhibitory Concentration (IC50) 9.114 nM
D-263MG cells
Glioblastoma
CVCL_1154 
Half Maximal Inhibitory Concentration (IC50) 9.314 nM
22RV1 cells
Prostate carcinoma
CVCL_1045 
Half Maximal Inhibitory Concentration (IC50) 9.425 nM
NCI-H1299 cells (MMAE resistant)
Lung large cell carcinoma
CVCL_0060 
Half Maximal Inhibitory Concentration (IC50) 9.753 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
Half Maximal Inhibitory Concentration (IC50) 9.948 nM
M14 cells
Melanoma
CVCL_1395 
Half Maximal Inhibitory Concentration (IC50) 9.968 nM
OS-RC-2 cells
Clear cell renal cell carcinoma
CVCL_1626 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 90 nM
Jurkat cells
T acute lymphoblastic leukemia
CVCL_0065 
[148]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 90 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[199]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 90 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[103]
Half Maximal Inhibitory Concentration (IC50) 90 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[257]
Half Maximal Inhibitory Concentration (IC50) 90 nM
PANC-1 cells
Pancreatic ductal adenocarcinoma
CVCL_0480 
[200]
Half Maximal Inhibitory Concentration (IC50) 90 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[221]
Half Maximal Inhibitory Concentration (IC50) 90 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[231]
Half Maximal Inhibitory Concentration (IC50) 90 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[76]
Half Maximal Inhibitory Concentration (IC50) 90 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[77]
Half Maximal Inhibitory Concentration (IC50) 90 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[229]
Half Maximal Inhibitory Concentration (IC50) 90.89 nM
NCI-H2452 cells
Pleural mesothelioma
CVCL_1553 
Half Maximal Inhibitory Concentration (IC50) 900 nM
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
[26]
Half Maximal Inhibitory Concentration (IC50) 900 nM
SK-HEP1 cells
Hepatoma
CVCL_0525 
[223]
Half Maximal Inhibitory Concentration (IC50) 91 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[187]
Half Maximal Inhibitory Concentration (IC50) 91.19 nM
LB373-MEL-D cells
Melanoma
CVCL_1367 
Half Maximal Inhibitory Concentration (IC50) 91.86 nM
NOS-1 cells
Osteosarcoma
CVCL_1610 
Half Maximal Inhibitory Concentration (IC50) 9170 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[319]
Half Maximal Inhibitory Concentration (IC50) 92.14 nM
KYSE-70 cells
Esophageal squamous cell carcinoma
CVCL_1356 
Half Maximal Inhibitory Concentration (IC50) 920 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[315]
Half Maximal Inhibitory Concentration (IC50) 920 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[282]
Half Maximal Inhibitory Concentration (IC50) 9290 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[319]
Half Maximal Inhibitory Concentration (IC50) 93.98 nM
8305C cells
Thyroid gland anaplastic carcinoma
CVCL_1053 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 937.56 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[39]
Half Maximal Inhibitory Concentration (IC50) 940 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[306]
Half Maximal Inhibitory Concentration (IC50) 940 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[206]
Half Maximal Inhibitory Concentration (IC50) 940 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[311]
Half Maximal Inhibitory Concentration (IC50) 9450 nM
MGC-803 cells
Gastric cancer
CVCL_5334 
[102]
Half Maximal Inhibitory Concentration (IC50) 9492.4 nM
LS1034 cells
Cecum adenocarcinoma
CVCL_1382 
Half Maximal Cell Growth Inhibitory Concentration (GI50) 95.06 nM
EKVX cells
Non-small cell lung carcinoma
CVCL_1195 
[39]
Half Maximal Inhibitory Concentration (IC50) 95.58 nM
H-EMC-SS cells
Extraskeletal myxoid chondrosarcoma
CVCL_1238 
Half Maximal Inhibitory Concentration (IC50) 950 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[212]
Half Maximal Inhibitory Concentration (IC50) 9520 nM
Eca-109 cells
Esophageal squamous cell carcinoma
CVCL_6898 
[119]
Half Maximal Inhibitory Concentration (IC50) 9550 nM
Caco-2 cells
Colon adenocarcinoma
CVCL_0025 
[89]
Half Maximal Inhibitory Concentration (IC50) 956.65 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
Half Maximal Inhibitory Concentration (IC50) 960 nM
SK-HEP1 cells
Hepatoma
CVCL_0525 
[76]
Half Maximal Inhibitory Concentration (IC50) 9621.56 nM
NCI-H1993 cells
Lung adenocarcinoma
CVCL_1512 
Half Maximal Inhibitory Concentration (IC50) 9670 nM
BGC-823 cells
Stomach adenocarcinoma
CVCL_3360 
[136]
Half Maximal Inhibitory Concentration (IC50) 970 nM
Farage cells
Normal
CVCL_0214 
[325]
Half Maximal Inhibitory Concentration (IC50) 970 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[107]
Half Maximal Inhibitory Concentration (IC50) 970 nM
MCF-10A cells
Normal
CVCL_0598 
[113]
Half Maximal Inhibitory Concentration (IC50) 9700 nM
BGC-823 cells
Stomach adenocarcinoma
CVCL_3360 
[137]
Half Maximal Inhibitory Concentration (IC50) 975.25 nM
NCI-H2291 cells
Lung adenocarcinoma
CVCL_1546 
Half Maximal Inhibitory Concentration (IC50) 98 nM
SNU-638 cells
Gastric carcinoma
CVCL_0102 
[194]
Half Maximal Inhibitory Concentration (IC50) 98 nM
SNU-638 cells
Gastric carcinoma
CVCL_0102 
[195]
Half Maximal Inhibitory Concentration (IC50) 98 nM
SNU-638 cells
Gastric carcinoma
CVCL_0102 
[196]
Half Maximal Inhibitory Concentration (IC50) 980 nM
CNE-2 cells
Normal
CVCL_6889 
[108]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 99 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[122]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 99 nM
Huh-7 cells
Adult hepatocellular carcinoma
CVCL_0336 
[227]
Half Maximal Inhibitory Concentration (IC50) 99 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[19]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 990 nM
Detroit 551 cells
Normal
CVCL_2434 
[208]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 990 nM
Detroit 551 cells
Normal
CVCL_2434 
[103]
Half Maximal Inhibitory Concentration (IC50) 990 nM
Detroit 551 cells
Normal
CVCL_2434 
[171]
Half Maximal Inhibitory Concentration (IC50) 9920 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[319]
Each Antibody-drug Conjugate Related to This Payload
References
Ref 1 Antitumor agents. 7. Synthesis and antitumor activity of novel hexacyclic camptothecin analogues. J Med Chem. 1994 Sep 16;37(19):3033-9. doi: 10.1021/jm00045a007.
Ref 2 Synthesis and antitumor activity of ring A- and F-modified hexacyclic camptothecin analogues. J Med Chem. 1998 Jun 18;41(13):2308-18. doi: 10.1021/jm970765q.
Ref 3 Synthesis and cytotoxicity of water soluble quaternary salt derivatives of camptothecin. Bioorg Med Chem Lett. 2004 Aug 2;14(15):4023-6. doi: 10.1016/j.bmcl.2004.05.032.
Ref 4 DNA topoisomerase I inhibitors: cytotoxic flavones from Lethedon tannaensis. J Nat Prod. 1996 Jul;59(7):701-3. doi: 10.1021/np960336f.
Ref 5 Biological activity of some coumarins from Sri Lankan Rutaceae. J Nat Prod. 1994 Apr;57(4):518-20. doi: 10.1021/np50106a013.
Ref 6 Frajunolides E-K, briarane diterpenes from Junceella fragilis. J Nat Prod. 2008 Sep;71(9):1551-6. doi: 10.1021/np800126f. Epub 2008 Sep 6.
Ref 7 Three types of cytotoxic natural caged-scaffolds: pure enantiomers or partial racemates. J Nat Prod. 2014 Jul 25;77(7):1562-71. doi: 10.1021/np400996k. Epub 2014 Jun 18.
Ref 8 Strychnobaillonine, an unsymmetrical bisindole alkaloid with an unprecedented skeleton from Strychnos icaja roots. J Nat Prod. 2014 Apr 25;77(4):1078-82. doi: 10.1021/np400908u. Epub 2014 Mar 4.
Ref 9 Bioactive furanonaphthoquinones from Crescentia cujete. J Nat Prod. 1993 Sep;56(9):1500-5. doi: 10.1021/np50099a008.
Ref 10 Limonoids showing selective toxicity to DNA repair-deficient yeast and other constituents of Trichilia emetica. J Nat Prod. 1998 Feb;61(2):179-84. doi: 10.1021/np9701687.
Ref 11 Cytotoxic and other compounds from Didymochlaena truncatula from the Madagascar rain forest. J Nat Prod. 2006 Feb;69(2):284-6. doi: 10.1021/np050351x.
Ref 12 Design and synthesis of 4-amino-2-phenylquinazolines as novel topoisomerase I inhibitors with molecular modeling. Bioorg Med Chem. 2011 Jul 15;19(14):4399-404. doi: 10.1016/j.bmc.2011.05.012. Epub 2011 May 20.
Ref 13 SnO 2 nanoparticles mediated nontraditional synthesis of biologically active 9-chloro-6, 13-dihydro-7-phenyl-5 H-indolo [3, 2-c]-acridine derivatives[J]. Medicinal Chemistry Research, 2011, 20: 732-737.
Ref 14 Antiparasitic hybrids of Cinchona alkaloids and bile acids. Eur J Med Chem. 2013 Aug;66:355-63. doi: 10.1016/j.ejmech.2013.06.004. Epub 2013 Jun 12.
Ref 15 Structure and in vitro antiparasitic activity of constituents of Citropsis articulata root bark. J Nat Prod. 2011 Oct 28;74(10):2286-9. doi: 10.1021/np2004825. Epub 2011 Oct 10.
Ref 16 Synthesis and structure-activity relationship of novel 1,4-diazabicyclo[2.2.2]octane derivatives as potent antimicrobial agents. Eur J Med Chem. 2015 May 5;95:563-73. doi: 10.1016/j.ejmech.2015.03.033. Epub 2015 Mar 17.
Ref 17 Lantadenes and their esters as potential antitumor agents. J Nat Prod. 2008 Jul;71(7):1222-7. doi: 10.1021/np800167x. Epub 2008 Jun 14.
Ref 18 Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues. J Med Chem. 2009 Oct 8;52(19):5937-49. doi: 10.1021/jm9005059.
Ref 19 Semisynthesis, cytotoxic activity, and oral availability of new lipophilic 9-substituted camptothecin derivatives. ACS Med Chem Lett. 2013 May 28;4(7):651-5. doi: 10.1021/ml400125z. eCollection 2013 Jul 11.
Ref 20 Synthesis and preliminary mechanistic evaluation of 5-(p-tolyl)-1-(quinolin-2-yl)pyrazole-3-carboxylic acid amides with potent antiproliferative activity on human cancer cell lines. Eur J Med Chem. 2014 Nov 24;87:140-9. doi: 10.1016/j.ejmech.2014.09.056. Epub 2014 Sep 20.
Ref 21 Prenylated Indole Diterpene Alkaloids from a Mine-Soil-Derived Tolypocladium sp. J Nat Prod. 2019 Feb 22;82(2):221-231. doi: 10.1021/acs.jnatprod.8b00589. Epub 2019 Jan 31.
Ref 22 New class of squalene-based releasable nanoassemblies of paclitaxel, podophyllotoxin, camptothecin and epothilone A. Eur J Med Chem. 2014 Oct 6;85:179-90. doi: 10.1016/j.ejmech.2014.07.035. Epub 2014 Jul 27.
Ref 23 Novel topoisomerase I inhibitors. Syntheses and biological evaluation of phosphorus substituted quinoline derivates with antiproliferative activity. Eur J Med Chem. 2018 Apr 10;149:225-237. doi: 10.1016/j.ejmech.2018.02.058. Epub 2018 Feb 22.
Ref 24 Bridged tricyclic sesquiterpenes from the tubercle nudibranch Phyllidia coelestis Bergh. J Nat Prod. 2013 Nov 22;76(11):2158-61. doi: 10.1021/np4007074. Epub 2013 Nov 7.
Ref 25 Molecular determinants of topoisomerase I poisoning by lamellarins: comparison with camptothecin and structure-activity relationships. J Med Chem. 2005 Jun 2;48(11):3796-807. doi: 10.1021/jm049060w.
Ref 26 Bioactive spirobisnaphthalenes from the endophytic fungus Berkleasmium sp. J Nat Prod. 2014 Oct 24;77(10):2151-60. doi: 10.1021/np400988a. Epub 2014 Sep 19.
Ref 27 Synthesis and biological evaluation of indeno[1,5]naphthyridines as topoisomerase I (TopI) inhibitors with antiproliferative activity. Eur J Med Chem. 2016 Jun 10;115:179-90. doi: 10.1016/j.ejmech.2016.03.031. Epub 2016 Mar 14.
Ref 28 Straightforward synthesis and biological evaluation as topoisomerase I inhibitors and antiproliferative agents of hybrid Chromeno[4,3-b][1,5]Naphthyridines and Chromeno[4,3-b][1,5]Naphthyridin-6-ones. Eur J Med Chem. 2019 Sep 15;178:752-766. doi: 10.1016/j.ejmech.2019.06.032. Epub 2019 Jun 14.
Ref 29 Fused chromeno and quinolino[1,8]naphthyridines: Synthesis and biological evaluation as topoisomerase I inhibitors and antiproliferative agents. Bioorg Med Chem. 2021 Jun 15;40:116177. doi: 10.1016/j.bmc.2021.116177. Epub 2021 Apr 27.
Ref 30 Synthesis of hybrid phosphorated indenoquinolines and biological evaluation as topoisomerase I inhibitors and antiproliferative agents. Bioorg Med Chem Lett. 2022 Feb 1;57:128517. doi: 10.1016/j.bmcl.2021.128517. Epub 2021 Dec 21.
Ref 31 14-Aminocamptothecins: their synthesis, preclinical activity, and potential use for cancer treatment. J Med Chem. 2011 Mar 24;54(6):1715-23. doi: 10.1021/jm101354u. Epub 2011 Feb 22.
Ref 32 Chemotherapeutic bone-targeted bisphosphonate prodrugs with hydrolytic mode of activation. Bioorg Med Chem Lett. 2008 Jan 15;18(2):816-20. doi: 10.1016/j.bmcl.2007.11.029. Epub 2007 Nov 17.
Ref 33 Synthesis and biological evaluation of C1-O-substituted-3-(3-butylamino-2-hydroxy-propoxy)-xanthen-9-one as topoisomerase II catalytic inhibitors. Eur J Med Chem. 2016 Nov 10;123:211-225. doi: 10.1016/j.ejmech.2016.07.046. Epub 2016 Jul 22.
Ref 34 Kabiramides J and K, trisoxazole macrolides from the sponge Pachastrissa nux. J Nat Prod. 2011 May 27;74(5):1288-92. doi: 10.1021/np100886y. Epub 2011 Mar 16.
Ref 35 Bifunctionalized amphilectane diterpenes from the sponge Stylissa cf. massa. J Nat Prod. 2012 Apr 27;75(4):789-92. doi: 10.1021/np200959j. Epub 2012 Feb 29.
Ref 36 Resin Glycosides from Ipomoea alba Seeds as Potential Chemosensitizers in Breast Carcinoma Cells. J Nat Prod. 2016 Dec 23;79(12):3093-3104. doi: 10.1021/acs.jnatprod.6b00782. Epub 2016 Nov 23.
Ref 37 Extending the record of bis--pyrone polypropionates from marine pulmonate mollusks. J Nat Prod. 2013 Nov 22;76(11):2065-73. doi: 10.1021/np400483c. Epub 2013 Nov 1.
Ref 38 Synthesis, anticancer activities and molecular modeling studies of novel indole retinoid derivatives. Eur J Med Chem. 2012 Dec;58:346-54. doi: 10.1016/j.ejmech.2012.10.013. Epub 2012 Oct 22.
Ref 39 PubChem BioAssay data set.
Ref 40 Synthesis and Biological Evaluation of Calothrixins B and their Deoxygenated Analogues. J Med Chem. 2018 Feb 8;61(3):1285-1315. doi: 10.1021/acs.jmedchem.7b01797. Epub 2018 Jan 22.
Ref 41 Synthesis and topoisomerase poisoning activity of A-ring and E-ring substituted luotonin A derivatives. Bioorg Med Chem. 2007 Jun 15;15(12):4237-46. doi: 10.1016/j.bmc.2007.03.067. Epub 2007 Mar 25.
Ref 42 Synthesis of new indeno[1,2-c]isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors. J Med Chem. 2000 Oct 5;43(20):3688-98. doi: 10.1021/jm000029d.
Ref 43 Synthesis and anticancer activity of simplified indenoisoquinoline topoisomerase I inhibitors lacking substituents on the aromatic rings. J Med Chem. 2004 Nov 4;47(23):5651-61. doi: 10.1021/jm040025z.
Ref 44 Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis. J Med Chem. 2005 Jul 28;48(15):4803-14. doi: 10.1021/jm050076b.
Ref 45 Synthesis and biological evaluation of bisindenoisoquinolines as topoisomerase I inhibitors. J Med Chem. 2006 Aug 24;49(17):5129-40. doi: 10.1021/jm060046o.
Ref 46 Synthesis of benz[d]indeno[1,2-b]pyran-5,11-diones: versatile intermediates for the design and synthesis of topoisomerase I inhibitors. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1846-9. doi: 10.1016/j.bmcl.2006.01.008. Epub 2006 Jan 25.
Ref 47 Investigation of the lactam side chain length necessary for optimal indenoisoquinoline topoisomerase I inhibition and cytotoxicity in human cancer cell cultures. J Med Chem. 2007 May 3;50(9):2040-8. doi: 10.1021/jm0613119. Epub 2007 Apr 3.
Ref 48 Nitrated indenoisoquinolines as topoisomerase I inhibitors: a systematic study and optimization. J Med Chem. 2007 Sep 6;50(18):4419-30. doi: 10.1021/jm070361q. Epub 2007 Aug 15.
Ref 49 Synthesis and biological evaluation of 14-(aminoalkyl-aminomethyl)aromathecins as topoisomerase I inhibitors: investigating the hypothesis of shared structure-activity relationships. Bioorg Med Chem. 2009 Oct 15;17(20):7145-55. doi: 10.1016/j.bmc.2009.08.066. Epub 2009 Sep 6.
Ref 50 Design, synthesis, and biological evaluation of 14-substituted aromathecins as topoisomerase I inhibitors. J Med Chem. 2008 Aug 14;51(15):4609-19. doi: 10.1021/jm800259e. Epub 2008 Jul 17.
Ref 51 Structure-based design, synthesis, and biological studies of new anticancer norindenoisoquinoline topoisomerase I inhibitors. J Med Chem. 2010 Mar 11;53(5):1979-89. doi: 10.1021/jm901649x.
Ref 52 The structure-activity relationships of A-ring-substituted aromathecin topoisomerase I inhibitors strongly support a camptothecin-like binding mode. Bioorg Med Chem. 2010 Aug 1;18(15):5535-52. doi: 10.1016/j.bmc.2010.06.040. Epub 2010 Jun 20.
Ref 53 Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors: investigating the relationships involving stereochemistry, hydrogen bonding, and biological activity. J Med Chem. 2011 Jul 28;54(14):4937-53. doi: 10.1021/jm101338z. Epub 2011 Jun 28.
Ref 54 7-azaindenoisoquinolines as topoisomerase I inhibitors and potential anticancer agents. J Med Chem. 2011 Sep 8;54(17):6106-16. doi: 10.1021/jm200719v. Epub 2011 Aug 8.
Ref 55 Azaindenoisoquinolines as topoisomerase I inhibitors and potential anticancer agents: a systematic study of structure-activity relationships. J Med Chem. 2012 Feb 23;55(4):1682-97. doi: 10.1021/jm201512x. Epub 2012 Feb 13.
Ref 56 Optimization of the lactam side chain of 7-azaindenoisoquinoline topoisomerase I inhibitors and mechanism of action studies in cancer cells. J Med Chem. 2014 Feb 27;57(4):1289-98. doi: 10.1021/jm401471v. Epub 2014 Feb 6.
Ref 57 Design, synthesis, and biological evaluation of O-2-modified indenoisoquinolines as dual topoisomerase I-tyrosyl-DNA phosphodiesterase I inhibitors. J Med Chem. 2014 May 22;57(10):4324-36. doi: 10.1021/jm500294a. Epub 2014 May 6.
Ref 58 Investigation of the Structure-Activity Relationships of Aza-A-Ring Indenoisoquinoline Topoisomerase I Poisons. J Med Chem. 2016 Apr 28;59(8):3840-53. doi: 10.1021/acs.jmedchem.6b00003. Epub 2016 Apr 12.
Ref 59 Design and Synthesis of Chlorinated and Fluorinated 7-Azaindenoisoquinolines as Potent Cytotoxic Anticancer Agents That Inhibit Topoisomerase I. J Med Chem. 2017 Jul 13;60(13):5364-5376. doi: 10.1021/acs.jmedchem.6b01870. Epub 2017 Jun 28.
Ref 60 Discovery of a novel series of quinolone and naphthyridine derivatives as potential topoisomerase I inhibitors by scaffold modification. J Med Chem. 2009 Sep 24;52(18):5649-61. doi: 10.1021/jm900469e.
Ref 61 Synthesis and Biological Evaluation of the First Triple Inhibitors of Human Topoisomerase 1, Tyrosyl-DNA Phosphodiesterase 1 (Tdp1), and Tyrosyl-DNA Phosphodiesterase 2 (Tdp2). J Med Chem. 2017 Apr 27;60(8):3275-3288. doi: 10.1021/acs.jmedchem.6b01565. Epub 2017 Apr 18.
Ref 62 Synthesis and antiproliferative activity of novel symmetrical alkylthio- and alkylseleno-imidocarbamates. Eur J Med Chem. 2011 Jan;46(1):265-74. doi: 10.1016/j.ejmech.2010.11.013. Epub 2010 Nov 27.
Ref 63 Structural variations on antitumour agents derived from bisacylimidoselenocarbamate. A proposal for structure-activity relationships based on the analysis of conformational behaviour. Eur J Med Chem. 2013 Aug;66:489-98. doi: 10.1016/j.ejmech.2013.06.001. Epub 2013 Jun 18.
Ref 64 CHMIS-C: a comprehensive herbal medicine information system for cancer. J Med Chem. 2005 Mar 10;48(5):1481-8. doi: 10.1021/jm049838d.
Ref 65 Optimization of the indenone ring of indenoisoquinoline topoisomerase I inhibitors. J Med Chem. 2007 Sep 6;50(18):4388-404. doi: 10.1021/jm070307+. Epub 2007 Aug 4.
Ref 66 Novel hexacyclic camptothecin derivatives. Part 1: synthesis and cytotoxicity of camptothecins with an A-ring fused 1,3-oxazine ring. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4095-7. doi: 10.1016/j.bmcl.2008.05.103. Epub 2008 Jun 12.
Ref 67 A novel thiazolidine compound induces caspase-9 dependent apoptosis in cancer cells. Bioorg Med Chem. 2012 Sep 1;20(17):5094-102. doi: 10.1016/j.bmc.2012.07.016. Epub 2012 Jul 20.
Ref 68 Synthesis and antiproliferative properties of N3/8-disubstituted 3,8-diazabicyclo[3.2.1]octane analogues of 3,8-bis[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methyl-piperazine. Eur J Med Chem. 2007 Mar;42(3):293-306. doi: 10.1016/j.ejmech.2006.11.013. Epub 2006 Dec 5.
Ref 69 Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12. J Med Chem. 2009 Aug 27;52(16):5176-87. doi: 10.1021/jm900365v.
Ref 70 Synthesis of indole inhibitors of silent information regulator 1 (SIRT1), and their evaluation as cytotoxic agents. Eur J Med Chem. 2020 Sep 15;202:112561. doi: 10.1016/j.ejmech.2020.112561. Epub 2020 Jul 2.
Ref 71 New antiprotozoal agents: Synthesis and biological evaluation of different 4-(7-chloroquinolin-4-yl) piperazin-1-yl)pyrrolidin-2-yl)methanone derivatives. Bioorg Med Chem Lett. 2017 Feb 1;27(3):460-465. doi: 10.1016/j.bmcl.2016.12.043. Epub 2016 Dec 18.
Ref 72 Synthesis and biological evaluation of rebeccamycin analogues modified at the imide moiety. Bioorg Med Chem Lett. 2012 Aug 1;22(15):5013-7. doi: 10.1016/j.bmcl.2012.06.016. Epub 2012 Jun 15.
Ref 73 Dimethoxybenzo[i]phenanthridine-12-carboxylic acid derivatives and 6H-dibenzo[c,h][2,6]naphthyridin-5-ones with potent topoisomerase I-targeting activity and cytotoxicity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5585-9. doi: 10.1016/j.bmcl.2004.08.070.
Ref 74 Synthesis of novel 6-(4-substituted piperazine-1-yl)-9-(-D-ribofuranosyl)purine derivatives, which lead to senescence-induced cell death in liver cancer cells. J Med Chem. 2012 Apr 12;55(7):3058-65. doi: 10.1021/jm3001532. Epub 2012 Mar 27.
Ref 75 Novel triazolothiadiazines act as potent anticancer agents in liver cancer cells through Akt and ASK-1 proteins. Bioorg Med Chem. 2016 Feb 15;24(4):858-72. doi: 10.1016/j.bmc.2016.01.013. Epub 2016 Jan 8.
Ref 76 Scaffold Diversity Inspired by the Natural Product Evodiamine: Discovery of Highly Potent and Multitargeting Antitumor Agents. J Med Chem. 2015 Aug 27;58(16):6678-96. doi: 10.1021/acs.jmedchem.5b00910. Epub 2015 Aug 19.
Ref 77 Discovery of Novel Polycyclic Heterocyclic Derivatives from Evodiamine for the Potential Treatment of Triple-Negative Breast Cancer. J Med Chem. 2021 Dec 9;64(23):17346-17365. doi: 10.1021/acs.jmedchem.1c01411. Epub 2021 Nov 29.
Ref 78 Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl pyridines. Bioorg Med Chem. 2010 May 1;18(9):3066-77. doi: 10.1016/j.bmc.2010.03.051. Epub 2010 Mar 27.
Ref 79 Synthesis of 2,4-diaryl chromenopyridines and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship. Eur J Med Chem. 2011 Aug;46(8):3201-9. doi: 10.1016/j.ejmech.2011.04.029. Epub 2011 Apr 29.
Ref 80 Structure-based hybridization, synthesis and biological evaluation of novel tetracyclic heterocyclic azathioxanthone analogues as potential antitumor agents. Eur J Med Chem. 2015 Oct 20;103:615-27. doi: 10.1016/j.ejmech.2014.09.050. Epub 2014 Sep 16.
Ref 81 3-Propionyl-thiazolidine-4-carboxylic acid ethyl esters: a family of antiproliferative thiazolidines. Medchemcomm. 2015;6(1):90-93.
Ref 82 Novel indolo-sophoridinic scaffold as Topo I inhibitors: Design, synthesis and biological evaluation as anticancer agents. Eur J Med Chem. 2018 Aug 5;156:479-492. doi: 10.1016/j.ejmech.2018.07.028. Epub 2018 Jul 17.
Ref 83 Synthesis and biological research of novel azaacridine derivatives as potent DNA-binding ligands and topoisomerase II inhibitors. Bioorg Med Chem. 2017 Jul 1;25(13):3437-3446. doi: 10.1016/j.bmc.2017.04.030. Epub 2017 May 4.
Ref 84 Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents. J Med Chem. 2013 Jul 11;56(13):5562-86. doi: 10.1021/jm400575x. Epub 2013 Jun 25.
Ref 85 Synthesis of novel hybrid quinolino[4,3-b][1,5]naphthyridines and quinolino[4,3-b][1,5]naphthyridin-6(5H)-one derivatives and biological evaluation as topoisomerase I inhibitors and antiproliferatives. Eur J Med Chem. 2020 Jun 1;195:112292. doi: 10.1016/j.ejmech.2020.112292. Epub 2020 Apr 3.
Ref 86 Humulane and germacrane sesquiterpenes from Ferula lycia. J Nat Prod. 2010 Apr 23;73(4):780-3. doi: 10.1021/np900827a.
Ref 87 Oxiranylmethyloxy or thiiranylmethyloxy-azaxanthones and -acridone analogues as potential topoisomerase I inhibitors. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6766-9. doi: 10.1016/j.bmcl.2009.09.091. Epub 2009 Sep 27.
Ref 88 New insight for fluoroquinophenoxazine derivatives as possibly new potent topoisomerase I inhibitor. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1520-4. doi: 10.1016/j.bmcl.2007.12.053. Epub 2007 Dec 25.
Ref 89 6-Substituted imidazo[1,2-a]pyridines: synthesis and biological activity against colon cancer cell lines HT-29 and Caco-2. Eur J Med Chem. 2011 Sep;46(9):4573-83. doi: 10.1016/j.ejmech.2011.07.036. Epub 2011 Jul 27.
Ref 90 Cytotoxic clerodane diterpenes from Zuelania guidonia. J Nat Prod. 2014 Mar 28;77(3):455-63. doi: 10.1021/np400672g. Epub 2014 Jan 31.
Ref 91 Lignans from the roots of Saururus chinensis. J Nat Prod. 2008 Oct;71(10):1771-4. doi: 10.1021/np8002723. Epub 2008 Oct 8.
Ref 92 Integration of a Diselenide Unit Generates Fluorogenic Camptothecin Prodrugs with Improved Cytotoxicity to Cancer Cells. J Med Chem. 2021 Dec 23;64(24):17979-17991. doi: 10.1021/acs.jmedchem.1c01362. Epub 2021 Dec 1.
Ref 93 11-Substituted 2,3-dimethoxy-8,9-methylenedioxybenzo[i]phenanthridine derivatives as novel topoisomerase I-targeting agents. Bioorg Med Chem. 2008 Sep 15;16(18):8598-606. doi: 10.1016/j.bmc.2008.08.018. Epub 2008 Aug 7.
Ref 94 12-Substituted 2,3-dimethoxy-8,9-methylenedioxybenzo[i]phenanthridines as novel topoisomerase I-targeting antitumor agents. Bioorg Med Chem. 2009 Apr 1;17(7):2877-85. doi: 10.1016/j.bmc.2009.02.023. Epub 2009 Feb 20.
Ref 95 Syntheses and biological evaluation of topoisomerase I-targeting agents related to 11-[2-(N,N-dimethylamino)ethyl]-2,3-dimethoxy-8,9-methylenedioxy-11H-isoquino[4,3-c]cinnolin-12-one (ARC-31). Bioorg Med Chem. 2008 Aug 15;16(16):7824-31. doi: 10.1016/j.bmc.2008.06.046. Epub 2008 Jun 26.
Ref 96 Synthesis of N-substituted 5-[2-(N-alkylamino)ethyl]dibenzo[c,h][1,6]naphthyridines as novel topoisomerase I-targeting antitumor agents. Bioorg Med Chem. 2008 Oct 15;16(20):9295-301. doi: 10.1016/j.bmc.2008.09.002. Epub 2008 Sep 5.
Ref 97 Novel topoisomerase I-targeting antitumor agents synthesized from the N,N,N-trimethylammonium derivative of ARC-111, 5H-2,3-dimethoxy-8,9-methylenedioxy-5-[(2-N,N,N-trimethylammonium)ethyl]dibenzo[c,h][1,6]naphthyridin-6-one iodide. Eur J Med Chem. 2009 Sep;44(9):3433-8. doi: 10.1016/j.ejmech.2009.02.004. Epub 2009 Feb 20.
Ref 98 Novel securinine derivatives as topoisomerase I based antitumor agents. Eur J Med Chem. 2016 Oct 21;122:149-163. doi: 10.1016/j.ejmech.2016.06.021. Epub 2016 Jun 15.
Ref 99 Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors. Eur J Med Chem. 2014 Jul 23;82:181-94. doi: 10.1016/j.ejmech.2014.05.047. Epub 2014 May 21.
Ref 100 Dihydroxylated 2,4,6-triphenyl pyridines: synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study. Eur J Med Chem. 2012 Mar;49:219-28. doi: 10.1016/j.ejmech.2012.01.015. Epub 2012 Jan 24.
Ref 101 Design, synthesis, and antitumor evaluation of 2,4,6-triaryl pyridines containing chlorophenyl and phenolic moiety. Eur J Med Chem. 2012 Jun;52:123-36. doi: 10.1016/j.ejmech.2012.03.010. Epub 2012 Mar 24.
Ref 102 Synthesis and biological evaluation of N-(carbobenzyloxy)-l-phenylalanine and N-(carbobenzyloxy)-l-aspartic acid--benzyl ester derivatives as potent topoisomerase II inhibitors. Bioorg Med Chem. 2017 Jun 15;25(12):3116-3126. doi: 10.1016/j.bmc.2017.03.065. Epub 2017 Apr 3.
Ref 103 Synthesis and antiproliferative evaluation of certain indeno[1,2-c]quinoline derivatives. Part 2. J Med Chem. 2010 Aug 26;53(16):6164-79. doi: 10.1021/jm1005447.
Ref 104 Derivatives of the new ring system indolo[1,2-c]benzo[1,2,3]triazine with potent antitumor and antimicrobial activity. J Med Chem. 1999 Jul 15;42(14):2561-8. doi: 10.1021/jm9806087.
Ref 105 In Silico Exploration and Biological Evaluation of Bispecific Peptides Derived from Anti-HER2 Antibodies and Peptide-Camptothecin Conjugates for HER2-Positive Breast Cancer. J Med Chem. 2022 Nov 24;65(22):15123-15139. doi: 10.1021/acs.jmedchem.2c00968. Epub 2022 Nov 9.
Ref 106 Novel 2-aryl-4-(4'-hydroxyphenyl)-5H-indeno[1,2-b]pyridines as potent DNA non-intercalative topoisomerase catalytic inhibitors. Eur J Med Chem. 2017 Jan 5;125:14-28. doi: 10.1016/j.ejmech.2016.09.019. Epub 2016 Sep 8.
Ref 107 Synthesis, biological evaluation, and molecular docking study of 3-(3'-heteroatom substituted-2'-hydroxy-1'-propyloxy) xanthone analogues as novel topoisomerase II catalytic inhibitor. Eur J Med Chem. 2011 Jun;46(6):1964-71. doi: 10.1016/j.ejmech.2011.01.011. Epub 2011 Jan 15.
Ref 108 Design, synthesis, biological evaluation and structure-activity relationship of sophoridine derivatives bearing pyrrole or indole scaffold as potential antitumor agents. Eur J Med Chem. 2018 Sep 5;157:665-682. doi: 10.1016/j.ejmech.2018.08.021. Epub 2018 Aug 9.
Ref 109 Synthesis and biological evaluation of new camptothecin derivatives obtained by modification of position 20. Bioorg Med Chem. 2010 Dec 15;18(24):8660-8. doi: 10.1016/j.bmc.2010.09.069. Epub 2010 Oct 7.
Ref 110 Synthesis and biological evaluation of a D-ring-contracted analogue of lamellarin D. Bioorg Med Chem. 2017 Nov 15;25(22):6137-6148. doi: 10.1016/j.bmc.2017.02.005. Epub 2017 Feb 9.
Ref 111 Cytotoxic steroidal saponins from Trillium kamtschaticum. Bioorg Med Chem Lett. 2017 Jun 1;27(11):2267-2273. doi: 10.1016/j.bmcl.2017.04.057. Epub 2017 Apr 19.
Ref 112 Design and synthesis of novel 2,4-diaryl-5H-indeno[1,2-b]pyridine derivatives, and their evaluation of topoisomerase inhibitory activity and cytotoxicity. Bioorg Med Chem. 2015 Jan 1;23(1):160-73. doi: 10.1016/j.bmc.2014.11.010. Epub 2014 Nov 11.
Ref 113 Design and synthesis of conformationally constrained hydroxylated 4-phenyl-2-aryl chromenopyridines as novel and selective topoisomerase II-targeted antiproliferative agents. Bioorg Med Chem. 2015 Oct 1;23(19):6454-66. doi: 10.1016/j.bmc.2015.08.018. Epub 2015 Aug 22.
Ref 114 Synthesis and preliminary bioevaluation of novel E-ring modified acetal analog of camptothecin as cytotoxic agents. Eur J Med Chem. 2012 Oct;56:1-9. doi: 10.1016/j.ejmech.2012.07.050. Epub 2012 Aug 7.
Ref 115 Stereochemical Structure Activity Relationship Studies (S-SAR) of Tetrahydrolipstatin. ACS Med Chem Lett. 2018 Feb 21;9(3):274-278. doi: 10.1021/acsmedchemlett.8b00050. eCollection 2018 Mar 8.
Ref 116 Synthesis and pharmacological evaluation of new methyloxiranylmethoxyxanthone analogues. Eur J Med Chem. 2010 Sep;45(9):4221-8. doi: 10.1016/j.ejmech.2010.06.017. Epub 2010 Jun 17.
Ref 117 Discovery of 4-anilinofuro[2,3-b]quinoline derivatives as selective and orally active compounds against non-small-cell lung cancers. J Med Chem. 2011 Jul 14;54(13):4446-61. doi: 10.1021/jm200046z. Epub 2011 Jun 3.
Ref 118 Effect of chlorine substituent on cytotoxic activities: Design and synthesis of systematically modified 2,4-diphenyl-5H-indeno[1,2-b]pyridines. Bioorg Med Chem Lett. 2016 Apr 1;26(7):1726-31. doi: 10.1016/j.bmcl.2016.02.053. Epub 2016 Feb 20.
Ref 119 Design, synthesis and biological evaluation of lapachol derivatives possessing indole scaffolds as topoisomerase I inhibitors. Bioorg Med Chem. 2016 Nov 15;24(22):5781-5786. doi: 10.1016/j.bmc.2016.09.034. Epub 2016 Sep 15.
Ref 120 Design, synthesis and biological evaluation of novel 7-alkylamino substituted benzo[a]phenazin derivatives as dual topoisomerase I/II inhibitors. Eur J Med Chem. 2015 Mar 6;92:540-53. doi: 10.1016/j.ejmech.2015.01.024. Epub 2015 Jan 12.
Ref 121 Camptothecin analogs with bulky, hydrophobic substituents at the 7-position via a Grignard reaction. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5377-81. doi: 10.1016/j.bmcl.2004.08.010.
Ref 122 Synthesis and biological evaluation of 5-aminoethyl benzophenanthridone derivatives as DNA topoisomerase IB inhibitors. Eur J Med Chem. 2019 Sep 15;178:81-92. doi: 10.1016/j.ejmech.2019.05.074. Epub 2019 May 30.
Ref 123 Discovery of novel bis-evodiamine derivatives with potent antitumor activity. Bioorg Med Chem. 2022 Jul 1;65:116793. doi: 10.1016/j.bmc.2022.116793. Epub 2022 May 6.
Ref 124 Lactone Derivatives Produced by a Phaeoacremonium sp., an Endophytic Fungus from Senna spectabilis. J Nat Prod. 2017 May 26;80(5):1674-1678. doi: 10.1021/acs.jnatprod.5b00828. Epub 2017 Apr 20.
Ref 125 Design, synthesis and evaluation of 4-substituted anthra[2,1-c][1,2,5]thiadiazole-6,11-dione derivatives as novel non-camptothecin topoisomerase I inhibitors. Bioorg Med Chem Lett. 2017 May 1;27(9):1929-1933. doi: 10.1016/j.bmcl.2017.03.039. Epub 2017 Mar 18.
Ref 126 7-Cycloalkylcamptothecin derivatives: Preparation and biological evaluation. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4107-9. doi: 10.1016/j.bmcl.2009.06.010. Epub 2009 Jun 6.
Ref 127 Novel bioactive clerodane diterpenoids from the leaves and twigs of Casearia sylvestris. J Nat Prod. 2002 Feb;65(2):95-9. doi: 10.1021/np010459m.
Ref 128 Semisynthesis of mallotus B from rottlerin: evaluation of cytotoxicity and apoptosis-inducing activity. J Nat Prod. 2013 Sep 27;76(9):1724-30. doi: 10.1021/np400433g. Epub 2013 Sep 17.
Ref 129 3-(2,6-Dichloro-benzyloxy)-11-oxo-olean-12-ene-29-oic acid, a semisynthetic derivative of glycyrrhetic acid: synthesis, antiproliferative, apoptotic and anti-angiogenesis activity. Medchemcomm. 2015;6(4):564-575.
Ref 130 Cytotoxic and apoptosis-inducing activities against human lung cancer cell lines of cassaine diterpenoids from the bark of Erythrophleum fordii. Bioorg Med Chem Lett. 2017 Jul 1;27(13):2946-2952. doi: 10.1016/j.bmcl.2017.05.006. Epub 2017 May 4.
Ref 131 Isoaurostatin, a novel topoisomerase inhibitor produced by Thermomonospora alba. J Nat Prod. 2001 Feb;64(2):204-7. doi: 10.1021/np0004606.
Ref 132 Design and one-pot synthesis of new 7-acyl camptothecin derivatives as potent cytotoxic agents. Bioorg Med Chem Lett. 2012 Dec 15;22(24):7659-61. doi: 10.1016/j.bmcl.2012.10.002. Epub 2012 Oct 11.
Ref 133 Candenatenins A-F, phenolic compounds from the heartwood of Dalbergia candenatensis. J Nat Prod. 2009 Aug;72(8):1395-8. doi: 10.1021/np900077h.
Ref 134 Preparation of novel ring-A fused azole derivatives of betulin and evaluation of their cytotoxicity. Eur J Med Chem. 2017 Jan 5;125:629-639. doi: 10.1016/j.ejmech.2016.09.065. Epub 2016 Sep 21.
Ref 135 Synthesis of cytotoxically active derivatives based on alkylated 2,3-seco-triterpenoids. Eur J Med Chem. 2017 Nov 10;140:74-83. doi: 10.1016/j.ejmech.2017.09.005. Epub 2017 Sep 6.
Ref 136 Cytotoxic triterpenoid saponins acylated with monoterpenic acid from Pithecellobium lucidum. J Nat Prod. 2008 Jan;71(1):41-6. doi: 10.1021/np0703794. Epub 2007 Dec 21.
Ref 137 Cytotoxic oleanane triterpene saponins from Albizia chinensis. J Nat Prod. 2009 Apr;72(4):632-9. doi: 10.1021/np800576s.
Ref 138 Synthesis and biological evaluation of 6-fluoro-3-phenyl-7-piperazinyl quinolone derivatives as potential topoisomerase I inhibitors. Eur J Med Chem. 2016 Oct 21;122:465-474. doi: 10.1016/j.ejmech.2016.06.054. Epub 2016 Jul 1.
Ref 139 Acylshikonin analogues: synthesis and inhibition of DNA topoisomerase-I. J Med Chem. 1995 Mar 17;38(6):1044-7. doi: 10.1021/jm00006a025.
Ref 140 Cytotoxicity and topo I targeting activity of substituted 10--nitrogenous heterocyclic aromatic group derivatives of SN-38. Eur J Med Chem. 2010 Jul;45(7):3200-6. doi: 10.1016/j.ejmech.2010.03.013. Epub 2010 Mar 16.
Ref 141 Synthesis and Antiproliferative and Metabolic Evaluations of Novel Securinine Derivatives. ACS Med Chem Lett. 2016 Feb 2;7(4):403-7. doi: 10.1021/acsmedchemlett.5b00441. eCollection 2016 Apr 14.
Ref 142 Synthesis and cytotoxic activity of 7-oxo-7H-dibenz[f,ij]isoquinoline and 7-oxo-7H-benzo[e]perimidine derivatives. J Med Chem. 2001 Jun 7;44(12):2004-14. doi: 10.1021/jm010041l.
Ref 143 Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines. J Med Chem. 2003 Mar 13;46(6):1049-54. doi: 10.1021/jm020420u.
Ref 144 Synthesis and anti-cancer activity evaluation of novel prenylated and geranylated chalcone natural products and their analogs. Eur J Med Chem. 2015 Mar 6;92:439-48. doi: 10.1016/j.ejmech.2015.01.007. Epub 2015 Jan 6.
Ref 145 Synthesis and SAR study of new hydroxy and chloro-substituted 2,4-diphenyl 5H-chromeno[4,3-b]pyridines as selective topoisomerase II-targeting anticancer agents. Bioorg Med Chem. 2018 May 1;26(8):1909-1919. doi: 10.1016/j.bmc.2018.02.035. Epub 2018 Feb 22.
Ref 146 Rational design and semisynthesis of betulinic acid analogues as potent topoisomerase inhibitors. J Nat Prod. 2009 Sep;72(9):1643-50. doi: 10.1021/np900312u.
Ref 147 Tessaric acid derivatives induce G2/M cell cycle arrest in human solid tumor cell lines. Bioorg Med Chem. 2009 Sep 1;17(17):6251-6. doi: 10.1016/j.bmc.2009.07.053. Epub 2009 Jul 25.
Ref 148 Structural simplification of bioactive natural products with multicomponent synthesis. 3. Fused uracil-containing heterocycles as novel topoisomerase-targeting agents. J Med Chem. 2011 Apr 14;54(7):2012-21. doi: 10.1021/jm1009428. Epub 2011 Mar 9.
Ref 149 Antiproliferative activity of withanolides against human breast cancer cell lines. J Nat Prod. 2010 May 28;73(5):966-8. doi: 10.1021/np9006734.
Ref 150 Design, synthesis and evaluation of novel sophoridinic imine derivatives containing conjugated planar structure as potent anticancer agents. Bioorg Med Chem. 2018 Aug 7;26(14):4136-4144. doi: 10.1016/j.bmc.2018.07.001. Epub 2018 Jul 2.
Ref 151 Indole alkaloids and other constituents of Rauwolfia serpentina. J Nat Prod. 2005 Jun;68(6):848-52. doi: 10.1021/np058007n.
Ref 152 Synthesis, modification, and cytotoxic evaluation of 2,3-secotriterpenic -ketoesters. Bioorg Med Chem Lett. 2018 Dec 15;28(23-24):3752-3760. doi: 10.1016/j.bmcl.2018.10.014. Epub 2018 Oct 11.
Ref 153 Synthesis and biological evaluation of new substituted thioglycolurils, their analogues and derivatives. Eur J Med Chem. 2017 Nov 10;140:141-154. doi: 10.1016/j.ejmech.2017.09.009. Epub 2017 Sep 7.
Ref 154 A new phenolic series of indenopyridinone as topoisomerase inhibitors: Design, synthesis, and structure-activity relationships. Bioorg Med Chem. 2018 Oct 1;26(18):5212-5223. doi: 10.1016/j.bmc.2018.09.021. Epub 2018 Sep 20.
Ref 155 Design, synthesis, and structure-activity relationships of new benzofuro[3,2-b]pyridin-7-ols as DNA topoisomerase II inhibitors. Bioorg Med Chem Lett. 2018 Feb 15;28(4):566-571. doi: 10.1016/j.bmcl.2018.01.048. Epub 2018 Feb 3.
Ref 156 N-2-(Phenylamino) Benzamide Derivatives as Dual Inhibitors of COX-2 and Topo I Deter Gastrointestinal Cancers via Targeting Inflammation and Tumor Progression. J Med Chem. 2022 Aug 11;65(15):10481-10505. doi: 10.1021/acs.jmedchem.2c00635. Epub 2022 Jul 22.
Ref 157 Synthesis and biological evaluation of novel A-ring modified hexacyclic camptothecin analogues. J Med Chem. 2001 May 10;44(10):1594-602. doi: 10.1021/jm0004751.
Ref 158 Biological profile of new apoptotic agents based on 2,4-pyrido[2,3-d]pyrimidine derivatives. Bioorg Med Chem. 2007 Feb 15;15(4):1659-69. doi: 10.1016/j.bmc.2006.12.010. Epub 2006 Dec 12.
Ref 159 Synthesis of 2,6-diaryl-substituted pyridines and their antitumor activities. Eur J Med Chem. 2008 Apr;43(4):675-82. doi: 10.1016/j.ejmech.2007.05.002. Epub 2007 May 27.
Ref 160 Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem. 1989 Mar;32(3):715-20. doi: 10.1021/jm00123a038.
Ref 161 Synthesis and antitumor activity of novel substituted uracil-1'(N)-acetic acid ester derivatives of 20(S)-camptothecins. Eur J Med Chem. 2017 Jan 5;125:1235-1246. doi: 10.1016/j.ejmech.2016.11.013. Epub 2016 Nov 8.
Ref 162 Cytotoxicity and TOP1-targeting activity of 8- and 9-amino derivatives of 5-butyl- and 5-(2-N,N-dimethylamino)ethyl-5H-dibenzo[c,h][1,6]naphthyridin-6-ones. Eur J Med Chem. 2009 Apr;44(4):1471-6. doi: 10.1016/j.ejmech.2008.09.048. Epub 2008 Oct 11.
Ref 163 Optimization of the Natural Product Calothrixin A to Discover Novel Dual Topoisomerase I and II Inhibitors with Improved Anticancer Activity. J Med Chem. 2022 Jun 9;65(11):8040-8061. doi: 10.1021/acs.jmedchem.2c00615. Epub 2022 May 25.
Ref 164 Synthesis of 6-formyl-pyridine-2-carboxylate derivatives and their telomerase inhibitory activities. Bioorg Med Chem Lett. 2003 Feb 24;13(4):609-12. doi: 10.1016/s0960-894x(02)01041-7.
Ref 165 Synthesis and biological evaluation of 6-substituted indolizinoquinolinediones as catalytic DNA topoisomerase I inhibitors. Eur J Med Chem. 2015 Aug 28;101:525-33. doi: 10.1016/j.ejmech.2015.07.007. Epub 2015 Jul 8.
Ref 166 Synthesis and in vitro cytotoxicity of hexacyclic camptothecin analogues. Bioorg Med Chem Lett. 1999 Nov 15;9(22):3203-6. doi: 10.1016/s0960-894x(99)00555-7.
Ref 167 2,6-Dithienyl-4-furyl pyridines: Synthesis, topoisomerase I and II inhibition, cytotoxicity, structure-activity relationship, and docking study. Bioorg Med Chem Lett. 2010 Jan 1;20(1):42-7. doi: 10.1016/j.bmcl.2009.11.041. Epub 2009 Nov 14.
Ref 168 Synthesis and bio-evaluation of novel quinolino-stilbene derivatives as potential anticancer agents. Bioorg Med Chem. 2015 Dec 15;23(24):7629-40. doi: 10.1016/j.bmc.2015.11.007. Epub 2015 Nov 7.
Ref 169 Cytotoxic phloroglucinols from the leaves of Myrtus communis. J Nat Prod. 2012 Feb 24;75(2):225-9. doi: 10.1021/np2009219. Epub 2012 Jan 25.
Ref 170 The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J Med Chem. 2000 Oct 19;43(21):3970-80. doi: 10.1021/jm000144o.
Ref 171 Synthesis and antiproliferative evaluation of 9-methoxy-6-(piperazin-1-yl)-11H-indeno[1,2-c]quinoline-11-one derivatives. Part 4. Medchemcomm. 2014;5(7):937-948.
Ref 172 Synthesis and evaluation of new 6-amino-substituted benzo[c]phenanthridine derivatives. J Med Chem. 1993 Nov 12;36(23):3686-92. doi: 10.1021/jm00075a025.
Ref 173 Synthesis and biological activity of novel inhibitors of topoisomerase I: 2-aryl-substituted 2-bis-1H-benzimidazoles. Eur J Med Chem. 2011 Feb;46(2):659-69. doi: 10.1016/j.ejmech.2010.11.046. Epub 2010 Dec 8.
Ref 174 Design, synthesis and biological evaluation of 3-arylisoquinoline derivatives as topoisomerase I and II dual inhibitors for the therapy of liver cancer. Eur J Med Chem. 2022 Jul 5;237:114376. doi: 10.1016/j.ejmech.2022.114376. Epub 2022 Apr 18.
Ref 175 A resveratrol analog, phoyunbene B, induces G2/M cell cycle arrest and apoptosis in HepG2 liver cancer cells. Bioorg Med Chem Lett. 2012 Mar 1;22(5):2114-8. doi: 10.1016/j.bmcl.2011.12.095. Epub 2012 Jan 16.
Ref 176 Synthesis and antitumor activity of lapathoside D and its analogs. Eur J Med Chem. 2012 Jul;53:1-12. doi: 10.1016/j.ejmech.2012.02.032. Epub 2012 Mar 28.
Ref 177 Synthesis and antiproliferative activity of helonioside A, 3',4',6'-tri-O-feruloylsucrose, lapathoside C and their analogs. Eur J Med Chem. 2012 Dec;58:418-30. doi: 10.1016/j.ejmech.2012.10.034. Epub 2012 Oct 27.
Ref 178 Concise synthesis and antiproliferative activity evaluation of ellipticine quinone and its analogs. Eur J Med Chem. 2017 Aug 18;136:1-13. doi: 10.1016/j.ejmech.2017.04.071. Epub 2017 Apr 28.
Ref 179 Concise synthesis of carbazole-1,4-quinones and evaluation of their antiproliferative activity against HCT-116 and HL-60 cells. Eur J Med Chem. 2016 Oct 4;121:561-577. doi: 10.1016/j.ejmech.2016.05.065. Epub 2016 Jun 3.
Ref 180 Substituted 2-arylquinazolinones: Design, synthesis, and evaluation of cytotoxicity and inhibition of topoisomerases. Eur J Med Chem. 2015 Oct 20;103:69-79. doi: 10.1016/j.ejmech.2015.08.040. Epub 2015 Aug 28.
Ref 181 Design, synthesis, cytotoxic activity and molecular docking studies of new 20(S)-sulfonylamidine camptothecin derivatives. Eur J Med Chem. 2016 Jun 10;115:109-20. doi: 10.1016/j.ejmech.2016.02.070. Epub 2016 Mar 3.
Ref 182 Eucalypglobulusals A-J, Formyl-Phloroglucinol-Terpene Meroterpenoids from Eucalyptus globulus Fruits. J Nat Prod. 2018 Dec 28;81(12):2638-2646. doi: 10.1021/acs.jnatprod.8b00430. Epub 2018 Dec 13.
Ref 183 Synthesis, structure, and cytotoxicity studies of some fungal isochromanes. J Nat Prod. 2013 Sep 27;76(9):1737-45. doi: 10.1021/np400460m. Epub 2013 Sep 13.
Ref 184 Cytotoxic components from the leaves of Erythrophleum fordii induce human acute leukemia cell apoptosis through caspase 3 activation and PARP cleavage. Bioorg Med Chem Lett. 2021 Jan 1;31:127673. doi: 10.1016/j.bmcl.2020.127673. Epub 2020 Nov 5.
Ref 185 Rubiyunnanins C-H, cytotoxic cyclic hexapeptides from Rubia yunnanensis inhibiting nitric oxide production and NF-B activation. Bioorg Med Chem. 2010 Dec 1;18(23):8226-34. doi: 10.1016/j.bmc.2010.10.019. Epub 2010 Oct 31.
Ref 186 Design, synthesis and biological evaluation of benzimidazole-rhodanine conjugates as potent topoisomerase II inhibitors. Medchemcomm. 2018 Jun 2;9(7):1194-1205. doi: 10.1039/c8md00278a. eCollection 2018 Jul 1.
Ref 187 Synthesis of benzo[3,4]azepino[1,2-b]isoquinolin-9-ones from 3-arylisoquinolines via ring closing metathesis and evaluation of topoisomerase I inhibitory activity, cytotoxicity and docking study. Bioorg Med Chem. 2011 Sep 15;19(18):5311-20. doi: 10.1016/j.bmc.2011.08.006. Epub 2011 Aug 8.
Ref 188 Multiple biological active 4-aminopyrazoles containing trifluoromethyl and their 4-nitroso-precursors: Synthesis and evaluation. Eur J Med Chem. 2020 Dec 15;208:112768. doi: 10.1016/j.ejmech.2020.112768. Epub 2020 Aug 23.
Ref 189 Water-soluble derivatives of evodiamine: Discovery of evodiamine-10-phosphate as an orally active antitumor lead compound. Eur J Med Chem. 2021 Aug 5;220:113544. doi: 10.1016/j.ejmech.2021.113544. Epub 2021 May 24.
Ref 190 New tricks for an old natural product: discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure-activity relationship analysis and biological evaluations. J Med Chem. 2012 Sep 13;55(17):7593-613. doi: 10.1021/jm300605m. Epub 2012 Aug 22.
Ref 191 Effects of substituent pattern on the intracellular target of antiproliferative benzo[b]thiophenyl chromone derivatives. Eur J Med Chem. 2021 Oct 15;222:113578. doi: 10.1016/j.ejmech.2021.113578. Epub 2021 May 25.
Ref 192 Design, synthesis, and biological evaluations of tumor-targeting dual-warhead conjugates for a taxoid-camptothecin combination chemotherapy. J Med Chem. 2014 Jul 10;57(13):5777-91. doi: 10.1021/jm500631u. Epub 2014 Jun 19.
Ref 193 Synthesis and topoisomerases inhibitory activity of heteroaromatic chalcones. Bioorg Med Chem. 2016 Nov 15;24(22):5921-5928. doi: 10.1016/j.bmc.2016.09.051. Epub 2016 Sep 21.
Ref 194 Design, docking, and synthesis of novel indeno[1,2-c]isoquinolines for the development of antitumor agents as topoisomerase I inhibitors. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3531-4. doi: 10.1016/j.bmcl.2007.04.064. Epub 2007 Apr 25.
Ref 195 3-Arylisoquinolines as novel topoisomerase I inhibitors. Bioorg Med Chem. 2011 Jan 15;19(2):724-34. doi: 10.1016/j.bmc.2010.10.057. Epub 2010 Nov 2.
Ref 196 Design, synthesis and docking study of 5-amino substituted indeno[1,2-c]isoquinolines as novel topoisomerase I inhibitors. Bioorg Med Chem. 2011 Mar 15;19(6):1924-9. doi: 10.1016/j.bmc.2011.01.064. Epub 2011 Feb 3.
Ref 197 A-ring and E-ring modifications of the cytotoxic alkaloid Luotonin A: Synthesis, computational and biological studies. Bioorg Med Chem. 2020 May 1;28(9):115443. doi: 10.1016/j.bmc.2020.115443. Epub 2020 Mar 16.
Ref 198 Synthesis and antitumor characterization of pyrazolic analogues of the marine pyrroloquinoline alkaloids: wakayin and tsitsikammamines. J Med Chem. 2006 May 18;49(10):2979-88. doi: 10.1021/jm051247f.
Ref 199 Synthesis and antiproliferative evaluation of certain indeno[1,2-c]quinoline derivatives. Bioorg Med Chem. 2008 Mar 15;16(6):3153-62. doi: 10.1016/j.bmc.2007.12.028. Epub 2007 Dec 23.
Ref 200 New somatostatin-drug conjugates for effective targeting pancreatic cancer. Bioorg Med Chem. 2018 Jul 30;26(13):3825-3836. doi: 10.1016/j.bmc.2018.06.032. Epub 2018 Jun 30.
Ref 201 Topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of dihydroxylated 2,6-diphenyl-4-aryl pyridines. Bioorg Med Chem. 2015 Jul 1;23(13):3638-54. doi: 10.1016/j.bmc.2015.04.002. Epub 2015 Apr 9.
Ref 202 A new series of 2-phenol-4-aryl-6-chlorophenyl pyridine derivatives as dual topoisomerase I/II inhibitors: Synthesis, biological evaluation and 3D-QSAR study. Eur J Med Chem. 2016 May 4;113:228-45. doi: 10.1016/j.ejmech.2016.02.050. Epub 2016 Feb 22.
Ref 203 CRM1 inhibitory and antiproliferative activities of novel 4'-alkyl substituted klavuzon derivatives. Bioorg Med Chem. 2017 Aug 15;25(16):4444-4451. doi: 10.1016/j.bmc.2017.06.030. Epub 2017 Jun 19.
Ref 204 Derivatives of grindelic acid: from a non-active natural diterpene to synthetic antitumor derivatives. Eur J Med Chem. 2013 Sep;67:28-38. doi: 10.1016/j.ejmech.2013.06.013. Epub 2013 Jun 18.
Ref 205 Symmetric dimers of ent-kaurane diterpenoids with cytotoxic activity from Croton tonkinensis. Bioorg Med Chem Lett. 2012 Jan 15;22(2):1122-4. doi: 10.1016/j.bmcl.2011.11.116. Epub 2011 Dec 6.
Ref 206 Identification of (1S,4S)-2,5-diazabicyclo[2.2.1]heptane-dithiocarbamate-nitrostyrene hybrid as potent antiproliferative and apoptotic inducing agent against cervical cancer cell lines. Eur J Med Chem. 2018 Feb 25;146:621-635. doi: 10.1016/j.ejmech.2018.01.020. Epub 2018 Jan 10.
Ref 207 Synthesis, cytotoxicity and structure-activity relationship of indolizinoquinolinedione derivatives as DNA topoisomerase IB catalytic inhibitors. Eur J Med Chem. 2018 May 25;152:195-207. doi: 10.1016/j.ejmech.2018.04.040. Epub 2018 Apr 22.
Ref 208 Synthesis and antiproliferative evaluation of certain iminonaphtho[2,3-b]furan derivatives. Bioorg Med Chem. 2010 Jul 15;18(14):5172-82. doi: 10.1016/j.bmc.2010.05.062. Epub 2010 Jun 10.
Ref 209 The self-assembly of a camptothecin-lysine nanotube. Bioorg Med Chem Lett. 2016 Jun 15;26(12):2834-2838. doi: 10.1016/j.bmcl.2016.04.056. Epub 2016 Apr 21.
Ref 210 Discovery and Optimization of Pyrrolopyrimidine Derivatives as Selective Disruptors of the Perinucleolar Compartment, a Marker of Tumor Progression toward Metastasis. J Med Chem. 2022 Jun 23;65(12):8303-8331. doi: 10.1021/acs.jmedchem.2c00204. Epub 2022 Jun 13.
Ref 211 Hybrids of privileged structures benzothiazoles and pyrrolo[2,1-c] [1,4]benzodiazepin-5-one, and diversity-oriented synthesis of benzothiazoles. Eur J Med Chem. 2012 Apr;50:27-38. doi: 10.1016/j.ejmech.2012.01.014. Epub 2012 Jan 14.
Ref 212 Synthesis, antitumor activity, and structure-activity relationship study of trihydroxylated 2,4,6-triphenyl pyridines as potent and selective topoisomerase II inhibitors. Eur J Med Chem. 2014 Sep 12;84:555-65. doi: 10.1016/j.ejmech.2014.07.058. Epub 2014 Jul 18.
Ref 213 Synthesis and evaluation of antibacterial and antitumor activities of new galactopyranosylated amino alcohols. Eur J Med Chem. 2016 Jan 27;108:203-210. doi: 10.1016/j.ejmech.2015.11.037. Epub 2015 Nov 24.
Ref 214 Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity.
Ref 215 A new scaffold of topoisomerase I inhibitors: Design, synthesis and biological evaluation. Eur J Med Chem. 2016 Nov 29;124:326-339. doi: 10.1016/j.ejmech.2016.08.045. Epub 2016 Aug 23.
Ref 216 Synthesis and evaluation as potential anticancer agents of novel tetracyclic indenoquinoline derivatives. Bioorg Med Chem. 2013 Mar 1;21(5):1143-9. doi: 10.1016/j.bmc.2012.12.026. Epub 2013 Jan 3.
Ref 217 Antifungal and cytotoxic activity of withanolides from Acnistus arborescens. J Nat Prod. 2010 Jul 23;73(7):1313-7. doi: 10.1021/np100201p.
Ref 218 Indole alkaloids from two cultured cyanobacteria, Westiellopsis sp. and Fischerella muscicola. Bioorg Med Chem. 2012 Sep 1;20(17):5290-5. doi: 10.1016/j.bmc.2012.06.030. Epub 2012 Jul 5.
Ref 219 Cascade synthetic strategies opening access to medicinal-relevant aliphatic 3- and 4-membered N-heterocyclic scaffolds. Eur J Med Chem. 2022 Aug 5;238:114438. doi: 10.1016/j.ejmech.2022.114438. Epub 2022 May 6.
Ref 220 An adjustable release rate linking strategy for cytotoxin-peptide conjugates. Bioorg Med Chem Lett. 2003 Mar 10;13(5):799-803. doi: 10.1016/s0960-894x(03)00016-7.
Ref 221 Nontoxic combretafuranone analogues with high in?vitro antibacterial activity. Eur J Med Chem. 2018 Jan 1;143:843-853. doi: 10.1016/j.ejmech.2017.11.078. Epub 2017 Nov 29.
Ref 222 Synthesis of 4-N-polyaromatic substituted podophyllotoxins: DNA topoisomerase inhibition, anticancer and apoptosis-inducing activities. Bioorg Med Chem. 2010 Dec 15;18(24):8493-500. doi: 10.1016/j.bmc.2010.10.042. Epub 2010 Nov 10.
Ref 223 Scaffold Hopping of Natural Product Evodiamine: Discovery of a Novel Antitumor Scaffold with Excellent Potency against Colon Cancer. J Med Chem. 2020 Jan 23;63(2):696-713. doi: 10.1021/acs.jmedchem.9b01626. Epub 2020 Jan 10.
Ref 224 Abietane and C20-norabietane diterpenes from the stem bark of Fraxinus sieboldiana and their biological activities. J Nat Prod. 2010 Nov 29;73(11):1914-21. doi: 10.1021/np100583u. Epub 2010 Oct 20.
Ref 225 Oligosaccharide-camptothecin conjugates as potential antineoplastic drugs: Design, synthesis and biological evaluation. Eur J Med Chem. 2020 Sep 15;202:112509. doi: 10.1016/j.ejmech.2020.112509. Epub 2020 Jun 30.
Ref 226 Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I. J Med Chem. 1995 Feb 3;38(3):395-401. doi: 10.1021/jm00003a001.
Ref 227 Discovery, Synthesis, and Evaluation of Oxynitidine Derivatives as Dual Inhibitors of DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1), and Potential Antitumor Agents. J Med Chem. 2018 Nov 21;61(22):9908-9930. doi: 10.1021/acs.jmedchem.8b00639. Epub 2018 Oct 31.
Ref 228 Synthesis of Methoxy-, Methylenedioxy-, Hydroxy-, and Halo-Substituted Benzophenanthridinone Derivatives as DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) Inhibitors and Their Biological Activity for Drug-Resistant Cancer. J Med Chem. 2021 Jun 10;64(11):7617-7629. doi: 10.1021/acs.jmedchem.1c00318. Epub 2021 May 19.
Ref 229 Identification of new halogen-containing 2,4-diphenyl indenopyridin-5-one derivative as a boosting agent for the anticancer responses of clinically available topoisomerase inhibitors. Eur J Med Chem. 2022 Jan 5;227:113916. doi: 10.1016/j.ejmech.2021.113916. Epub 2021 Oct 11.
Ref 230 Chemical constituents of the bark of Machilus wangchiana and their biological activities. J Nat Prod. 2009 Dec;72(12):2145-52. doi: 10.1021/np900504a.
Ref 231 Rational design, synthesis, and evaluation of novel 2,4-Chloro- and Hydroxy-Substituted diphenyl Benzofuro[3,2-b]Pyridines: Non-intercalative catalytic topoisomerase I and II dual inhibitor. Eur J Med Chem. 2017 Feb 15;127:318-333. doi: 10.1016/j.ejmech.2017.01.003. Epub 2017 Jan 2.
Ref 232 Dihydroxylated 2,6-diphenyl-4-chlorophenylpyridines: Topoisomerase I and II dual inhibitors with DNA non-intercalative catalytic activity. Eur J Med Chem. 2017 Jun 16;133:69-84. doi: 10.1016/j.ejmech.2017.03.048. Epub 2017 Mar 27.
Ref 233 Cryptolepine and aromathecin based mimics as potent G-quadruplex-binding, DNA-cleavage and anticancer agents: Design, synthesis and DNA targeting-induced apoptosis. Eur J Med Chem. 2019 May 1;169:144-158. doi: 10.1016/j.ejmech.2019.02.072. Epub 2019 Mar 4.
Ref 234 Artemisinin Derivatives with Antimelanoma Activity Show Inhibitory Effect against Human DNA Topoisomerase 1. ACS Med Chem Lett. 2020 Apr 10;11(5):1035-1040. doi: 10.1021/acsmedchemlett.0c00131. eCollection 2020 May 14.
Ref 235 Spirooxindole-pyrrolidine heterocyclic hybrids promotes apoptosis through activation of caspase-3. Bioorg Med Chem. 2019 Jun 15;27(12):2487-2498. doi: 10.1016/j.bmc.2019.03.011. Epub 2019 Mar 5.
Ref 236 Design, synthesis of DNA-interactive 4-thiazolidinone-based indolo-/pyrroloazepinone conjugates as potential cytotoxic and topoisomerase I inhibitors. Eur J Med Chem. 2022 Aug 5;238:114465. doi: 10.1016/j.ejmech.2022.114465. Epub 2022 May 18.
Ref 237 Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem. 1991 Jan;34(1):98-107. doi: 10.1021/jm00105a017.
Ref 238 Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in?vitro antiplasmodial and antitrypanosomal activities. Eur J Med Chem. 2015 Jul 15;100:10-7. doi: 10.1016/j.ejmech.2015.05.044. Epub 2015 Jun 1.
Ref 239 Synthesis, transformation and biological evaluation of 2,3-secotriterpene acetylhydrazones and their derivatives. Eur J Med Chem. 2013 Oct;68:203-11. doi: 10.1016/j.ejmech.2013.07.016. Epub 2013 Aug 9.
Ref 240 2-Chlorophenyl-substituted benzofuro[3,2-b]pyridines with enhanced topoisomerase inhibitory activity: The role of the chlorine substituent. Bioorg Med Chem Lett. 2017 Aug 1;27(15):3279-3283. doi: 10.1016/j.bmcl.2017.06.025. Epub 2017 Jun 9.
Ref 241 Discovery and Biological Evaluations of Halogenated 2,4-Diphenyl Indeno[1,2-b]pyridinol Derivatives as Potent Topoisomerase II-Targeted Chemotherapeutic Agents for Breast Cancer. J Med Chem. 2019 Sep 12;62(17):8194-8234. doi: 10.1021/acs.jmedchem.9b00970. Epub 2019 Aug 22.
Ref 242 Convenient synthesis of indeno[1,2-c]isoquinolines as constrained forms of 3-arylisoquinolines and docking study of a topoisomerase I inhibitor into DNA-topoisomerase I complex. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5763-7. doi: 10.1016/j.bmcl.2007.08.062. Epub 2007 Aug 29.
Ref 243 Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues. J Med Chem. 1998 Dec 31;41(27):5410-9. doi: 10.1021/jm980400l.
Ref 244 Novel 4-(4-substituted amidobenzyl)furan-2(5H)-one derivatives as topoisomerase I inhibitors. Eur J Med Chem. 2017 Feb 15;127:187-199. doi: 10.1016/j.ejmech.2016.12.035. Epub 2016 Dec 20.
Ref 245 Synthesis and topoisomerase II inhibitory and cytotoxic activity of oxiranylmethoxy- and thiiranylmethoxy-chalcone derivatives. Bioorg Med Chem Lett. 2011 Jan 1;21(1):211-4. doi: 10.1016/j.bmcl.2010.11.037. Epub 2010 Nov 12.
Ref 246 Novel 4-(piperazin-1-yl)quinolin-2(1H)-one bearing thiazoles with antiproliferative activity through VEGFR-2-TK inhibition. Bioorg Med Chem. 2021 Jun 15;40:116168. doi: 10.1016/j.bmc.2021.116168. Epub 2021 Apr 22.
Ref 247 Discovery and Mechanistic Study of Tailor-Made Quinoline Derivatives as Topoisomerase 1 Poison with Potent Anticancer Activity. J Med Chem. 2019 Apr 11;62(7):3428-3446. doi: 10.1021/acs.jmedchem.8b01938. Epub 2019 Apr 2.
Ref 248 Development of a metabolically stable topoisomerase I poison as anticancer agent. Eur J Med Chem. 2020 Sep 15;202:112551. doi: 10.1016/j.ejmech.2020.112551. Epub 2020 Jul 2.
Ref 249 Design, synthesis and screening of benzimidazole containing compounds with methoxylated aryl radicals as cytotoxic molecules on (HCT-116) colon cancer cells. Eur J Med Chem. 2021 Jan 1;209:112870. doi: 10.1016/j.ejmech.2020.112870. Epub 2020 Oct 17.
Ref 250 Synthesis and antiproliferative activity of indolizinophthalazine-5,12-dione derivatives, DNA topoisomerase IB inhibitors. Eur J Med Chem. 2010 Sep;45(9):3938-42. doi: 10.1016/j.ejmech.2010.05.048. Epub 2010 Jun 1.
Ref 251 Cucurbitane glucosides from the root of Machilus yaoshansis. J Nat Prod. 2011 Nov 28;74(11):2431-7. doi: 10.1021/np200706n. Epub 2011 Nov 1.
Ref 252 Synthesis and cytotoxic activity of nitric oxide-releasing isosteviol derivatives. Bioorg Med Chem Lett. 2014 May 1;24(9):2202-5. doi: 10.1016/j.bmcl.2014.03.004. Epub 2014 Mar 12.
Ref 253 The cytotoxic potential of cationic triangulenes against tumour cells. Medchemcomm. 2019 Aug 21;10(11):1881-1891. doi: 10.1039/c9md00305c. eCollection 2019 Nov 1.
Ref 254 Pseudoirroratin A, a new cytotoxic ent-kaurene diterpene from Isodon pseudo-irrorata. J Nat Prod. 2002 Feb;65(2):215-7. doi: 10.1021/np010420h.
Ref 255 Chemical constituents of Heteroplexis micocephala. J Nat Prod. 2009 Jun;72(6):1184-90. doi: 10.1021/np900213w.
Ref 256 Chalcones, inhibitors for topoisomerase I and cathepsin B and L, as potential anti-cancer agents. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3320-4. doi: 10.1016/j.bmcl.2013.03.106. Epub 2013 Apr 5.
Ref 257 Synthesis and antitumor activity of biotinylated camptothecin derivatives as potent cytotoxic agents. Bioorg Med Chem Lett. 2019 Jan 15;29(2):234-237. doi: 10.1016/j.bmcl.2018.11.049. Epub 2018 Nov 27.
Ref 258 Identification of 3-(benzazol-2-yl)quinoxaline derivatives as potent anticancer compounds: Privileged structure-based design, synthesis, and bioactive evaluation in?vitro and in?vivo. Eur J Med Chem. 2019 Mar 1;165:293-308. doi: 10.1016/j.ejmech.2019.01.004. Epub 2019 Jan 11.
Ref 259 Cytotoxic and antibacterial beilschmiedic acids from a Gabonese species of Beilschmiedia. J Nat Prod. 2012 Jul 27;75(7):1319-25. doi: 10.1021/np300241d. Epub 2012 Jul 3.
Ref 260 Biologically active arborinane-type triterpenoids and anthraquinones from Rubia yunnanensis. J Nat Prod. 2011 Oct 28;74(10):2069-80. doi: 10.1021/np2002918. Epub 2011 Oct 5.
Ref 261 1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships. Eur J Med Chem. 2019 Dec 1;183:111700. doi: 10.1016/j.ejmech.2019.111700. Epub 2019 Sep 16.
Ref 262 Synthesis and cytotoxic activity of pyridazino[1',6':1,2]pyrido[3,4-b]indol-5-inium derivatives as anti-cancer agents. Bioorg Med Chem Lett. 2002 Sep 16;12(18):2611-4. doi: 10.1016/s0960-894x(02)00472-9.
Ref 263 Antimalarial Activities of Alkyl Cyclohexenone Derivatives Isolated from the Leaves of Poupartia borbonica. J Nat Prod. 2017 Jun 23;80(6):1750-1757. doi: 10.1021/acs.jnatprod.6b01019. Epub 2017 May 30.
Ref 264 Chemical Constituents of the Roots of Euphorbia micractina. J Nat Prod. 2009 Sep;72(9):1620-6. doi: 10.1021/np900305j.
Ref 265 3-(3-Butylamino-2-hydroxy-propoxy)-1-hydroxy-xanthen-9-one acts as a topoisomerase II catalytic inhibitor with low DNA damage. Eur J Med Chem. 2013 Nov;69:139-45. doi: 10.1016/j.ejmech.2013.07.048. Epub 2013 Aug 11.
Ref 266 Design, synthesis and potent cytotoxic activity of novel 7-(N-[(substituted-sulfonyl)piperazinyl]-methyl)-camptothecin derivatives. Bioorg Med Chem Lett. 2017 Apr 15;27(8):1750-1753. doi: 10.1016/j.bmcl.2017.02.066. Epub 2017 Feb 28.
Ref 267 Design, semisynthesis and potent cytotoxic activity of novel 10-fluorocamptothecin derivatives. Bioorg Med Chem Lett. 2017 Oct 15;27(20):4694-4697. doi: 10.1016/j.bmcl.2017.09.012. Epub 2017 Sep 8.
Ref 268 Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of 2-phenyl- or hydroxylated 2-phenyl-4-aryl-5H-indeno[1,2-b]pyridines. Bioorg Med Chem. 2015 Jul 1;23(13):3499-512. doi: 10.1016/j.bmc.2015.04.031. Epub 2015 Apr 28.
Ref 269 Selection of evodiamine as a novel topoisomerase I inhibitor by structure-based virtual screening and hit optimization of evodiamine derivatives as antitumor agents. J Med Chem. 2010 Nov 11;53(21):7521-31. doi: 10.1021/jm100387d.
Ref 270 Rotenoids and flavonoids with anti-invasion of HT1080, anti-proliferation of U937, and differentiation-inducing activity in HL-60 from Erycibe expansa. Bioorg Med Chem. 2007 Feb 1;15(3):1539-46. doi: 10.1016/j.bmc.2006.09.024. Epub 2006 Dec 8.
Ref 271 Synthesis, mode of action, and biological activities of rebeccamycin bromo derivatives. J Med Chem. 1999 May 20;42(10):1816-22. doi: 10.1021/jm980702n.
Ref 272 Synthesis of ferulic ester dimers, functionalisation and biological evaluation as potential antiatherogenic and antiplasmodial agents. Bioorg Med Chem. 2007 Sep 15;15(18):6018-26. doi: 10.1016/j.bmc.2007.06.047. Epub 2007 Jun 29.
Ref 273 New benzo[5,6]pyrrolizino[1,2-b]quinolines as cytotoxic agents. Bioorg Med Chem Lett. 2004 May 3;14(9):2363-5. doi: 10.1016/j.bmcl.2004.01.097.
Ref 274 Cytotoxic azaphilone alkaloids from Chaetomium globosum TY1. Bioorg Med Chem Lett. 2013 May 15;23(10):2945-7. doi: 10.1016/j.bmcl.2013.03.044. Epub 2013 Mar 21.
Ref 275 Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors. J Med Chem. 1997 Jun 20;40(13):2040-6. doi: 10.1021/jm970044r.
Ref 276 Novel 7-substituted camptothecins with potent antitumor activity. J Med Chem. 2000 Oct 19;43(21):3963-9. doi: 10.1021/jm000944z.
Ref 277 Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity. J Med Chem. 2001 Sep 27;44(20):3264-74. doi: 10.1021/jm0108092.
Ref 278 Synthesis and pharmacological evaluation of novel non-lactone analogues of camptothecin. Bioorg Med Chem Lett. 2003 Aug 18;13(16):2731-5. doi: 10.1016/s0960-894x(03)00534-1.
Ref 279 Synthesis and biological evaluation of 3-substituted 2-oxindole derivatives as new glycogen synthase kinase 3 inhibitors. Bioorg Med Chem. 2019 May 1;27(9):1804-1817. doi: 10.1016/j.bmc.2019.03.028. Epub 2019 Mar 15.
Ref 280 A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability. Eur J Med Chem. 2014 Aug 18;83:366-73. doi: 10.1016/j.ejmech.2014.06.050. Epub 2014 Jun 25.
Ref 281 Fluorescein hydrazones: A series of novel non-intercalative topoisomerase II catalytic inhibitors induce G1 arrest and apoptosis in breast and colon cancer cells. Eur J Med Chem. 2017 Jan 5;125:49-67. doi: 10.1016/j.ejmech.2016.09.004. Epub 2016 Sep 12.
Ref 282 New benzoxanthone derivatives as topoisomerase inhibitors and DNA cross-linkers. Bioorg Med Chem. 2010 Feb;18(3):1010-7. doi: 10.1016/j.bmc.2009.12.069. Epub 2010 Jan 4.
Ref 283 Design, synthesis, mechanisms of action, and toxicity of novel 20(s)-sulfonylamidine derivatives of camptothecin as potent antitumor agents. J Med Chem. 2014 Jul 24;57(14):6008-18. doi: 10.1021/jm5003588. Epub 2014 Jul 8.
Ref 284 Synthesis and cytotoxic studies of novel 5-phenylisatin derivatives and their anti-migration and anti-angiogenic evaluation. Eur J Med Chem. 2018 Aug 5;156:800-814. doi: 10.1016/j.ejmech.2018.07.032. Epub 2018 Jul 25.
Ref 285 Molecular docking study on anticancer activity of plant-derived natural products[J]. Medicinal chemistry research, 2010, 19: 817-835.
Ref 286 Natural Product Evodiamine with Borate Trigger Unit: Discovery of Potent Antitumor Agents against Colon Cancer. ACS Med Chem Lett. 2020 Feb 28;11(4):439-444. doi: 10.1021/acsmedchemlett.9b00513. eCollection 2020 Apr 9.
Ref 287 Resorcylic acid lactones with cytotoxic and NF-B inhibitory activities and their structure-activity relationships. J Nat Prod. 2011 May 27;74(5):1126-31. doi: 10.1021/np200062x. Epub 2011 Apr 22.
Ref 288 Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells. J Nat Prod. 2007 Dec;70(12):1884-8. doi: 10.1021/np070332i. Epub 2007 Dec 13.
Ref 289 Cells lacking DNA topoisomerase II beta are resistant to genistein. J Nat Prod. 2007 May;70(5):763-7. doi: 10.1021/np060609z. Epub 2007 Apr 6.
Ref 290 Design, synthesis and in vitro cytotoxicity evaluation of 5-(2-carboxyethenyl)isatin derivatives as anticancer agents. Bioorg Med Chem Lett. 2014 Jan 15;24(2):591-4. doi: 10.1016/j.bmcl.2013.12.001. Epub 2013 Dec 8.
Ref 291 Calothrixins, a new class of human DNA topoisomerase I poisons. J Nat Prod. 2009 Mar 27;72(3):438-42. doi: 10.1021/np8007232.
Ref 292 Novel C-ring analogues of 20(S)-camptothecin. Part 3: synthesis and their in vitro cytotoxicity of A-, B- and C-ring analogues. Bioorg Med Chem Lett. 2000 Feb 21;10(4):369-71. doi: 10.1016/s0960-894x(00)00005-6.
Ref 293 Caesalminaxins A-L, cassane diterpenoids from the seeds of Caesalpinia minax. J Nat Prod. 2013 Dec 27;76(12):2210-8. doi: 10.1021/np400545v. Epub 2013 Dec 4.
Ref 294 In vitro cytotoxic activity of abietane diterpenes from Peltodon longipes as well as Salvia miltiorrhiza and Salvia sahendica. Bioorg Med Chem. 2011 Aug 15;19(16):4876-81. doi: 10.1016/j.bmc.2011.06.067. Epub 2011 Jun 29.
Ref 295 Synthesis of an immunoconjugate of camptothecin. Bioorg Med Chem Lett. 2002 Jan 21;12(2):217-9. doi: 10.1016/s0960-894x(01)00707-7.
Ref 296 Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase II catalytic inhibitor. Bioorg Med Chem. 2016 Apr 15;24(8):1898-908. doi: 10.1016/j.bmc.2016.03.017. Epub 2016 Mar 8.
Ref 297 Synthesis of chromeno[3,4-b]indoles as Lamellarin D analogues: a novel DYRK1A inhibitor class. Eur J Med Chem. 2012 Mar;49:379-96. doi: 10.1016/j.ejmech.2012.01.040. Epub 2012 Jan 25.
Ref 298 Nitro and amino substitution in the D-ring of 5-(2-dimethylaminoethyl)- 2,3-methylenedioxy-5H-dibenzo[c,h][1,6]naphthyridin-6-ones: effect on topoisomerase-I targeting activity and cytotoxicity. J Med Chem. 2003 May 22;46(11):2254-7. doi: 10.1021/jm020498a.
Ref 299 A series of alpha-amino acid ester prodrugs of camptothecin: in vitro hydrolysis and A549 human lung carcinoma cell cytotoxicity. J Med Chem. 2010 Feb 11;53(3):1038-47. doi: 10.1021/jm901029n.
Ref 300 Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT). J Med Chem. 1999 Sep 9;42(18):3623-8. doi: 10.1021/jm990124q.
Ref 301 Vasorelaxant activity of diterpenes from Croton zambesicus and synthetic trachylobanes and their structure-activity relationships. J Nat Prod. 2007 Jun;70(6):910-7. doi: 10.1021/np0603976. Epub 2007 Jun 5.
Ref 302 Camptothecin and minor-groove binder hybrid molecules: synthesis, inhibition of topoisomerase I, and anticancer cytotoxicity in vitro. J Med Chem. 1997 Jan 17;40(2):216-25. doi: 10.1021/jm9605804.
Ref 303 Bisintercalating threading diacridines: relationships between DNA binding, cytotoxicity, and cell cycle arrest. J Med Chem. 2003 Dec 18;46(26):5790-802. doi: 10.1021/jm030253d.
Ref 304 Design, synthesis, and biological evaluation of callophycin A and analogues as potential chemopreventive and anticancer agents. Bioorg Med Chem. 2011 Nov 1;19(21):6182-95. doi: 10.1016/j.bmc.2011.09.020. Epub 2011 Sep 16.
Ref 305 Molecular design, synthesis and docking study of benz[b]oxepines and 12-oxobenzo[c]phenanthridinones as topoisomerase 1 inhibitors. Bioorg Med Chem Lett. 2009 May 1;19(9):2444-7. doi: 10.1016/j.bmcl.2009.03.058. Epub 2009 Mar 18.
Ref 306 New diterpenoids from Caesalpinia species and their cytotoxic activity. Bioorg Med Chem Lett. 2010 May 1;20(9):2847-50. doi: 10.1016/j.bmcl.2010.03.048. Epub 2010 Mar 12.
Ref 307 Synthesis of polyozellin, a prolyl oligopeptidase inhibitor, and its structural revision. Bioorg Med Chem Lett. 2018 Mar 1;28(5):930-933. doi: 10.1016/j.bmcl.2018.01.054. Epub 2018 Jan 31.
Ref 308 2-Thienyl-4-furyl-6-aryl pyridine derivatives: synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study. Bioorg Med Chem. 2010 Jan 1;18(1):377-86. doi: 10.1016/j.bmc.2009.10.049. Epub 2009 Oct 29.
Ref 309 Inhibitory activities against topoisomerase I and II by polyhydroxybenzoyl amide derivatives and their structure-activity relationship. Bioorg Med Chem Lett. 2004 Apr 5;14(7):1669-72. doi: 10.1016/j.bmcl.2004.01.060.
Ref 310 2-Alkynoic fatty acids inhibit topoisomerase IB from Leishmania donovani. Bioorg Med Chem Lett. 2012 Oct 1;22(19):6185-9. doi: 10.1016/j.bmcl.2012.08.019. Epub 2012 Aug 10.
Ref 311 Synthesis of 2-(thienyl-2-yl or -3-yl)-4-furyl-6-aryl pyridine derivatives and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship. Bioorg Med Chem. 2010 Mar 15;18(6):2245-2254. doi: 10.1016/j.bmc.2010.01.065. Epub 2010 Feb 4.
Ref 312 A new strategy to improve the metabolic stability of lactone: discovery of (20S,21S)-21-fluorocamptothecins as novel, hydrolytically stable topoisomerase I inhibitors. J Med Chem. 2013 Oct 24;56(20):7902-10. doi: 10.1021/jm400906z. Epub 2013 Oct 9.
Ref 313 Monodisperse oligoethylene glycols modified Camptothecin, 10-Hydroxycamptothecin and SN38 prodrugs. Bioorg Med Chem Lett. 2019 Feb 15;29(4):581-584. doi: 10.1016/j.bmcl.2018.12.059. Epub 2018 Dec 27.
Ref 314 Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs. J Med Chem. 1993 Sep 3;36(18):2689-700. doi: 10.1021/jm00070a013.
Ref 315 Antiproliferative Dimeric Aporphinoid Alkaloids from the Roots of Thalictrum cultratum. J Nat Prod. 2017 Nov 22;80(11):2893-2904. doi: 10.1021/acs.jnatprod.7b00387. Epub 2017 Nov 13.
Ref 316 Regioselective synthesis and cytotoxicities of camptothecin derivatives modified at the 7-, 10- and 20-positions. Bioorg Med Chem Lett. 2003 Nov 3;13(21):3739-41. doi: 10.1016/j.bmcl.2003.08.012.
Ref 317 Selective phenolic acylation of 10-hydroxycamptothecin using poly (ethylene glycol) carboxylic acid. Bioorg Med Chem Lett. 2003 Feb 10;13(3):577-80. doi: 10.1016/s0960-894x(02)00926-5.
Ref 318 Paradigm shift of "classical" HDAC inhibitors to "hybrid" HDAC inhibitors in therapeutic interventions. Eur J Med Chem. 2021 Jan 1;209:112844. doi: 10.1016/j.ejmech.2020.112844. Epub 2020 Sep 17.
Ref 319 Synthesis of benzo-annulated tryptanthrins and their biological properties. Bioorg Med Chem. 2012 Aug 15;20(16):4962-7. doi: 10.1016/j.bmc.2012.06.034. Epub 2012 Jul 2.
Ref 320 Antitumor agents 294. Novel E-ring-modified camptothecin-4-anilino-4'-O-demethyl-epipodophyllotoxin conjugates as DNA topoisomerase I inhibitors and cytotoxic agents. Bioorg Med Chem. 2012 Jul 15;20(14):4489-94. doi: 10.1016/j.bmc.2012.05.030. Epub 2012 May 19.
Ref 321 Cytotoxic triterpenoids from the rhizomes of Astilbe chinensis. J Nat Prod. 2009 Jul;72(7):1241-4. doi: 10.1021/np900028v.
Ref 322 Synthesis and anti-cancer activity evaluation of 5-(2-carboxyethenyl)-isatin derivatives. Eur J Med Chem. 2016 Apr 13;112:145-156. doi: 10.1016/j.ejmech.2015.12.050. Epub 2016 Feb 6.
Ref 323 Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins. J Med Chem. 2000 Jun 1;43(11):2285-9. doi: 10.1021/jm000129j.
Ref 324 Synthesis of polyfunctionalized piperidone oxime ethers and their cytotoxicity on HeLa cells. Bioorg Med Chem Lett. 2011 Nov 15;21(22):6678-86. doi: 10.1016/j.bmcl.2011.09.063. Epub 2011 Sep 21.
Ref 325 DrugMatrix in vitro pharmacology data.